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ABSTRACT
Vascular aging plays a central role in health problems and mortality in older people. 
Apart from the impact of several classical cardiovascular risk factors on the vasculature, 
chronological aging remains the single most important determinant of cardiovascular 
problems. The causative mechanisms by which chronological aging mediates its impact, 
independently from classical risk factors, remain to be elucidated. In recent years evi-
dence has accumulated that unrepaired DNA damage may play an important role. Ob-
servations in animal models and in humans indicate that under conditions during which 
DNA damage accumulates in an accelerated rate, functional decline of the vasculature 
takes place in a similar but more rapid or more exaggerated way than occurs in the ab-
sence of such conditions. Also epidemiological studies suggest a relationship between 
DNA maintenance and age-related cardiovascular disease. Accordingly, mouse models 
of defective DNA repair are means to study the mechanisms involved in biological aging 
of the vasculature. We here review the evidence of the role of DNA damage in vascular 
aging, and present mechanisms by which genomic instability interferes with regulation 
of the vascular tone. In addition, we present potential remedies against vascular aging 
induced by genomic instability. Central to this review is the role of diverse types of DNA 
damage (telomeric, non-telomeric and mitochondrial), of cellular changes (apoptosis, 
senescence, autophagy), cyclin-dependent kinase inhibitors, senescence-associated 
secretory phenotype (SASP)/senescence-messaging secretome (SMS), insulin and 
insulin-like growth factor 1 (IGF-1) signaling), the adenosine monophosphate-activated 
protein kinase (AMPK)-mammalian target of rapamycin (mTOR)-nuclear factor kappa B 
(NFκB) axis, reactive oxygen species (ROS) vs. endothelial nitric oxide synthase (eNOS)-
cyclic guanosine monophosphate (cGMP) signaling, phosphodiesterase (PDE) 1 and 5 
and diet restriction.
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1. INTRODuCTION
Cardiovascular diseases (CVD) are the leading cause of death worldwide, responsible 
for killing 17.3 million persons per year.1 The onset of CVD is triggered by vascular 
endothelial alterations characterized by an impaired endothelium-dependent vaso-
dilation, the overproduction of pro-inflammatory and prothrombotic molecules, and 
oxidative stress.2 Age is the strongest independent predictor for CVD in risk scores in 
middle-aged persons, and an important determinant for cardiovascular health in the 
population aged 65 or older.3, 4 Aging is characterized by the complex interaction of 
cellular and molecular mechanisms that leads to a collection of functional problems. 
Focusing on the vasculature, such problems are closely associated with each other, and 
include worsened vasodilation, increased arterial stiffness and overt remodeling of the 
extracellular matrix, diffuse intimal thickening and a dysfunctional endothelium.4 The 
mechanisms through which age actually contributes to cardiovascular risk remain the 
subject of speculation. From a classical perspective, modifiable risk factors promote and 
modulate molecular mechanisms that, as time progresses, culminate in an imbalance in 
the production vs. scavenging of ROS (i.e., superoxide anions, hydrogen peroxide and 
hydroxyl radicals), increasing ROS levels, and, as a consequence, reducing the bioavail-
ability of nitric oxide (NO).5, 6 NO is crucial in the maintenance of vascular homeostasis, 
including in the regulation of vascular dilation, the modulation of cell growth and the 
prevention of thrombosis.7 In the absence of a healthy endothelium, these factors 
gradually increase the pathologic phenotype of the vasculature up to the point that 
cardiovascular events occur.
While this paradigm explains vascular aging in view of classical risk factors as caus-
ative mechanisms, a recently proposed alternative view on vascular aging has emerged 
that presents new mechanistic alternatives for understanding the process of vascular 
aging.8 In this novel paradigm, causal mechanisms for the process of aging itself, most 
notably genomic instability, including telomere attrition, drive the detrimental changes 
occurring increasingly with (biological) aging (Figure 1). The involvement of these causal 
factors of aging in general have been discussed elsewhere.9 In the present review we 
summarize the evidence that supports the role of genomic instability in vascular aging. 
In addition, we present mechanisms through which genomic instability generates the 
functional changes that are typical for the aging vasculature.
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2. GENOMIC INSTABIlITy AND AGING: A ShORT OuTlINE Of ThE BASIC 
PRINCIPlES
2.1. DNA Repair Systems
The maintenance of genomic integrity is critical for the prevention of aging of organ-
isms. To safeguard genomic integrity, cells are equipped with several genomic main-
tenance systems that sense and repair DNA damage.10, 11 The sources of DNA damage 
are very diverse and range from intrinsic molecular reactions within DNA molecules 
such as hydrolysis, attacks by endogenous metabolic products, and ROS, to damage 
by exogenous physical and chemical entities such as chemotherapy and UVB light.12 
To account for the different types of DNA damage, cells are equipped with multiple 
DNA repair pathways. Each repair system is responsible for a specific subset of lesions, 
although partial overlap can occur depending on the type of DNA lesion that needs to 
be repaired. At least six DNA repair pathways can be listed in mammalian cells: (1) the 
direct reversal pathway, which executes the direct reversal of chemical modifications of 
nucleotides; (2) mismatch repair (MMR), which repairs base pair mismatches; (3) base 
excision repair (BER), repairing mainly oxidized and alkylation lesions in the nucleus and 
mitochondria, as well as single-strand breaks; (4) nucleotide excision repair (NER), to 
correct transcription-disturbing bulky adducts; (5) homologous recombination (HR); 
and (6) non-homologous end joining (NHEJ), which correct single- and double-strand 
breaks.10, 13 Telomere maintenance requires further specialized proteins.14 Hypothetically, 
the classical cardiovascular risk factors initiate ROS-induced DNA damage and thus con-
tribute to genomic instability-related vascular aging (Figure 1). Although some factors 
that lead to (vascular) genomic instability have been identified, the road to identification 
of all relevant contributors is still long (Figure 1).8, 15
2.2. Aging: The Interplay between Genomic Damage, the Survival Response 
and Cellular Senescence
Unrepaired genomic damage enables the generation of harmful mutations that can be 
transferred to new cells during proliferation. This puts complex organisms at the poten-
tial risk of rapidly developing dysfunctional tissues or even tumors. As a protective mea-
sure, accumulating unrepaired DNA damage triggers a switch in biological pathways 
from a phenotype supporting growth to one favoring maintenance of the organism, a 
switch often referred to as the “survival response”.16 However, the switch is believed to 
contribute to the typical changes that occur during aging, as demonstrated in humans 
and animals with defective DNA maintenance.16
To avoid the harmful consequences of genomic instability, such as cancer, complex 
organisms have developed protective cellular mechanisms, namely apoptosis and cel-
lular senescence. Whereas apoptosis embodies the loss of (dysfunctional) tissue due 
13
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figure 1. Etiology of vascular aging based on genomic instability as a causal factor. Classical and unidenti-
fi ed risk factors contribute to various types of DNA lesions. Unrepaired lesions accumulating during life lead 
to a growing set of pathophysiological changes that, either independently or in mutual interaction, lead to 
progressive vascular aging. The putative role of transcriptional problems or mutations herein needs to be 
established. The survival response may have benefi cial (increased Nrf2-regulated antioxidants) as well as 
detrimental (decreased IGF-1 signaling, pro-infl ammatory status) eff ects (see text and Ref. [8]).
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to programmed cell death, which might account for loss of organ function, cellular 
senescence has a more intricate relationship with aging tissues. Senescent cells undergo 
cell cycle arrest and thus can no longer replicate, although they remain metabolically 
active and often acquire a SASP, an immunogenic phenotype consisting of interleukins, 
pro-inflammatory cytokines, and growth factors.17 It is believed that this results in an 
increased susceptibility to age-associated disease, including cancer and cardiovascular 
disease.17 As a consequence of cellular senescence, the organisms age and become 
susceptible to age-associated diseases. Paradoxically, the accumulation of senescent 
cells with age, which is believed to result from an inefficient clearance by the immune 
system, might also help delay tissue dysfunction through cell loss. Recently, however, 
it was shown that removal of senescent cells expressing the cyclin-dependent kinase 
inhibitor p16INK4A in genetically modified mice (INK-ATTAC mice) leads to a prolonged life 
and health span18, supporting a fundamental role for cellular senescence in aging. The 
mechanisms through which removal of senescent cells leads to these effects remain to 
be elucidated.
3. GENOMIC INSTABIlITy AS A CAuSAl fACTOR IN VASCulAR AGING: 
EVIDENCE IN huMANS
There is ample evidence that genomic instability is involved in vascular aging in hu-
mans. The following section highlights the observations that have accumulated until 
the present.
3.1. Cardiovascular Disease in Progeria Syndromes
The role of DNA damage in aging is further highlighted in human progeria syndromes. 
Human syndromes of progeria arise from mutations in genes involved in genomic 
maintenance in at least 75% of the known cases.19 Progeria syndromes provide a unique 
opportunity to study aging, but it should be noted that they are not a complete pheno-
copy, e.g., progeria patients show phenotypes that are rare during normal aging, such 
as clavicular agenesis in Hutchinson-Gilford progeria syndrome or the intensified risk of 
cancer in Werner syndrome.20 The relation of progeria to normal aging remains debat-
able.
Despite this continuing debate, it is intriguing to observe that several progeria syn-
dromes manifest severe, juvenile cardiovascular disease. Werner syndrome (WS) is char-
acterized by the premature onset of clinical signs of aging, such as cancer, osteoporosis 
and cardiovascular disease (diabetes mellitus type II and atherosclerosis).21 WS is caused 
by a WRN (Werner) gene mutation. WRN encodes a DNA helicase protein, Escherichia 
coli recQ-like helicase L2 (RECQL2), which is involved in DNA recombination, replication, 
15
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repair and transcription, and also in telomere maintenance.22 WS patients develop a 
considerable burden of atherosclerotic plaques in the coronary arteries and the aorta; 
calcification of the aortic valve is also frequently observed. Consequently, most WS 
patients die during middle age (average life expectancy is 46 years) due to myocardial 
infarction and stroke.21 A related disease called Bloom syndrome, a consequence of 
mutation of the RecQ helicase gene BLM, features telangiectasias (dilated blood vessels 
in the skin), but the function of blood vessels has not been extensively investigated, al-
though the occurrence of diabetes in these patients might be an important confounder 
in such investigations.23
Hutchinson-Gilford progeria syndrome (HGPS), perhaps the best-known progeroid 
disorder, is characterized by hair loss, pain in the joints, wrinkled skin, and cardiovascular 
problems.24 HGPS is caused, in most patients, by a point mutation in the lamin A gene 
(LMNA), which encodes the A-type nuclear lamins. The mutant lamin A, called progerin, 
remains fixed to the nuclear envelope causing various cellular changes, such as irregular 
nuclear shape and disorganization of heterochromatin, that lead to abnormal regulation 
of gene expression, therefore inducing premature aging. Death occurs around the age 
of 13 years mostly due to myocardial infarction or cerebrovascular events; however, in 
contrast to typical human aging or WS, atherosclerosis is very rare. Instead a major loss 
of vascular smooth muscle cells (VSMCs) in both big and small arteries is observed.25 
Interestingly, accumulation of prelamin A was observed in medial VSMCs and in ath-
erosclerotic lesions from normally aged individuals. Moreover, prelamin A colocalized 
with β-galactosidase-positive VSMCs, i.e., senescent VSMCs, and thus prelamin A was 
proposed as a marker of vascular aging in the general population.26
Excision repair cross-complementation group 1 (ERCC1)-xeroderma pigmentosum 
(XP) F is a structure-specific protein complex serving as an endonuclease that partici-
pates in the repair of several types of DNA lesions, mainly bulky, helix-distorting lesions 
that are repaired by the NER pathway, but also double-strand breaks and interstrand 
cross-links.27-29 Progeroid syndromes arising from ERCC1-XPF mutations, often unique 
cases as each of the mutations found until now has been encountered in individual 
patients, have been repeatedly reported as being characterized by hypertension.30 This 
is further accompanied by frailty, loss of subcutaneous fat, liver dysfunction, vision and 
hearing loss, renal insufficiency, bone marrow degeneration, and kyphosis.31 Although 
the hypertension observed in this syndrome might point at accelerated vascular aging, 
this still needs to be confirmed, certainly if one takes into consideration the presence of 
renal insufficiency in the patients suffering from this type of syndrome.
For other progeroid syndromes related to mutations in genomic DNA repair en-
zymes, data concerning vascular function are not available. It is uncertain whether this 
is an indication for the absence of vascular aging. Rather, more prominent problems in 
other organ systems or a focus on increased susceptibility to cancer might mask the 
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presence of cardiovascular problems. In general, the patients are very frail, and cases 
are rare. Extensive cardiovascular characterization of such patients is, therefore, a very 
challenging task, and perhaps even not without risk for the patients themselves.
3.2. Indicators of a Role of Genomic Instability in the General Population
The role of genomic instability in disorders of the vasculature or the consequences 
thereof is a question that becomes increasingly important for the general population. If, 
indeed, this mechanism is central in age-related cardiovascular disease, there are major 
implications for prediction and detection and prevention. Research on the role of ge-
nomic instability in cardiovascular risk prediction opens a new window into expanding 
our understanding of the pathophysiology and causative risk factors in age-related dis-
eases.8 The use of emerging markers of DNA damage, identified in vascular and cardiac 
ischemic cells, has provided evidence for this role.32 Part of the evidence comes from 
studies assessing the effect of ionizing radiation. An increased amount of circulating 
cell-free DNA and mitochondrial DNA (mtDNA) fragments has been observed in subjects 
exposed to low levels of ionizing radiation, suggesting the possible role of circulating 
DNA as a relevant biomarker of cellular damage.33 In turn, it has been established that 
there is an association between radiation exposure and indicators of accelerated vascular 
aging, coronary artery disease and stroke in occupationally exposed groups. Andreassi 
et al. observed that long-term, low level radiation exposure is positively correlated to 
early atherosclerosis, as identified by increased subclinical cIMT (carotid intima media 
thickness), and to telomere shortening, an indicator for genomic instability.34 This study 
also concluded that subjects with the Thr241Met polymorphism in the XRCC3 gene 
(gene coding for X-ray repair cross-complementing protein 3) have a greater susceptibil-
ity to radiation-induced vascular effects. Data of the Life Span study showed that people 
who had received an acute single dose of 1–2 Sv (sievert) had a significantly increased 
risk of mortality from myocardial infarction after 40 years of radiation exposure.35 Other 
evidence is provided by observation of DNA damage markers in vascular tissue and 
circulating cells. Several groups observed elevated levels of oxidative DNA damage in 
human atherosclerotic plaques compared to non-atherosclerotic vessels or in circulat-
ing cells of persons with arterial disease 36, 37. Likewise, several proteins involved in DNA 
repair including DNA-dependent protein kinase (DNA-PK), poly (ADP-ribose) polymerase 
1 (PARP-1), p53, and Apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE-1/Ref1), 
were up-regulated in plaques of carotid endarterectomy specimens compared with non-
atherosclerotic arteries.36 On the other hand, genetic association studies have shown a 
significant association of single nucleotide polymorphisms (SNPs) in NER-related genes 
with age-related vascular phenotypes. In the population of the AortaGen Consortium, 
comprising 20,634 participants from nine cohort studies, Durik et al. identified an asso-
ciation of the SNP rs2029298 (p-value: 1.04 × 10−4) in the Damage-Specific DNA Binding 
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Protein 2 (DDB2) gene with carotid-femoral pulse wave velocity, a measure of vascular 
stiffness.38 In addition, suggestive associations were found for eight SNPs located within 
or near ERCC5, ERCC6, general transcription factor IIH (GTF2H) subunit 1 and 3 (GTF2H3, 
GTF2H1), and ERCC2.38 Verschuren et al. showed, in data from the GENDER (GENetic 
DEterminants of Restenosis) and PROSPER (Patient-centered Research Into Outcomes 
Stroke Patients Prefer and Effectiveness Research) studies comprising 6110 coronary 
artery disease (CAD) patients in total, that genetic variations in the NHEJ repair system 
are associated with risk for CAD.39 In addition, several smaller studies have shown asso-
ciations between polymorphisms in single DNA repair genes and risk of coronary artery 
disease, as reviewed elsewhere.40 Interesting to note is also the finding that statins were 
found to improve DNA damage detection, which might be a mechanism leading to the 
improvement of atherosclerosis next to the reduction of lipids and oxidative stress.41, 42
3.3. Telomere Shortening
Human chromosomes are normally capped by telomeres that protect the end-segment 
of chromosomes between cell divisions. Since telomeres do not fully replicate during 
mitosis, they gradually become shorter as individuals age.43 Defects in telomerase activ-
ity, abnormalities in DNA polymerase to synthesize terminal ends of the DNA, and the 
inhibition of the sheltering component telomeric repeat-binding factor 2 (TRF2) leads 
to an accelerated velocity of telomere shortening between cell divisions, which induces 
cellular senescence when the telomere reaches a critical length.43 Telomere shortening 
promotes chromosome end fusion, chromosomal abnormalities and aneuploidy, sug-
gesting that loss of chromosome end protection is correlated to genome instability.44 
Studies using knockout mouse models have established that the targeted deletion 
of 53BP1 and TRF2 genes is one of the main mechanisms involved in double-strand 
breaks and an increase of non-reciprocal translocations caused by telomere shorten-
ing.45 In addition, RNA template of telomerase (TERC)−/− and high mobility group box 
1 (HMGB1)−/− mice exhibit a reduced/null telomerase activity and telomere dysfunc-
tion, triggering aging-like cellular changes.46, 47 Population-based studies suggest that 
telomere shortening plays a role in the onset of vascular aging-related phenotypes. 
Individuals with a shorter mean telomere length exhibit a two-fold risk of abdominal 
aortic aneurysm compared to those with a higher telomere length (odds ratio = 2.30, 
p = 0.005).48, 49 Moreover, an association between telomere shortening and the follow-
ing CVD risk factors has been found: atherosclerosis, arterial stiffness (as measured by 
carotid-femoral pulse wave velocity), smoking, insulin resistance, type 1 and type 2 dia-
betes, obesity, hypertension and up-regulation of the renin–angiotensin–aldosterone 
system.50-57 Likewise, an increased level of telomere shortening, via increased oxidative 
DNA damage, has been identified in circulating endothelial progenitor cells (EPC) in CAD 
patients with metabolic syndrome.58 These observations suggest that oxidative stress-
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induced telomere shortening in EPC may accelerate vascular dysfunction, promoting 
the onset and progression of CAD due to a lack of vascular repair.58 Despite the fact that 
the association of telomere shortening with aging and vascular-related disorders has 
been demonstrated, its potential use as a biomarker of age-related diseases remains 
unclear.59-61
3.4. Cyclin-Dependent Kinase Inhibitor 2 (CDNK2) A and B
Further exploring the role of genomic instability–induced cellular senescence in vascular 
aging, gene variations in senescence regulators have been associated with age-related 
vascular disease in humans. Several studies have provided insight about the risk associa-
tion of the 9p21 locus with aging-related cardiovascular diseases such as atherosclerosis 
and aortic aneurysm.62 This chromosomal region codes for two cyclin-dependent kinase 
inhibitor genes, CDKN2A, comprising codes for p16INK4A and p14ARF (p19ARF in mice), and 
CDKN2B, coding for p15INK4B. These CDKs are key molecules involved in the regulation 
of cellular replication, among others in vascular cells.63 Genetic polymorphisms in this 
chromosomal region have indicated that 9p21 variation has a significant influence in 
the genetic expression of CDKN2A and CDKN2B in VSMCs, which could increase the sus-
ceptibility to CAD.64 In addition, differential expression of CDNK2A and CDNK2B has been 
observed in senescent cells in vitro and in aging tissues of rodents and humans.65 Thus, 
the measurement of the expression of these genes has led to their use as a potential 
biomarker of biological age.66 Most of the studies have determined the role of CDNK2A 
and CDNK2B in aging by focusing on human tumors, concluding that the deletion and 
silencing of the CDKN2A–CDKN2B locus are among the most frequent genetic events 
found in human cancer cells.67 Thus, CDNK2A and B play a central role in diseases of 
aging.
4. GENOMIC INSTABIlITy AS A CAuSAl fACTOR IN VASCulAR AGING: 
EVIDENCE fROM ANIMAl MODElS
4.1. Telomerase-Deficient (TERC−/− and TERT−/−) Mice
Telomerase-deficient mouse models have been developed by knocking out TERC, TERC−/− 
mice, or the telomerase reverse transcriptase (TERT−/− mice). Homozygous TERT−/− and 
TERC−/− mice display short telomeres and a similar phenotype, but the TERC−/− mice have 
been studied more comprehensively. The telomeres of the TERC−/− mice shorten at a rate 
of ~5 kb in every subsequent generation (G). In conscious TERC−/− mice, higher systolic 
blood pressures were observed in mice from G1 compared with wild-type mice, whereas 
in G3 mice, both systolic and diastolic blood pressures were increased compared with 
wild-type and G1 mice.68 The differences in blood pressure between TERC−/− and wild-
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type mice appear to be caused by an increased production of endothelin-1 in the 
TERC−/−.68
4.2. Mouse Models of Genomic Instability Associated with human Progeria
Different mouse models of WS have been developed with either a complete knockout 
of the WRN protein, the transgenic expression of human WRN lacking helicase activity, 
or the in-frame deletion of the helicase domain. Depending on the model studied, the 
extent of the aging phenotype varies. The models lacking RecQ helicase activity show 
increased genomic instability and have increased visceral fat, high fasting triglycerides 
and cholesterol levels, insulin resistance and hyperglycemia.69 Telomere shortening ap-
pears to be pivotal in the development of some of these metabolic changes70, which are 
relevant analogues for human cardiovascular risk factors. In these models no vascular 
problems were reported, except, perhaps, decreased wound healing, which might 
implicate worsened angiogenesis.
A mouse model of HGPS expressing human progerin showed aberrations that were 
largely restricted to the vascular system. Recapitulating the vascular phenotype seen 
in patients with HGPS, these mice exhibited an increasing loss of VSMCs in the lamina 
media of large arteries.71 Those changes were accompanied by a reduced vasodilator re-
sponse to the NO donor sodium nitroprusside. Interestingly, the endothelium is initially 
undamaged, but with progression of the vessel damage, some loss in the endothelium 
is observed in 12-month-old mice.71
Mice lacking proper function of the versatile DNA repair enzyme ERCC1 show many 
features of accelerated aging. Ercc1−/− mice display a severe aging phenotype featur-
ing frailty, osteoporosis, neurodegeneration, atrophic epidermis, sarcopenia, liver and 
kidney dysfunction and bone marrow degeneration.72 Ercc1−/− mice only live four weeks, 
while mice with reduced ERCC1 function due to a combined exon 7 deletion allele and 
a null allele (Ercc1d/−, Ercc1−/Δ7 or Ercc1Δ/−) live longer (up to 30 weeks). The Ercc1Δ/− mice 
are healthy up to an age of eight weeks, when they start developing a gradual aging 
phenotype. In our previous study we found that Ercc1Δ/− mice had an increased systolic 
blood pressure compared to wild-type mice.38 They also display a decreased vasodilator 
response in their microvasculature.38 Microvascular function was assessed by hind leg 
reactive hyperemia using a laser Doppler technique, which measures superficial resis-
tance vessels and possibly represents both endothelium-dependent and endothelium-
independent relaxations.73-75 Those microvascular changes resemble the ones seen 
in aged rodents as well as in humans, and, strikingly, these changes in humans are at 
least partly independent of classical cardiovascular risk factors.73, 76 Another important 
characteristic of the human vascular aging phenotype that was recapitulated in the 
Ercc1Δ/− mice includes greater stiffness, as measured by pressure-diameter relationships 
in the carotid arteries.38 While aortic tissue from Ercc1Δ/− contains increased amounts of 
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senescent cells, the contribution of cellular senescence to vascular dysfunction remains 
uncertain.38
Other genetic models add to the evidence, linking vascular senescence with vas-
cular pathology and disease. Mice carrying the human XPD R722W mutation, so-called 
XpdTTD mice, show signs of accelerated vascular aging. In humans, the mutation in XPD 
causes trichothiodystrophy (TTD) which is characterized by postnatal growth failure, 
UV sensitivity, neurological degeneration, cachexia, osteoporosis and a shortened life 
span.77 The XpdTTD mice show a similar phenotype, but the onset and severity of progeria 
is slower compared to Ercc1Δ/− mice. We assessed vascular function in XpdTTD mice at 26 
and 52 weeks and observed significantly reduced vasodilator responses to acetylcholine 
in aortic rings at 52 weeks compared to 26-week-old XpdTTD and wild-type mice.38
4.3. Mitochondrial DNA Maintenance Defects
ApoE-deficient mice lacking protein kinase ATM (ataxia telangiectasia mutated), a 
protein pivotal in DNA damage detection, showed accelerated development of athero-
sclerosis.78 This was attributed to increased mtDNA damage leading to malignant meta-
bolic changes. Further exploring the involvement of DNA (mtDNA), polymerase gamma 
(POLG) performs DNA synthesis inside the mitochondria, and thus mutations in POLG 
cause mitochondrial disorders. A mouse model with an mtDNA mutator phenotype, 
conferred by a homozygous mutation in POLG, has been used to study the role of mito-
chondrial function and aging. In early adulthood the POLG mutant mice develop many 
features of premature aging such as weight loss, reduced subcutaneous fat, kyphosis, 
osteoporosis, cardiomyopathy and a reduced life span.79 Oxidative stress and respiratory 
chain dysfunction due to the accumulation of mtDNA point mutations in protein-coding 
genes of the respiratory chain complexes are considered to contribute to the premature 
aging phenotype of the POLG mutator mice. Using a double POLG/ApoE low-density 
lipoprotein (LDL) receptor knock-out, it was shown that instability of mtDNA might 
contribute to atherosclerosis. POLG−/−/ApoE−/− mice had increased atherosclerosis in the 
brachiocephalic artery and descending aorta as compared to POLG+/+/ApoE−/− controls. 
The POLG−/−/ApoE−/− mice also exhibited reduced body weight, reduced fat mass, hyper-
lipidemia and apoptosis of VSMCs.80 Apart from vascular effects, POLG mutant mice de-
velop cardiac hypertrophy and dilatation, impairment of systolic and diastolic function, 
and increased cardiac fibrosis within 13 months of age.81 Overexpression of catalase in 
the mitochondria of these mice attenuated the malignant cardiac phenotype, providing 
evidence for the role of oxidative stress in the development of cardiomyopathy due to 
mtDNA instability.
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4.4. BubR1 Knockout
The spindle assembly checkpoint protein BubR1 has an important role in the mainte-
nance of genomic stability by ensuring the correct microtubule-kinetochore attachment 
and segregation of chromatids during mitosis.82
Mice with reduced expression of BubR1 (10% of normal levels) develop progressive 
aneuploidy and exhibit a vascular aging phenotype characterized by reduced arte-
rial elasticity, a reduced number of VSMCs, loss of endothelial-dependent relaxation, 
and increased production of superoxide anions. Apart from problems reminiscent 
of cardiovascular aging, BubR1 mice also show a variety of progeroid symptoms.83, 84 
Also, naturally aged wild-type mice have decreased BubR1 expression in different tis-
sues, suggesting that BubR1 may be a regulator in normal aging.18, 27, 83, 84 Clearance of 
p16INK4A-positive senescent cells with the INK-ATTAC strategy in BubR1 progeroid mice 
ameliorates several of the progeroid hallmarks. However, the cardiovascular problems 
are not rescued, which corresponds with the observation that these features are 
p16INK4A-independent in this model.85 Importantly, vascular aging in ERCC1-defective 
mice appears to be associated with p53- and p21Cip1 (or p21Waf1)-related senescence,8, 38 
and this might further explain the ineffectiveness of removing p16-positive cells to im-
prove cardiovascular function in BubR1 mice. Interestingly, it was recently shown that 
clearance of p16INK4A-positive senescent cells in non-progeroid mice increases the life 
span and reduces cardiac stress sensitivity.18, 85 This indicates that cellular senescence 
is indeed involved in deleterious cardiovascular phenotypes, involving both p16INK4A as 
well as p53- and p21-related senescence in a differential way.
4.5. Vascular functional/Pharmacological Changes Due to Genomic Instability
4.5.1. NO-cGMP Signaling
NO is a key participant in many physiological pathways such as vasodilation, neuro-
transmission, and macrophage-mediated immunity. In the vascular endothelium, NO is 
produced from the substrate l-arginine by the enzyme eNOS (or nitric oxide synthase 
type III). The eNOS is activated by increased cytoplasmic Ca2+ levels, as induced, among 
others, by binding of vasodilatory (neuro)hormones to their G protein-coupled recep-
tors.86 Evidence provided up to date suggests that there is a reciprocal relationship 
between defective eNOS activity and genomic instability. During vascular aging, there is 
an increased production of ROS.87 This ROS can be partly produced by eNOS, when the 
enzyme is in a so-called uncoupled state due to a reduced expression of the cofactor 
tetrahydrobiopterin (BH4), as has been shown in aging rats.88 ROS coming from this and 
other sources, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
or mitochondria, react with NO to form harmful free radicals, including peroxynitrite 
(ONOO−) and N2O3. The overproduction of ROS not only leads to a gradual reduction 
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of NO bioavailability in the vasculature, but in addition can cause single-strand DNA 
breaks, 7,8-dihydro-8-oxoguanine and other oxidative lesions.89
The aberrant eNOS function is closely associated with dysfunction as observed 
in aged and diseased blood vessels. In eNOS−/− mice, systemic hypertension, altered 
vascular remodeling, dysfunctional angiogenesis and a prothrombotic phenotype 
have been observed.90-94 In human atherosclerosis, eNOS mRNA expression was shown 
to be decreased in endothelial cells of advanced atherosclerotic plaques, which is ac-
companied by overt DNA damage.36 In addition, eNOS uncoupling has been reported 
in patients with endothelial dysfunction as a consequence of diabetes, hypertension, 
hypercholesterolemia and smoking, linking the mechanism to classical risk factors.95
Apart from a potential role of eNOS dysfunction in the production of DNA lesions, 
genomic instability itself causes dysfunction of NO signaling. Organ bath studies and 
molecular analyses in Ercc1Δ/− mechanistically explained the decreased vasodilator 
responses.38 These experiments showed that NO-mediated responses, eNOS expression, 
and eNOS activation through phosphorylation serine 1177 were decreased. Increased 
generation of ROS, a central mechanism in age-related decreased NO-dependent va-
sodilation, was partly responsible for the diminished vasodilation in Ercc1Δ/− mice since 
anti-oxidants such as N-acetylcysteïne and BH4 improved vasodilation.38 Therefore, 
faulty eNOS activation and genomic instability appear to form a vicious circle leading to 
progressive endothelial dysfunction and accelerated vascular aging (Figure 3). In paral-
lel to endothelial dysfunction, Ercc1Δ/− mice show impaired VSMC function but whether 
the ERCC1 functional mutation has effects downstream of NO production (i.e. in cGMP 
responsiveness or metabolism in VSMCs), and whether this occurs at the level of cGMP 
generation by soluble guanylyl cyclase (sGC), protein kinase G Iα responsiveness to 
cGMP or cGMP metabolism by phosphodiesterases (PDEs) remains an important ques-
tion in relation to therapeutic options (Figure 3).
5. PERSPECTIVES
5.1. Directions for future Studies Establishing the Role of Genomic Instability
Although the evidence summarized above strongly indicates a major role of genomic 
instability in vascular aging, important questions remain to be solved. Firstly, there is 
the question as to whether the accelerated vascular aging features that are observed 
are due to local vascular processes, or whether they are the consequence of the gen-
eral accelerated deterioration in mouse models of genomic instability. Tissue-specific 
inactivation of DNA repair enzymes is a means to explore this question. To this end, 
endothelial cell- and VSMC-specific Cre recombinase strains and mouse strains with 
Plox sites in DNA repair genes of interest are available, but still need to be combined. 
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Furthermore, the mechanisms that are the interface between genomic instability and 
derailment of vascular signaling systems need to be resolved. Cellular senescence has 
been mentioned as an option, but apoptosis is also a candidate mechanism. The role of 
cellular senescence vs. vascular cell apoptosis in vascular aging remains an important 
question. Although previously discussed mouse studies provide compelling evidence, 
the role of cellular senescence in vivo in human aging remains unclear, mostly due to 
the absence of specific biomarkers that can provide information about the state of cells 
in tissues.96 Restricting this to vascular aging, no conclusive evidence for a causal role of 
cellular senescence in vascular aging, let alone that induced by genomic instability, has 
been published yet. The aforementioned results in INK-ATTAC models on a wild-type 
mouse background, and in ERCC1-defective mice, are, however, highly indicative 18, 38. 
Models combining constructs to eliminate senescent cells in a background of vascular-
specific genomic instability are putative tools to further establish this mechanism.
Another mechanism could be stem cell exhaustion, which requires comprehensive 
analysis of vascular cell progenitors in mice with increased genomic instability. In ERCC1-
deficient mice, reduced hematopoietic progenitor cell reserves have been observed.97 
Since hematopoietic cells generate vascular progenitor cells98, there is indeed a motive 
to explore this possibility.
Whether genomic instability in nuclear DNA outside of telomeres mediates vascular 
dysfunction through mutations or transcriptional dysfunction as caused by DNA lesions 
is a most important question that remains to be explored (Figure 1). Since DNA lesions 
have been repeatedly reported (see above), this is a very realistic option.
5.2. Towards New Interventions in Vascular Aging Caused by Genomic 
Instability
The awareness that genomic instability and cellular senescence arising thereof play a 
key role in general and in vascular aging opens new possibilities to prevent age-related 
cardiovascular disease. In particular, life-extending therapies that have been identified 
thus far are candidate interventions to decelerate vascular aging. In addition, interven-
tions that prevent vascular genomic instability or readily improve NO-cGMP signaling 
are eligible for such purposes. We delineate the various options here.
5.2.1. Rapamycin, mTOR and Autophagy
During aging, increasing dysfunction related to a progressive failure of maintenance 
and repair pathways takes place as aberrant macromolecules, dysfunctional organelles 
and DNA damage may accumulate in cells and tissues.99 Therefore, cellular maintenance 
mechanisms are crucial to preserve normal cellular functions. Autophagy, one of the 
main cellular preservation processes, is involved in the degradation of long-lived pro-
teins and dysfunctional organelles as well as in the maintenance of the cell in case of 
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failure of macromolecule repair.100 With age the rate of autophagy and protein degra-
dation declines.101, 102 Importantly, genetic ablation of Atg7, an important mediator of 
autophagy, causes an accelerated appearance of vascular aging hallmarks in mice.103 
Autophagy-modifying drugs, such as rapamycin, inhibit the mammalian target of 
rapamycin complex 1 (mTORC1) and control the activation of autophagy-related sig-
naling pathways. Rapamycin (also known as sirolimus) increases longevity and delays 
pathological lesions in mice.104 Furthermore, the therapeutic use of rapamycin or related 
drugs prevents age-related diseases such as cancer and cardiovascular diseases in ani-
mal models.105, 106 In addition, the pleiotropic anti-atherosclerotic effects of rapamycin 
have allowed the implementation of rapamycin-based therapies to prevent or delay 
the pathogenesis of atherosclerosis.107 Further, it has been reported that rapamycin 
improves endothelium-dependent vasodilation in old rodents.108 A potential beneficial 
effect of mTOR inhibition on vascular aging independent from autophagy regulation 
was proposed.109 This effect would be based on the regulation of a signaling network, 
consisting of mTOR, adenosine monophosphate-activated protein kinase (AMPK), and 
sirtuin (SIRT)-1. In this model, mTOR inhibition, in concert with SIRT-1 and AMPK activa-
tion, would counteract age-related vascular dysfunction thanks to modulation of the 
common transcription factors NFκB, FoxO and p53, that, when integrated, determine 
stress resistance, inflammation, ROS production, NO signaling, genomic instability 
and cellular senescence. Apart from this link to genomic instability and senescence, it 
has been found in a mouse model of Hutchinson-Gilford progeria that AMPK activa-
tion and mTOR inhibition occurs in conjunction with activation of autophagy.110 Thus, 
models of genomic instability appear to implicate the proposed mTOR–AMPK signaling 
interaction, with a link to the regulation of autophagy (Figure 2). However, the effect on 
vascular aging as based on genomic instability remains to be explored.
Discouraging the use of mTOR inhibition is the fact that rapamycin significantly 
attenuates both endothelial function and the expression of eNOS in human endothelial 
cell lines in vitro, although it does not cause endothelial cell death.111 Studies with mTOR-
inhibiting drugs, among others applied on coronary stents in patients with advanced 
arterial aging, have reported deleterious effects of such drugs on various variables of 
endothelial (dys)function, although conflicting results are abundant.112-116 It is unclear 
whether the conflicting results are dependent on the concentration of the mTOR in-
hibitor to which the endothelial cells are exposed, which presumably is very high in 
the case of drug-eluting stents. Although in cultured endothelial cells the increasing 
anti-inflammatory effect of increasing concentrations of mTOR inhibitors parallels the 
increasing cytostatic effect,117 this issue needs further inspection. We have also shown 
that rapamycin actually induces PAI-1 expression in cultured endothelial cells and in vivo 
in mice,118 so the net benefit of this drug in preventing senescence may be mixed at best.
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In summary, mTOR inhibition, on the one hand, seems to be an attractive hypotheti-
cal option to reduce vascular aging in relation to genomic instability, but the idea should 
be approached cautiously.
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figure 2. Molecular eff ectors of genomic instability that contribute to vascular aging, and the potential 
remedies (center of the chart) against that currently under development. Senescence, imbalanced NO vs. 
ROS production, infl ammation and changes in insulin signaling are detrimental when present while au-
tophagy, apoptosis and stress resistance have a benefi cial contribution to vascular aging. IGF-1 putatively 
has a detrimental eff ect, although this needs further scrutiny (Ref. [8]). Pointed arrows indicate stimulatory 
processes, while blunted arrows indicate inhibitory processes.
5.2.2. Senolytics and Inhibitors of Senescent Cell Signaling
Cellular senescence and the overproduction of SASP-associated proteins, also referred 
to as the senescence-messaging secretome (SMS), contributes to local and systemic dys-
function and disease. Therefore, the implementation of “senolytic” therapies has been 
approached as an intervention to specifi cally target senescent cells (Figure 2), eliminate 
them, and thus diminish the contribution of SASP and SMS.119 The use of senolytic drugs 
including dasatinib and quercetin has been eff ective in eliminating senescent primary 
mouse embryonic fi broblasts and senescent human fat cell progenitors. In vivo, the 
combination of these drugs reduced senescent cells in normal aged, radiation-exposed 
mice, and in Ercc1Δ/− mice.119 In addition, this study showed that periodic drug admin-
istration extended the health span in Ercc1Δ/− mice and delayed age-related symptoms 
and pathology, osteoporosis, and loss of intervertebral disc proteoglycans. Despite the 
evidence suggesting that interventions that reduce the number of senescent cells could 
mitigate age-related tissue dysfunction, the burden of cell senescence biomarkers and 
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SASP needs to be further studied and validated in humans. Therefore, the implementa-
tion of new therapies to reduce senescent cell number and SASP must be characterized.
Pioneer results from our group showed for the first time that modulation of the SMS 
can actually prevent the development of senescence in kl/kl mice, a mouse model of 
accelerated aging.120 In addition to contributing to the molecular fingerprint of senes-
cence, plasminogen activator inhibitor-1 (PAI-1) is essential and even sufficient for the 
induction of replicative senescence in vitro and is a critical downstream target of the 
tumor-suppressor p53.121, 122 The contribution of PAI-1 to cellular senescence is broadly 
relevant in the organism as a whole, and age-dependent increases in plasma PAI-1 levels 
have been identified in wild-type mice as they age, in murine models of accelerated 
aging (Klotho and BubR1H/H), and in humans.18, 123, 124 We observed that forced decrease 
of PAI-1 attenuated levels of the SMS factors insulin-like growth factor-binding protein 3 
(IGFBP3) and interleukin-6 in plasma of kl/kl mice to levels seen in wild-type (WT) mice. 
In addition, telomere integrity was partially protected in numerous tissues. Furthermore, 
the nuclear accumulation of the senescence marker p16INK4A was prevented. Similar 
observations were made in another aging-related model.125 It is important to note that 
IGFBP3 is also strongly affected in DNA repair-defective progeroid models, as are other 
components of the IGF-1 growth factor signaling pathway, placing this pathway in the 
center of genomic instability-related (vascular) aging.8, 126 Moreover, this link raises the 
exciting possibility that PAI-1 might be involved in genomic instability-related vascular 
aging (Figure 2). As a still remote possibility, PAI-1 might act as part of the SMS from cells 
that become senescent due to unrepaired DNA damage, thus transmitting a harmful 
signal to cells in which the genomic integrity is still warranted (Figure 3). Application 
of genetic or pharmacological inhibition of PAI-1 in models of genomic instability is 
therefore an attractive approach to test this hypothesis.
5.3. Dietary Restriction
In search of treatment perspectives, it is of course important to consider more general 
anti-aging and longevity-increasing interventions. Apart from the previously discussed 
possibility to employ rapamycin against vascular aging, dietary restriction (DR) is per-
haps the most important and well-known option. DR is a reduction of intake of food to 
the level that it results in low-normal levels of energy intake while avoiding malnutri-
tion.127 Claims of an effect of diet restriction on longevity date back as far as 3000 years. 
Studies that have taken place over many decades over the last century indeed confirm 
such an effect in various species, including yeast, worms, flies, spiders, rotifers, fish and 
rodents, demonstrating that DR is the most effective intervention to slow down aging 
and extend life expectancy.128-134
DR is known also to protect against age-related cardiovascular disease. Two main 
mechanisms can be involved: (1) reduction of the intake of harmful food, such as carbo-
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hydrates and polysaturated fats;135, 136 or (2) slowing down of the aging process itself. It 
has been shown that chronic DR improves the aging-related rise of blood pressure and 
vascular wall remodeling, as shown in rodents.137, 138 This eff ect can be attributed to the 
improvement of vascular relaxation, a consequence of decreased ROS and increased NO 
bioavailability. In addition, DR has been reported to attenuate cardiovascular disease in 
nonhuman primates.139, 140
It is not clear what the main mechanisms of the anti-aging eff ect of DR are. However, 
the reduction of genomic instability is a possibility. In a previous review we discussed 
that eff ects on oxidative stress-induced DNA and macromolecular damage are a puta-
tive mechanism.8 Reports have shown a possible eff ect of specifi c nutrient restriction 
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figure 3. The role of genomic instability (indicated by yellow stars) on NO-cGMP signaling, and its con-
sequences for age-related cardiovascular disease. Large, blue closed arrows indicate established relation-
ships: genomic instability primarily leads to endothelial eNOS dysfunction in endothelial cells (Section 
4.5.1). Large, blue open arrows refer to proposed mechanisms that were not fully explored: cellular senes-
cence caused by unrepaired DNA could aff ect healthy cells through SASP/SMS (Section 5.2.2.). The aff ected 
cells in turn might worsen vascular function through changes in eNOS-cGMP signaling. PDE1 subtype in-
hibitors and guanylyl cyclase (GC) stimulators are promising drugs to at least acutely improve vascular 
function. Their value for prevention of genomic instability and vascular aging needs to be assessed. PDE1A 
and 1C have a putative role in atherosclerosis, arteriosclerosis, reduced blood fl ow and hypertension (see 
Section 5.4). The role of both PDE1 subtypes in aging-related vasomotor dysfunction remains to be studied. 
Small, thick arrows pointing up or down indicate up- and down-regulation respectively. Blunt arrows indi-
cate inhibition, pointed thine arrow indicate stimulation.
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and of caloric restriction on markers of DNA damage and DNA repair capacity, and a 
plethora of publications regarding the association between food consumption and 
telomere length is available.141-144 This observation pleads for evaluation of the effects of 
DR on the general and vascular aspects of aging in models of genomic instability. Alter-
natively, effects on IGF-1/ growth hormone (GH) signaling, SIRT-1 and nutrient-sensing 
pathways might be at play (Figure 2).8 Since IGF-1/GH signaling is suppressed both 
after DR and in mouse models of genomic instability, this pathway apparently shares a 
common function in DR and the survival response in progeroid mice. Mouse models in 
which GH signaling is intentionally knocked out display increased longevity, and share 
features of the genetic program with genomic instability models.126 Therefore, IGF-1/GH 
suppression is a point of convergence between DR, genomic instability and longevity. 
Whether this convergence takes place after genomic instability to improve survival, 
contributes to improved genomic integrity, as proposed above, or both remains to be 
elucidated. The effect of dietary restriction therefore needs to be explored in models of 
genomic instability, importantly those involving evaluation of vascular aging. The role of 
altered GH vs. IGF-1/insulin therein on vascular function needs special attention as these 
pathways appear to have opposite effects, as previously explained.8
We here propose that the aforementioned relationship with mTOR and AMPK might 
also be important in DR effects (Figure 2). There is evidence that DR deactivates the 
mTOR-dependent signaling pathways, slowing aging and delaying aging-related dis-
eases.145 This suggests that DR and rapamycin can act together but have different effects 
on several pathways related to an increased longevity in young mice; therefore, the 
combination of both therapies could cause and exponential rise of lifespan in mice.146 It 
would be interesting to investigate if such an interaction also exists for the attenuation 
of vascular aging.
5.4. PDE Inhibition
An attractive aspect of PDE1 and 5 as drug targets is that there are several experimental 
and clinically approved drug candidates that might overcome the increased PDE activ-
ity. One is the selective PDE1 inhibitor IC86340, but unfortunately this drug appears not 
to be available anymore.147, 148 Other PDE1 inhibitors are under development.149 Further, 
there is the possibility to inhibit PDE5, or both PDE1 and 5. Sildenafil is a PDE5 inhibitor 
which also blocks PDE1 at high doses.150 Sildenafil was found to reduce both diastolic 
and systolic blood pressure in untreated hypertensive patients. However, due to Silde-
nafil’s short duration of action, research is focusing on new inhibitors such as tadalafil.151 
Vinpocetine is a PDE inhibitor with a preferential affinity for PDE1 over PDE5. Vinpocetine 
is an Food and Drug Adminstration (FDA)-approved nutriceutical and a registered drug 
in Eastern Europe, used to enhance cerebral blood flow and improve memory.152 PDE1 
inhibitors were also developed for the treatment of cognitive impairment associated 
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with schizophrenia.149 Such treatment inhibits injury-induced hypertrophy in human 
and rodent vessels, and decreases atherosclerosis in ApoE knockout mice.153, 154 There-
fore PDE1 inhibition is an attractive option for treating age-associated cardiovascular 
diseases. Until now, vinpocetine never found widespread application, for reasons that 
are unclear. Nevertheless, PDE1 inhibition has been identified as a potential drug target 
in atherosclerosis, and also in heart failure. In addition, this possibility should also be 
explored for DNA damage-induced decrease of VSMC relaxation, as explained earlier.
5.5. Reconsideration of Antioxidant Therapies
As explained above, ROS have been identified as a source of DNA damage, and therefore 
ROS scavenging is a potential treatment modality. Clinical studies applying ROS scaven-
gers (antioxidants) have, however, not resulted in benefits for patients suffering from 
cardiovascular diseases.155 Although this might be due to the fact that such interven-
tions might require the onset of intervention early in life, there is also a shortcoming in 
that the drugs might not reach the right place at the right time or even hamper healthy 
cellular signaling that is performed by ROS.156 A better targeted interaction of antioxi-
dant enzymes and ROS might overcome the latter shortcomings of exogenously applied 
ROS scavengers.
Nrf2 has been proposed as a “master regulator” of cytoprotective mechanisms and 
it could be associated with increased longevity and attenuating age-related diseases 
in mice.157 Therefore, Nrf2 gene regulation and the enhancement of the endogenous 
antioxidant capacity (Figure 2) could be an important therapeutic target to diminish 
the production of ROS, reducing DNA damage and their effects on vascular aging. Cer-
tainly, several drugs have been developed and tested to stimulate the bioavailability of 
NO through the regulation of the Nrf2/antioxidant response element (Nrf2/ARE). The 
combined action of NO and Nrf2/ARE signaling could improve vascular function and 
confer protection against vascular diseases.158 On the other hand, several alternatives to 
increase Nrf2 have been currently explored, including calorie restriction, ozone therapy, 
hyperbaric oxygen and physical exercise.159
5.6. Other vascular pathways potentially relevant in vascular aging 
5.6.1 The Renin-Angiotensin system
A potential mediator of blood pressure increase and decreased endothelium-dependent 
relaxation caused by DNA damage is activation of the renin-angiotensin system (RAS). 
The most prominent role of the RAS is considered to be blood pressure and fluid bal-
ance control; indeed, Angiotensin (Ang) II, the main bioactive hormone of this system, 
is strongly involved in hypertension, arteriosclerosis, vascular DNA damage and cell 
senescence, inflammation, oxidative stress, longevity and health span.160 Also, Ang II 
inhibits eNOS - NO - cGMP signaling.161
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A schematic overview of the RAS and clinically available pharmacological interven-
tions targeting this system is presented in Figure 4. Briefly, production of Ang II starts 
with angiotensinogen that is produced predominantly by the liver. Angiotensinogen 
is cleaved by renin to produce Ang I. Ang I is converted by angiotensin-converting en-
zyme (ACE) into Ang II, which can bind to either the Ang II type 1 (AT1 ) receptors or the 
Ang II type 2 (AT2 ) receptors. Signaling through the AT1 receptors has vasoconstrictive, 
pro-inflammatory and hypertrophic effects.162 For this reason the Ang II / AT1 receptor 
signaling is associated with hypertension, heart failure and renal failure. Interestingly, 
the Ang II / AT1 axis seems to be involved in aging of vascular smooth muscle cells and of 
endothelial progenitor cells.163 This evidence supports a role for Ang II / AT1 signaling in 
DNA damage related vascular dysfunction.
On the other hand, the effects of AT2 receptor stimulation in cardiovascular processes 
seem to be beneficial and include vasodilation and natriuresis. Besides AT2 effects, there 
is an endogenous pathway within the RAS called the ACE2/Ang-(1–7)/Mas receptor 
axis that counterregulates Ang II/AT1 effects. The ACE2/Ang-(1–7)/Mas receptor axis is 
antifibrotic, antiproliferative, natriuretic, vasodilatory, and endothelium-protective.164 
The RAS is affected by aging, but findings are contradictory. In general, it is believed that 
RAS activation plays a role in aging, and in age-related vascular dysfunction.165 Ang II, 
through ROS production, has also been reported to damage DNA.166 Nevertheless, the 
effect of DNA damage on RAS remains to be studied.
5.6.2 Endothelium-derived Hyperpolarization
In addition to the eNOS-NO-cGMP pathway the endothelium-derived hyperpolarization 
(EDH) pathway has a major contribution in the regulation of vasodilation. It is considered 
that while the eNOS-NO-cGMP pathway is more important in conduit vessels, EDH has 
a more prominent role in resistance vessels. EDH does not refer to one single molecule. 
Instead, several candidates have been proposed to act as EDH factors including the C-
type natriuretic peptide, lipoxygenases, arachidonic acid metabolites, potassium ions 
and H2O2. In general, EDH factors induce relaxation by activating small and intermediate 
calcium-dependent potassium channels.167
The importance of EDH is increased in certain conditions, such as in heart failure, 
essential hypertension and hypercholesterolemia, where a suppression of the eNOS-
NO-cGMP axis is observed. In these cases, preserved or upregulated EDH responses 
attenuate the consequences of impaired NO signaling. Moreover, part of the beneficial 
effects on the cardiovascular system achieved with interventions like ACE inhibition or 
PDE3 inhibition are due to enhanced EDH signaling.167 Hitherto it is not known how EDH 
is affected by DNA damage; although it has been reported that in murine saphenous 
arteries, the contribution of EDH to endothelium-dependent relaxations diminishes as 
the mice age.168
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6. SuMMARy
There is ample evidence that genomic instability is involved in vascular aging. Nuclear 
DNA lesions, among which is telomere erosion, and mitochondrial DNA damage are 
strongly associated with several main features of vascular aging, such as diminished va-
sodilator capacity and increased vasoconstriction, increased blood pressure, increased 
vascular stiffness and atherosclerosis. Pivotal cellular biological changes involved in 
these pathological features comprise cellular senescence, apoptosis, autophagy, stem 
cell exhaustion and altered proliferative capacity of vascular cells. The role of gene 
mutation and of compromised transcription remains unknown (Figure 1). Potential 
mediating signaling pathways involved include components of the survival response 
(Figure 1), notably antioxidants under regulation of Nrf2 (beneficial), increased inflam-
matory status (detrimental) and decreased IGF-1/GH signaling (detrimental), as well 
as the interplay between mTOR, AMPK and NFκB, SIRT-1, and PAI-1, p53- and p21- and 
p16-related signaling. Proposed remedies against genomic instability–related vascular 
aging include PAI-1 inhibition, mTOR inhibition, DR, senolytics, PDE1 and 5 inhibitors, 
drugs stimulating EDH and blockers of the RAS.
figure 4. Schematic overview of the Renin Angiotensin System and the clinically available interventions 
targeting the RAS. Renin cleaves Angiotensinogen to produce Angiotensin I which in turn is converted to 
Angiotensin II by the the Angiotensin-converting enzyme (ACE). Ang II can bind to AT1 or AT2 receptors. 
ACE2 can convert Ang I to Ang (1-9) and Ang II to Ang (1-7). Ang (1-7) then binds to the Mas receptor.
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 7. AIMS Of ThIS ThESIS
In this thesis the effect of DNA damage on the development of vascular damage is in-
vestigated. Also some potential interventions to treat the DNA damage-related vascular 
dysfunction are evaluated. In the present Chapter (1) we have summarized the evidence 
that supports the role of genomic instability in vascular aging and present mechanisms 
through which genomic instability generates the functional changes that are typical for 
the aging vasculature.
Previously, we identified in a mouse model of genomic instability due to defective 
DNA repair (Ercc1Δ/− mice), that accelerated age-related vascular dysfunction takes place 
and that this was characterized by a decreased NO/cGMP responsiveness and increased 
cellular senescence in the vascular smooth muscle layer. Therefore in Chapter 2 we in-
vestigate which component of the eNOS-NO-cGMP pathway is dysregulated in vascular 
smooth muscle cells, whether cellular senescence plays a role in this dysregulation, and 
if genetic variants of involved components of this pathway are involved in the increased 
risk of age-related vascular disease in humans.
Despite the evidence presented in Chapter 2 and previous work, one important 
question that remains is whether the observed accelerated decline of vasodilation in 
Ercc1Δ/- mice arises from defective local vascular DNA repair or if it is a consequence of the 
systemic deterioration these mice endure. To address if local DNA repair defects leads to 
changes as observed in Ercc1Δ/− mice, in Chapters 3 and 4 we respectively investigate 
cardiovascular function in mouse models with specific loss of genome maintenance 
in vascular endothelial and smooth muscle cells. In Chapter 3 Ercc1 was specifically 
knocked-out out in endothelial cells while in Chapter 4 DNA maintenance was crippled 
by specific deletion of the FACE1/Zmpste24 gene. This model was chosen because of the 
observation by Shanahan et al. that faulty prelamin A to lamin A conversion character-
izes vascular aging in healthy humans and Hutchinson Gilford progeria patients.26 When 
lamin A is not properly processed it remains fixed to the nuclear envelope, causing 
various cellular changes such as irregular nuclear shape, disorganization of heterochro-
matin and defective recruitment of DNA repair factors that lead to abnormal regulation 
of gene expression, thereby inducing premature aging.
In Chapter 5 we examine the effects of two well-known vasoprotective interven-
tions: lifestyle intervention, with dietary restriction (DR), vs. pharmacotherapy, with 
chronic blockade of the Angiotensin II (Ang II) AT1 receptor. DR is known to be an effec-
tive anti-aging intervention. It was found that DR ameliorates the vasodilator dysfunc-
tion observed in Ercc1Δ/− mice, however; it is not known which vasodilatory signaling 
pathway is improved. Ang II has an important role in hypertension, arteriosclerosis, vas-
cular DNA damage, inflammation and oxidative stress. Moreover, Ang II inhibits eNOS-
NO-cGMP signaling. However, it is not known how genomic instability influences RAS 
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activity. Hence, in Chapter 5 we set out to identify which vasodilatory signaling pathway 
is improved by DR in Ercc1∆/- mice and if DR affects the vasoconstrictor responses to Ang 
II. Also, we evaluated the effect of chronic AT1 receptor blockade on endothelial function 
and blood pressure in AL-fed Ercc1∆/- mice.
Aging changes the palette of major contributors to disturbed tone regulation. It is 
known that in humans decreased eNOS-NO-cGMP signaling contributes to the endothe-
lial dysfunction observed in aging and cardiovascular diseases. In some conditions such 
as essential hypertension and hypercholesterolemia, impaired eNOS-NO-cGMP signal-
ing is compensated by endothelium-derived hyperpolarization (EDH), and in fact EDH is 
unaffected by genomic instability. In Chapter 6 we discuss findings from a recent study 
presenting proof of principle for a new class of antihypertensive drugs. The candidate 
lead compound targets EDH based on the oxidative activation of PKGIα, independently 
of cGMP. Drugs that improve EDH signaling could have great therapeutic relevance 
beyond hypertension, and might also be useful in the context of vascular aging due to 
genomic instability.
Complementary to chapter 6, in Chapter 7 we investigate the involvement of 
PKGIα in EDH-induced vasodilation of porcine coronary arteries exposed to bradykinin, 
light, H2O2 and L-S-nitrosocysteine. Finally, Chapter 8 provides a summary and future 
perspectives.
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ABBREVIATIONS
ACE Angiotensin-converting enzyme
AMPK adenosine monophosphate-activated protein kinase
Ang Angiotensin
APE-1/Ref1 Apurinic/apyrimidinic endonuclease 1/redox factor 1
ApoE ApoE, Apolipoprotein E
ARE antioxidant response element
AT1 Angiotensin II type 1 receptor
AT2 Angiotensin II type 2 receptor
ATM ataxia telangiectasia mutated
BER base excision repair
CAD coronary artery disease
CDNK2 cyclin-dependent kinase inhibitor 2
cGMP cyclic guanosine monophosphate
cIMT carotid intima media thickness
CVD cardiovascular diseases
DDB2 Damage-Specific DNA Binding Protein 2
DNA-PK DNA-dependent protein kinase
DR dietary restriction
EDH endothelium-derived hyperpolarization
eNOS endothelial nitric oxide synthase
EPC endothelial progenitor cells
Ercc1 excision repair cross-complementation group 1 
GH growth hormone
GTF2H general transcription factor IIH
HGPS Hutchinson-Gilford progeria syndrome
HMBG-1 high mobility group box 1
hMSC human mesenchymal stem cells
HR homologous recombination
IGF1 insulin-like growth factor 1 
IGFBP3 insulin-like growth factor-binding protein 3 
INK-ATTAC mice genetically modified mice in which cells expressing the cyclin-dependent kinase 
inhibitor p16INK4A are being removed by apoptosis due to caspase 8 activation
LMNA lamin A gene
MMR mismatch repair
MtDNA mitochondrial DNA
mTOR(C1) mammalian target of rapamycin (complex 1)
NADPH nicotinamide adenine dinucleotide phosphate
NER nucleotide excision repair
NHEJ non-homologous end joining
35
Introduction
1
NfkB nuclear factor kappa B
NO nitric oxide
Nrf2 transcription factor NF-E2-related factor-2
PAI-1 plasminogen activator inhibitor-1
PARP-1 poly [ADP-ribose] polymerase 1
PDE phosphodiesterase
POLG polymerase gamma
RAS Renin angiotensin system
RecQ Escherichia coli recQ-like helicase
ROS reactive oxygen species 
SASP senescence-associated secretory phenotype
(s)GC (soluble) guanylyl cyclase 
SIRT-1 sirtuin-1
SMS senescence-messaging secretome
SNP single nucleotide polymorphism
T2DM type 2 diabetes mellitus
TERC RNA template of telomerase
TERT telomerase reverse transcriptase
TRF2 telomeric repeat-binding factor 2
TTD trichothiodystrophy
VSMC vascular smooth muscle cell
WRN Werner gene
WS Werner Syndrome 
XP xeroderma pigmentosum
XRCC3 gene coding for x-ray repair cross-complementing protein 3
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ABSTRACT
Reduced nitric oxide – cyclic guanosine monophosphate (cGMP) signaling is observed 
in age-related vascular disease. We hypothesize that this disturbed signaling involves ef-
fects of genomic instability, a primary causal factor in aging, on vascular smooth muscle 
cells, and that the underlying mechanism plays a role in human age-related vascular 
disease. To test our hypothesis we combined experiments in mice with genomic instabil-
ity (Ercc1Δ/- mice), human VSMC cultures and population GWAs studies. Aortic rings of 
Ercc1Δ/- showed 43% reduced responses to the soluble guanylyl cyclase (sGC) stimulator 
sodium nitroprusside (SNP). Inhibition of phosphodiesterase (PDE) 1 and 5 normalized 
SNP relaxing effects in Ercc1Δ/- to wild-type (WT) levels. PDE1C levels were increased in 
lung and aorta. cGMP hydrolysis by PDE in lungs was higher in Ercc1Δ/-. No differences in 
activity or levels of cGMP-dependent protein kinase 1 or sGC were observed in Ercc1Δ/- 
mice vs. WT. Senescent human VSMC showed elevated PDE1A and PDE1C and PDE5 
mRNA levels (by 11.6-, 9- and 2.3-fold respectively), which associated with markers of 
cellular senescence. Conversely, PDE1 inhibition lowered expression of these markers. 
Human genetic studies revealed significant associations of PDE1A single nucleotide 
polymorphisms with diastolic blood pressure (β= 0.28, p= 2.47x10-5) and carotid intima 
media thickness (β= -0.006, p= 2.89x10-5 ). In summary, these results show that genomic 
instability and cellular senescence in VSMC increase PDE1 expression. This might play a 
role in to aging-related loss of vasodilator function, VSMC senescence, increased blood 
pressure and vascular hypertrophy.
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INTRODuCTION
Since the identification of endothelial nitric oxide (NO) as an important vasodilator 
signal in blood vessels acting through second messenger cyclic guanosine monophos-
phate (cGMP) in vascular smooth muscle cells (VSMC), many studies have shown that 
this vascular signaling pathway is disturbed in cardiovascular diseases.1, 2 It is now widely 
assumed that disturbed NO-cGMP signaling is importantly involved in the pathogenesis 
of age-related vascular dysfunction and cardiovascular disease resulting thereof.3, 4 How-
ever, actual evidence in humans is not abundant. A recent combined human genetic 
study with mouse experiments shows that mutations in the human cGMP-producing 
machinery, consisting of soluble guanylyl cyclase and chaperonin containing t-complex 
polypeptide subunit η (CCTη), a protein that stabilizes soluble guanylyl cyclase, increases 
the risk of myocardial infarction due to increased thrombogenesis.5 Since this is a rare 
variant leading to increased familial risk for myocardial infarction, it is unclear whether 
this potential pathogenic mechanism acts in the general population. Even more recently 
it was found that genetic variants in phosphodiesterase (PDE) type 1A, an enzyme that 
degrades cGMP, might contribute to dysregulation of blood pressure.6 Notably, dys-
regulation of PDE1 sub-types has been suggested to play a role in atherosclerosis and a 
potential target for treatment of VSMC and cardiomyocyte dysfunction.7-12 However, it is 
unclear which function of cGMP would be involved. Also it is unclear what circumstances 
related to vascular aging would lead to decreased levels of this cyclic nucleotide.
Previously, we identified that genomic instability, a principle causal factor of the 
biological process of organismal aging, contributes to vascular aging.13 A pivotal find-
ing in this previous work was that in mice with genomic instability due to genetically 
induced defective DNA repair accelerated age-related vascular dysfunction takes place, 
and that this was hallmarked by a decreased NO-cGMP responsiveness and increased 
cellular senescence in the VSMC layer. We therefore hypothesize that genomic instabil-
ity causes dysregulation of the cGMP production and metabolism machinery in VSMC, 
that cellular senescence plays a role in this dysregulation, and that genetic variants of 
involved components of this machinery are involved in increased risk of age-related 
vascular disease in humans.
To test our hypothesis we first explored the effect of genomic instability in mice on 
cGMP-induced vasodilator function and key enzymes of this signaling pathway. Subse-
quently, we explored the role of cellular senescence on the cGMP pathway in primary 
cultures of human arterial VSMC. Finally, we used genetic association studies in human 
cohorts to explore if there is a role of genetic variants in PDE genes on age-related hu-
man vascular disease.
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MATERIAlS AND METhODS
To accomplish our aims we followed an integrative approach combining experiments in 
animal models, human VSMC cultures and population GWAs studies.
Animals
A thorough description of the generation and of the overall phenotype of Ercc1Δ/− mice 
can be found in previous publications.14, 15 Ercc1Δ/- mice of 16 weeks in an F1 hybrid Fvb/
C57Bl/6, background and their wild-type littermates (WT) of the same age were bred at 
the Erasmus MC animal facility. The animals were housed in individually ventilated cages 
with access to normal chow and water ad libitum. As required by Dutch law, all animal 
studies were approved by an independent Animal Ethical Committee.
Experiments in human VSMC
To assess the effect of cellular senescence PDE sub-types, human VSMCs were obtained 
from normal medial aortic explants from 5 donors (20-54 years old) and cultured in M199 
with 20% FBS and antibiotic supplements and passaged 1:2 as described previously.16 
Serial passaging until senescence was performed, and RNA was isolated at different pas-
sages. cDNA was prepared from 5 μg of total RNA to quantify expression of the PDE1A, 
PDE1C and PDE5A genes and senescence markers p16 and p21.
Reciprocally, the effect of PDE1 and PDE5 inhibition on p16 and p21 was tested 
in n=6 samples from 3 independent duplicate experiments. Coronary artery smooth 
muscle cells Passage 6 (CC-2583, Lonza) cultured in DMEM + 10% FCS were treated with 
vinpocetine 10 μmol/L or sildenafil 100 nmol/L and incubated for 24 hours after which 
RNA isolation was performed and. cDNA was prepared from 500 ng of total RNA.
Organ bath experiments
Ercc1Δ/- and WT mice were asphyxiated in a CO2 chamber. The thoracic aortas were 
isolated and stored overnight in cold, oxygenated Krebs-Henseleit buffer (in mmol/L: 
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4) 
solution. The following day, vessel segments were mounted in 6-mL organ baths (Dan-
ish Myograph Technology, Aarhus, Denmark) containing Krebs-Henseleit buffer at 37ºC 
and oxygenated with 95% O2 and 5% CO2. The tension was normalized to 90% of the 
estimated diameter at 100 mm Hg effective transmural pressure. Maximum contractile 
responses were determined using 100 mmol/L KCl. After washout of KCl, preconstriction 
was elicited with 30 nmol/L U46619 resulting in 50-100% of the previously obtained 100 
mmol/L KCl precontraction. During preconstriction, relaxation concentration-response 
curves (CRCs) were constructed to sodium nitroprusside (SNP) and diethylammonium 
(Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA NONOate). To detect a possible 
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NO/sGC/cGMP independent vasorelaxant activity of SNP, we performed SNP CRCs after 
inactivation of sGC with 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 μmol/L). 
To investigate the involvement of increased activity of PDE enzyme in VSMC dysfunction 
of Ercc1Δ/- mice, segments were preincubated for 20 minutes with 100 nmol/L sildenafil 
or 10 μmol/L vinpocetine. Sildenafil and vinpocetine were used together with 100 
μmol/L L-NAME, to allow the measurement of the response to exogenous NO donor SNP 
in the absence of endogenous NO. To test for differences in cGMP-dependent protein 
kinase 1α (PKGI) sensitivity, CRCs to 8- Bromo-β-phenyl-1,N²-ethenoguanosine-3’,5’-
cyclicmonophosphate (8-Br-PET-cGMP) were constructed during NOS inhibition with 
L-NAME (100 µmol/L).
Next, we investigated which part of the downstream signaling of sGC is altered, 
focusing on cGMP production, PKG activation and PDE activity.
Cyclic GMP measurement
To measure SNP-induced cGMP production, vessel segments (5–10 mg) were exposed 
to SNP (100 µmol/L) in 6 mL oxygenated Krebs bicarbonate solution for 5 min at 37ºC 
in the presence of the PDE inhibitor 3-isobutyl-1-methyl-xanthine (IBMX) (100 mmol/L). 
Tissues were subsequently frozen in liquid nitrogen, and stored at -80ºC. To determine 
cGMP, frozen tissues were homogenized in 0.5 mL 0.1 mol/L HCl using a stainless-steel 
ultraturrax (Polytron). Homogenates were centrifuged at 3300 g, and cGMP was mea-
sured in 300 μL supernatant by ELISA following acetylation (R&D Systems, Minneapolis, 
U.S.A.). Experiments were performed in quadruplicate, and results are expressed as 
pmol/mg protein. The lower limit of detection was 0.1 pmol/mg protein. The protein 
concentration was determined using bicinchoninic acid (BCA) protein assay.
Measurement of PDE5 activity
To measure the cGMP hydrolyzing activity of PDE5, lung tissue of Ercc1Δ/- and WT mice 
was isolated, frozen in liquid nitrogen and stored at -80ºC. Frozen tissues were crushed in 
liquid nitrogen and then homogenized at 0ºC in a buffer solution containing 50 mmol/L 
Tris HCl pH 7.5, 1.5 mmol/L EDTA, 1 mmol/L DTT, Roche complete protease inhibitor 
cocktail, phosphatase Inhibitor Cocktail 1, and 1 mmol/L sodium orthovanadate. In or-
der to assure appropriate linear kinetics of cGMP hydrolysis, protein concentration of all 
samples was determined and subsequently they were diluted to yield 15%-30% of total 
hydrolysis. Diluted sample, containing 0.9 mg/mL protein was added to an assay buffer 
(40 mmol/L Tris HCl, pH 7.5, 10 mmol/L MgCl2, 0.2 mg/mL BSA, 1 mmol/L EGTA, 1 µmol/L 
cGMP) containing 105 counts per minute [3H]-cGMP per sample. Homogenization buffer 
without protein was used as a negative control and undiluted protein solution (8 mg/
mL) was used to determine full hydrolysis. Assay mixture was incubated at 30ºC for 30 
minutes. After that the reaction was stopped by heating the mixture to 100ºC. Subse-
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quently the mixture was cooled by placing it on ice and [3H]-5’-GMP was further hydro-
lyzed by incubation for 30 min at 37°C with 0.25 mg/mL Ophiophagus hannah snake 
venom to 3H-guanosine. Following incubation, 1 mL of Dowex ion exchange slurry was 
added (1:0.9:0.1 mixture of Dowex AG-1X8/water:methanol) and shaken for 2 minutes 
on an Eppendorf shaker. The mixture was centrifuged for 4 minutes at 18000 g and 700 
µL of supernatant was added to a scintillation cocktail and the number of counts per 
minute was determined.
Quantitative Real-Time PCR analyses
Quantitative real-time PCR was performed in a StepOne thermal cycler (UK, Applied 
Biosystems) using the SYBR Green PCR Master Mix (UK, Applied Biosystems) following 
manufacturer’s recommendations. β-actin (ACTB), hypoxanthine phosphoribosyltrans-
ferase 1 (HPRT-1) and TATA-box-binding protein (TBP) DNA quantitation was performed 
in parallel on all samples and were used as endogenous references to normalize varia-
tions in DNA recovery and amplification efficiency.
The sense and antisense primers for human PDE were: PDE1A: 5’-CCT-ATG-TGG-CAA-
GCA-GCT-CA-3’; 5’-CCC-ATC-ACT-CAT-GGA-GCC-TT-3’; PDE1C: 5’-GCA-GCC-AGA-AGC-
CAT-TGA-AA-3’; 5’-GGA-GTG-ACA-TTG-TCC-AGC-GA-3’; PDE5A: 5’-GAT-TGC-TGC-ACT-
AAG-CCA-CG-3’; 5’-AGT-GGA-TGT-TCA-CTT-CGC-TGT-3’.
The sense and antisense primers for human p16 and p21 were: p16: 5’-TCG-CGA-
TGT-CGC-ACG-GTA-3’, 5’-ATC-GGG-GAT-GTC-TGA-GGG-AC -3’; p21: 5’-CCA-GCA-TGA-
CAG-ATT-TCT-ACC-AC-3’, 5’-CTT-CCT-GTG-GGC-GGA-TTA-GG-3’. Expression values of 
PDE subspecies and p16 and p21 were corrected for expression levels of at least two of 
the following house-keeping genes: TBP, HPRT-1, ACTB, or tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide (YWHAZ). All PCR 
reactions were performed in duplicates. Generally, results did not show qualitative 
difference after correction for the different house-keeping genes. The house-keeping 
gene that gave the most conservative result with respect to differences between groups 
was chosen for data presentation and statistical analyses. Data were considered to be 
unreliable if less than 2 of the house-keeping genes could be measured, if CT was on 
average higher than 34 or if duplicate measurements showed strong dissimilarities. 
Data of senescent human cells from each of the 5 cultures are expressed relative to the 
expression at the lowest passage of cells from each explant, which was set at 1. The 
lowest passage is the passage number needed to obtain sufficient amounts of mRNA 
and protein for PCR and Western blot analyses, which in this study occurred at passage 
number 6.
53
Phosphodiesterase 1 and vascular aging
2
Western blot analyses
From a separate group of mice, 4 aortic ring segments per mouse were mounted in 
organ baths to evoke responses to KCl, U46619, acetylcholine and finally SNP in order to 
recreate the organ bath experimental conditions of our previous studies.13 Immediately 
after the final SNP responses, the rings of each individual mouse were pooled and snap 
frozen in liquid nitrogen. Aortic tissue was crushed at -80°C and resuspended in ice 
cold radioimmunoprecipitation assay (RIPA) buffer (50 mmol/L HCl pH 7.4, 150 mmol/L 
NaCl, 1% NP-40, 0.25% Na-deoxycholate and 1 mmol/L EDTA) containing protease 
and phosphatase-inhibitors (1mmol/L PMSF, 1 mmol/L NaVO4, 1 mmol/L NaF, 1 μg/mL 
aprotinin, 1 μg/mL pepstatin and 1 μg/mL leupeptin) to extract total protein. The lysates 
were cleared by centrifugation.
Protein content of the murine aortic and human VSMCs lysates was determined 
with the BCA method (Thermo Scientific). Lysates were subsequently run on a criterion 
bis/tris gradient gel, and blotted to a nitrocellulose membrane.
For sGCα1, sGCβ1 and PKGIα membranes were blocked with 1:1 odyssey blocking 
buffer:PBS and were subsequently incubated with antibodies diluted in 1:1 odyssey 
blocking buffer:PBS against sGCα1 and sGCβ1 (provided by HHHW Schmidt17; 1:2000 
and 1:1000 respectively) and PKGIα (Santa Cruz Biotechnology, diluted 1:750). Primary 
antibodies were detected with secondary antibodies labeled with the near infrared 
dye IRdye800 and visualized with an Odyssey detection system. Protein expression 
levels were normalized to the house-keeping protein glyceraldehyde-3-phosphate 
dehydrogenase(GAPDH) in each run.
For PDE1A, membranes were blocked with 5% BSA Tris Buffered Saline with Tween 
(TBS-T), whereas for PDE1C and PDE5, 5% dried skimmed milk powder in TBS-T was 
used. Subsequently incubation with the primary antibodies was as follows. In mice lung 
tissue: PDE1A (Santa Cruz, SC-67734 1:500 in 5% BSA TBS-T), PDE1C (Santa Cruz, SC-
67323 1:1000 in 5% dried skimmed milk powder in TBS-T), PDE5 (Alexis Biochemicals, 
ALX-210-099 1:1000 in 5% dried skimmed milk powder in TBS-T) and p-PDE5 (FabGen-
nix, PPD5-140AP 1:1000 in 5% dried skimmed milk powder in TBS-T).
In human VSMCs: PDE1A (Santa Cruz, SC-67737 1:500 dilution in 5% BSA in TBS-T) 
and (Santa Cruz, SC-374602 1:100 in 5% dried skimmed milk powder in TBS-T), PDE1C 
(Santa Cruz, SC-376474 1:100 in 3% dried skimmed milk powder in TBS-T), PDE5 (Alexis 
Biochemicals, ALX-210-099 1:1000 dilution in 5% % dried skimmed milk powder in TBS-
T) and p21 (Cell Signalling, Cat: 2947 1:250 in 2% BSA TBS-T).
Primary antibodies were detected with a HRP- conjugated antibody (Bio-Rad 1:2000 
in 1% dried skimmed milk powder in TBS-T). For visualization, we used an enhanced 
chemiluminiscent substrate for detection of HRP (Pierce ECL Western Blotting Substrate, 
Thermo Scientific). Protein expression levels were normalized to the house-keeping 
protein Actin in each run.
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Genetic association studies
We investigated the association of single nucleotide polymorphisms in the PDE1A, PDE1C 
and PDE5A genes with blood pressure (BP), pulse pressure (PP), carotid-femoral pulse 
wave velocity (CFPWV), common carotid intima media thickness (cIMT) and coronary 
artery disease (CAD). To provide sufficient statistical power, we used data from different 
consortia as follows: The look-up for the association between the PDE1A, PDE1C and 
PDE5A single nucleotide polymorphisms and BP and PP was done in the International 
Consortium of Blood Pressure Genome-Wide Association Studies (ICBP-GWAS).18 ICBP-
GWAS includes ~ 200,000 participants of European ancestry from 35 studies. Analyses 
were adjusted for sex, age, age squared, body mass index and ancestry principal compo-
nents. Individuals who had received treatment for hypertension were imputed to have 
15 mmHg higher systolic blood pressure (SBP) and 10 mmHg higher diastolic blood 
pressure (DBP) than the observed measurements.
For CFPWV we used data from The AortaGen Consortium which comprises 20,634 
individuals of European ancestry from 9 cohort studies.19 As CFPWV increases nonlinearly 
and displays striking variance inflation with advancing age, its distribution is strongly 
right skewed. CFPWV also varies depending on the method used to measure transit 
distance. Therefore, genetic association analyses were performed using a sex-specific 
standardized residual that was based on the inverse of CFPWV, which normalizes the 
distribution, and that was further adjusted for age, age squared, height, and weight.
The look-up for the association between the PDE single nucleotide polymorphisms and 
cIMT was done using data from the Cohorts for heart and aging research in genomic epi-
demiology (CHARGE) GWAS meta-analysis, which includes 31,210 participants of European 
ancestry. cIMT was determined by ultrasonography and analyses are age and sex adjusted.20
The look-up for CAD was done using the CARDIoGRAM GWAS meta-analysis data.21 
This meta-analysis comprises 22 GWAS studies of European ancestry involving 22,233 
cases and 64,762 controls. Analyses were adjusted for age (onset of the first event for 
cases or time of recruitment for controls) and gender.
Statistical methods
Data are presented as mean ± SEM. Statistical analysis between the groups of single 
values was performed by two-sided Student’s t test. Differences in dose-response 
curves were tested by ANOVA for repeated measures (general linear model – repeated 
measures (GLM-RM); under the assumption of sphericity of the data). Differences were 
considered significant at p<0.05. Log10-transformed SNP concentrations at which the 
half-maximal response occurred (pEC50) were estimated with sigmoid curve fitting 
software (GraphPad Prism5).
For the genetic association studies 868 single nucleotide polymorphisms were 
selected: 400 inside the PDE1A gene, 358 in the PDE1C and 110 in the PDE5A gene .To ob-
55
Phosphodiesterase 1 and vascular aging
2
tain the number of independent tests single nucleotide polymorphisms in high linkage 
disequilibrium, as defined by a pairwise r2 ≥ 0.7, were excluded using the prune option in 
Plink.22 This resulted in 174 independent single nucleotide polymorphisms. A significance 
threshold of p <2.87x10-4 after applying Bonferroni correction (0.05/174=2.87x10-4) was 
considered significant.
RESulTS
Studies in mice
Vascular smooth muscle function in Ercc1Δ/- mice
The responses of Ercc1Δ/- mouse aortae to the highest concentrations of SNP were 
reduced by 43% (P=0.0002, Table 1) and by 20% in response to the highest dose of DEA-
NONOate (P=0.0014). Due to the higher variability of the responses to DEA NONOate all 
further studies were performed with SNP.
The SNP response was entirely dependent on sGC activation, since ODQ fully elimi-
nated the responsiveness to SNP in WT and Ercc1Δ/- (Figure 1).
Table 1. Pharmacodynamic parameters of SNP concentration-response curves
pEC50 Emax
control sildenafil vinpocetine control sildenafil vinpocetine
WT -7.8±0.2 -8.8±0.1 # -8.4±0.1 -85.5±4.3 -93.4±3.1 -96.4±1.2
Ercc1Δ/- -7.7±0.4 -8.4±0.1 #  -8.2±0.1 # -48.6± 7.6  -74.9±5.2 #  -87.4±3.1 #
pEC50: Log10-transformed SNP concentrations at which the half-maximal response occurred. Emax: maximal 
effect of SNP (% of U46619 precontraction). # p<0.05, t-test compared with control
Key enzymes in cGMP signaling
Soluble guanylate cyclase: We did not observe a significant reduction of cGMP produc-
tion in Ercc1Δ/- aortae during PDE inhibition with IBMX (Figure 2A). Moreover, the protein 
levels of α- and β- subunits of sGC measured by Western blotting in aortic tissue were 
not different in Ercc1Δ/- as compared to WT animals (Figures 2B, 2C).
Phosphodiesterase activity: Both the PDE5 inhibitor sildenafil (100 nmol/L) and 
the PDE1 inhibitor vinpocetine (10 µmol/L) significantly increased responses to SNP as 
compared over the entire concentration-effect range in Ercc1Δ/- and WT mice (p<0.05, 
GLM-RM test). In Ercc1Δ/- the increase of SNP responses induced by vinpocetine was 
significantly higher than by sildenafil (p<0.05 GLM-RM on entire concentration effect 
range for SNP, sildenafil vs. vinpocetine). Looking further into qualitative aspects of the 
SNP effects, potency of SNP increased significantly by ~10-fold in Ercc1Δ/- for both PDE 
inhibitors, and also for sildenafil in WT mice, whereas in WT mice potentiation by vinpo-
cetine did not reach significance (Table 1). In addition, the 2 drugs increased Emax in 
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Ercc1Δ/- mice by 53% (p=0.03) and 80% (p=0.0023), respectively, whereas no statistically 
significant increase was observed in WT animals (Figures 3A-3D).
Using an enzyme-kinetic assay to measure PDE activity, we observed a 35% increase 
(P=0.0119) of cGMP-hydrolyzing activity in the lungs of Ercc1Δ/- mice as compared to 
WT mice. Sildenafil 100 nmol/L completely abolished hydrolysis in both Ercc1Δ/- and WT 
animals (Figure 3E). The results from qPCR experiments point out that PDE5 mRNA is 
downregulated in both aorta and lung of Ercc1Δ/- (Figure 4A). When checking for protein 
expression, which was only possible in lung samples, PDE5 protein followed the same 
pattern as PDE5 mRNA, i.e. levels were decreased (Figure 4B). In addition, phosphoryla-
tion of PDE5 protein at Ser92 was decreased (Figure 4B). Subsequently, PDE1 sub-types 
were measured. The aortic PDE1A and PDE1C mRNA expression were highly variable, 
and although the average in aortic PDE1C was higher in Ercc1Δ/- no significant difference 
with WT animals were found (Figure 4C). Aortic PDE1A mRNA levels were very low (CT 
> 34) and could only be measured in 4 out of 6 samples (Figure 4C). Aortic PDE protein 
levels were too low to be measured. In an attempt to obtain an impression of PDE1 
protein in the vasculature we performed Western blots in the highly vascularized lung. 
As in agreement with aortic mRNA levels, lung PDE1A protein levels were not different, 
whereas PDE1C protein was significantly increased in Ercc1Δ/- mice (Figure 4D).
cGMP-dependent protein kinase type-1: The responses to the cell-permeable PKGI 
agonist PT-8Br-cGMP were identical in Ercc1Δ/- and WT aortas (Figure 5A). In agreement 
with this observation, the protein levels of PKGI in aortic tissue, measured by Western 
blotting were not different in Ercc1Δ/- as compared to WT animals (Figure 5B).
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figure 1. VSMC relaxing responses in progeroid Ercc1Δ/- mice. Relaxation of thoracic aortas from 16 week 
old Ercc1Δ/- and WT mice in response to the endothelium-independent vasodilator SNP (A) and to DEA-
NONOate (B) were measured in organ bath setups during precontraction with U46619. Due to the higher 
variability of the responses to DEA NONOate all further studies were performed with SNP. The sGC inhibitor 
ODQ was added 20 min before SNP. *P<0.05 (GLM-RM, control compared with PDE inhibition). Numbers of 
observations are given in parentheses.
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Studies in human VSMC
To study the relation between PDE1 expression and cellular senescence, passage-
dependent expression of PDE1 and p16 and p21, a cyclin-dependent kinase and an 
accepted senescence marker13, 23, 24 was studied in 5 VSMC cultures, typical results from 
one of the cultures are presented in figures 6A- 6D. There was a passage-dependent 
increase of PDE1A and PDE1C mRNA levels, and this corresponded with an increase in 
p16 and p21. Summary results are presented in figure 6E, senescent human aortic VSMC 
showed a significant 11.6- and 9-fold increase of PDE1A and PDE1C mRNA levels respec-
tively (Figure 6A and 6B), whereas the PDE5 level was only modestly increased (Figure 
6E, p=0.06). The pattern on the PDE1C protein expression (Figure 7A) corresponded with 
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figure 2. cGMP production and sGC 
subunit protein levels in thoracic aortas 
of Ercc1Δ/- mice. Production of cGMP in 
aortic tissue of Ercc1Δ/- and WT mice with 
and without stimulation with SNP 10-5 
mol/L for 5 minutes (A). sGC α1 and β1 
sub-types (B,C) protein levels were mea-
sured with Western blot and corrected 
for GAPDH levels. Numbers of observa-
tions are given in parentheses
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qPCR data and p21 protein expression (Figure 7B) but we could not specifically detect 
PDE1A nor PDE5 protein in human samples despite trying several different antibodies. 
When we treated VSMCs with the PDE1 and 5 inhibitors vinpocetine and sildenafil to 
accomplish loss-of-function of the PDEs we found that vinpocetine (predominant PDE1 
inhibition) lowered both p16 and p21 expression, whereas sildenafil (predominant PDE5 
inhibition) only appeared to affect p21 (Figure 7C and 7D).
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figure 3. Effects of PDE inhibitors on SNP-induced 
relaxations and PDE activity in Ercc1Δ/- lungs. Re-
laxation of isolated thoracic aorta segments from 
Ercc1Δ/- and WT animals to SNP studied in organ 
bath setups during contraction induced by U46619 
in the absence and presence of sildenafil and vin-
pocetine (A-D). cGMP hydrolysis in lung of Ercc1Δ/- 
as compared to WT mice, in the presence or ab-
sence of sildenafil (E). #, *P<0.05 (t-test, GLM-RM 
respectively). Numbers of observations are given in 
parentheses.
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figure 4. Expression of PDE1 and 5 sub-types in mouse tissues. Aortic and lung PDE5 mRNA (A) and lung 
protein expression (B), PDE1A and 1C aortic mRNA expression (C) and lung protein expression (D) were 
measured with qPCR and WB, correspondingly. *P<0.05 (t-test). Numbers of observations are given in pa-
rentheses.
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figure 5. Responses to PKGI activator and PKGIα protein levels in aortic tissue of Ercc1Δ/- mice. Relaxation 
of thoracic aortas from 16 week old Ercc1Δ/- and WT mice to cell membrane-permeable PKGI activator PT-
8Br-cGMP during U46619-induced contraction, as measured in organ bath setups (A). PKGIα protein levels 
were measured with Western blot and corrected for GAPDH levels (B). Numbers of observations are given 
in parentheses.
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Genetic association studies
Since in vitro cellular senescence is not synonymous for vascular aging, we tested the 
involvement of PDE1 and PDE5 by means of genetic association studies. After Bonferroni 
correction for multiple testing, 14 SNPs in the PDE1A gene remained significantly associ-
ated with DBP at the threshold of p ≤ 2.87x 10-4 (Table 2, Figure 8A). The biggest effect 
size was found for the SNP rs1430158 (β= 0.281, p= 2.47x10-5). We found 6 SNPs in the 
PDE1A gene significantly associated with cIMT (Table 2, Figure 8B). Among all rs2887202 
showed the lowest p value (β= -0.0061, p= 2.89x10-5)
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figure 6. mRNA expression of PDE1, p16 and p21 
in human VSMCs. Pattern of PDE1A (A), PDE1C (B), 
p16 (C) and p21 (D) mRNA expression at different 
passages measured with qPCR. PDE1A, 1C and 5 
mRNA expression in young versus senescent hu-
man VSMCs was measured with qPCR. Fold expres-
sion values were Log2 transformed, *P<0.05. (E). All 
CT values of mRNA expression were corrected for 
the TBP gene expression
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The results for the association of the SNPs in the PDE1A, PDE1C and PDE5 genes with 
SBP, DBP, PP, CFPWV, cIMT and CAD at 2.87x 10-4 < p < 0.05 are presented in supplemen-
tary table 1. There are some suggestive associations of PDE5A with SBP (rs6844263, β= 
0.312, p= 1.60x10-3) and DBP (rs1155577, β= 0.214, p= 5.16x10-4), and of PDE1A with PP 
(rs17343395, β= -0.354, p= 5.05x10-3) and cIMT (rs12989198, β= -0.0053, p= 3.28x10-4). 
One SNP in the PDE1C gene showed a suggestive association with CAD (rs10226190, β= 
0.080, p= 5.75x10-3). CFPWV did not show any association that might be relevant.
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figure 7. Protein expression of PDE1C and p21 in human VSMCs and mRNA expression of p16 and p21 
in human VSMCs treated with PDE1 and 5 inhibitors. Pattern of PDE1C (A) and p21 (B) protein expression 
at diff erent passages measured with WB. Protein levels were corrected for β-actin levels. p16 (C) and p21 
(D) mRNA expression in control, vinpocetine- and sildenafi l-treated VSMCs. *P<0.05. All CT values of mRNA 
expression were corrected for the ACTB gene expression.
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Table 2. Significant associations at the threshold of p ≤ 2.87x 10-4 of the single-nucleotide polymorphisms 
(SNP) in the PDE1A gene with DBP and cIMT
Chromosome Allele
SNP n Position Coded frequency Beta se p Outcome
rs1430158 2 182970373 T 0.77 0.282 0.067 2.47 x10-5 DBP
rs833166 2 182917392 T 0.78 0.278 0.068 4.85 x10-5 DBP
rs10497597 2 182971998 T 0.23 0.269 0.068 6.84 x10-5 DBP
rs2623431 2 182922232 T 0.78 0.266 0.068 8.61 x10-5 DBP
rs833168 2 182919236 T 0.78 0.264 0.068 9.56 x10-5 DBP
rs16823124 2 182932372 G 0.78 0.254 0.066 1.35 x10-4 DBP
rs16823150 2 182952598 T 0.81 0.254 0.067 1.65 x10-4 DBP
rs1438065 2 182927238 G 0.78 0.249 0.067 1.79 x10-4 DBP
rs11682598 2 182927925 G 0.78 0.248 0.067 1.90 x10-4 DBP
rs864417 2 182918692 T 0.75 0.250 0.067 1.94 x10-4 DBP
rs12693302 2 182919688 G 0.26 0.248 0.067 1.96 x10-4 DBP
rs12996836 2 182920273 T 0.25 0.248 0.067 1.97 x10-4 DBP
rs7558737 2 182948186 T 0.22 0.243 0.067 2.84 x10-4 DBP
rs10931009 2 182949102 T 0.22 0.243 0.067 2.87 x10-4 DBP
rs2887202 2 183029113 A 0.58 -0.006 0.002 2.89 x10-5 cIMT
rs934264 2 183033988 T 0.58 -0.006 0.002 4.14 x10-5 cIMT
rs1897104 2 183058624 A 0.42 0.006 0.002 8.91 x10-5 cIMT
rs10931012 2 182998273 A 0.40 0.006 0.002 1.70 x10-4 cIMT
rs11684406 2 183001113 T 0.60 -0.006 0.002 1.70 x10-4 cIMT
rs17343416 2 182994934 T 0.59 -0.005 0.002 2.38x10-4 cIMT
DISCuSSION
In our studies in mice with accelerated vascular aging due to genomic instability we 
found decreased vasodilator function and increased cGMP metabolism in lung tissue 
that can both be restored by PDE1 and 5 inhibition, whereas the highly vascularized 
lung shows increased PDE1C expression. In humans, VSMC senescence, which can be 
caused by genomic instability, also leads to increased PDE1, and possibly also PDE5 
activity, while in the general population SNPs in the PDE1A gene are associated with 
increased DBP and cIMT, two hallmarks of human age-related vascular dysfunction. 
Therefore, in general our data suggest that increase of PDE1A and C in VSMC might play 
a pivotal role ageing-related vasodilator dysfunction and vascular hypertrophy, and that 
this increase is linked to cellular senescence, a consequence of genomic instability. A 
similar observation, but with more reservations, can be made for PDE5.
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figure 8. Regional plots for the association between PDE1A Single Nucleotide Polymorphisms and Dia-
stolic Blood Pressure and Intima Media Thickness. Regional association plot showing –log10 (p-values) for 
all PDE1A SNPs ordered by their chromosomal position and DBP (A) and IMT (B).
Each SNP is colored according to its correlation with the SNP showing the lowest p-value (index SNP) within 
the region as specified in the color scheme.
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Several pieces of evidence demonstrate that reduced cGMP responsiveness is 
important in the context of vascular aging. Our currently reported data, and those previ-
ously reported, showed reduced responses to SNP in Ercc1Δ/- mice, which can be restored 
by the preferential PDE1 inhibitor vinpocetin. Also, others have shown in aged rats that 
arterial relaxing responses to SNP progressively reduced with increasing age.25, 26 In 
comparison to our previous study13, the present study shows that apart from reduced 
eNOS signaling, genomic instability causes reduced responsiveness to cGMP due to an 
increased metabolism of this nucleoside and apparently not due to changes in cGMP 
production or PKG activity. This is suggested by our observation that PDE inhibition 
fully restored SNP responses in Ercc1Δ/- to the level of WT, and that sGC and PKG do not 
appear to be changing in activity or in expression levels. The complete restoration of 
SNP responses by vinpocetine and sildenafil also suggest that it is unlikely that other 
sub-types than PDE 1 and 5 are involved. In contrast to our previous study13, we here 
show the comparison with both vinpocetine and sildenafil on complete SNP dose re-
sponse curves to explore the relative involvement of PDE1 and PDE5. Our comparisons 
show that in WT sildenafil has the more pronounced effect in WT, whereas in Ercc1Δ/- the 
effect of vinpocetine appears to dominate. Although sildenafil and vinpocetine are not 
strictly specific inhibitors, and have affinity for both PDE sub-types, these data suggest 
that in Ercc1Δ/- the contribution of PDE1 relative to PDE5 with regard to decreased cGMP 
signaling is increased. This is also supported by the western blot and PCR data obtained 
in aortic and in lung tissue. Unfortunately, we were not able to quantify PDE protein 
levels in the mouse aorta to provide more evidence for which PDE sub-type is involved 
in the vasculature. Yet, the highly vascularized lung tissue did show increased PDE1C 
levels, and similar observations were made in human senescent VSMCs, suggesting that 
particularly this sub-type is of interest for further investigation.
Compared to other studies on the effect of aging on SNP responses, a reduction of 
maximal SNP response, as observed in our mice, only appears in normal male Wistar rats 
at an age of 90 weeks or higher, and at 130 weeks and older even a decline in the response 
to 8-Br-cGMP has been observed.26 In humans, a reduction of VSMC responsiveness to 
NO donors in relation to age is not observed in brachial arteries as readily as the decline 
of endothelial function,27, 28 even with concomitant essential hypertension,29, 30 although 
in some studies this reduction did occur.31 VSMC dilator dysfunction also occurs in the 
later stages of chronic heart failure (CHF),32-37 while in mild-to-moderate heart failure, 
such VSMC dysfunction was found to be predictive of worsening CHF.38 When taking the 
data of normally aging animals and humans together, it seems that VSMC dysfunction 
develops in a progressive stage of vascular aging, concomitant with vessel disease. In 
line with this observation, in our model, where aging of both endothelial cells and VSMC 
is accelerated by ablation of DNA repair, both cell types are affected, and VSMC dysfunc-
tion can be demonstrated at a young age.
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Relevant to advanced vascular aging is the occurrence of senescence vascular cells. 
When we measured the gene expression of three PDEs sub-types in human VSMCs, we 
found that predominantly PDE1A and PDE1C mRNA levels increased with increasing 
passages and p16 and p21 expression. The association between VSMC senescence and 
PDE1 sub-types was confirmed when we treated VSMCs with vinpocetin, which caused 
a reduced p16 and p21 mRNA expression. PDE5 inhibition only reduced p21 mRNA ex-
pression, again pointing to a stronger association of senescence with PDE1. Overall, our 
results show that PDE1 and cell senescence are reciprocally associated and suggest that 
PDE1 might even be involved in regulation of VSMC senescence. Other roles for PDE1 in 
the aging vasculature have been proposed previously. As VSMCs age, their phenotype 
changes from a contractile to a synthetic state in which they exhibit increased prolifera-
tion, migration and production of extracellular matrix proteins thus contributing to the 
neointima formation in aged vessels. It has been shown that PDE1A localization is dif-
ferent in contractile compared with synthetic VSMCs; in contractile VSMCs in the media 
PDE1A is predominantly cytoplasmic, whereas in synthetic VMSCs in the neointima, it is 
nuclear and associated with VSMC proliferation.39 The impact of cytoplasmic PDE1 sub-
types on decreased vasodilator capacity is most probably reflected in our organ bath 
studies in mice and the genetic association with DBP in humans. The role of PDE1A gene 
variants in cIMT may be related to nuclear localization of the enzyme.
In our candidate gene look-up using GWAS data we found several single nucleotide 
polymorphisms in the PDE1A gene that confirms a role in DBP and cIMT. A role for DBP 
regulation by PDE1A was also suggested recently in another genetic association study6; 
however, the mechanism underlying this association was not described. There is also a 
suggestive role for PDE5A in DBP. Although none of the associations with SBP, PP, CFPW 
and CAD reached our significance threshold, there are several suggestive associations.
The variability in associations with respect to the clinical variable that is explored 
suggests that PDE1 and 5 would be involved in very specific functions in the vascular 
system. For instance, DBP might be relatively more dependent on basal tone of vascular 
smooth muscle cells and medial thickness and less dependent on cardiac contractil-
ity and vascular compliance, as determined by changes in extracellular matrix, than 
SBP and PP. CAD is an even more complex phenomenon, involving also inflammation, 
dyslipidemia and thrombogenesis. In other words, our genetic association study might 
hint at the most relevant biological role of PDE1A, and perhaps also of PDE5, which 
would be in regulation of vasomotor function and vascular remodeling by increasing 
VSMC proliferation and migration39; remodeling processes that alter the vessel tone and 
therefore blood pressure.40 
It might seem remarkable that PDE1C SNPs did not show associations, with the 
exception of perhaps a weak relationship with PP and CAD. However, this observation 
does not necessarily mean that PDE1C is not important for human vascular disease. It 
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might simply be explained by the absence of a relevant genetic variant. Our mouse data 
and previous studies in human VSMC and atherosclerotic tissue are very suggestive for 
a relevant role of PDE1C.10, 41 In addition, the fact that the mRNA and protein levels of 
PDE1A and PDE1C are increasing more than those of PDE5 does not mean that both 
type 1 sub-types are more important. Our data show relative increases of gene product, 
and this is not indicative for the absolute contribution of each PDE sub-type. In fact, 
previous studies show that PDE1 sub-type expression might be low in cultured VSMC, 
hence leading to high increases of gene expression relative to baseline even in the case 
that absolute increases are small.42 
Drugs affecting cGMP levels are potential pharmacological tools for the treatment 
of age-related cardiovascular disease. NO donors for the treatment of angina pectoris 
and PDE5 inhibitors for the treatment of erectile dysfunction and reduction of blood 
pressure in pulmonary hypertension are already being used in patients.43-45 Vinpocetine 
is a PDE inhibitor with a preferential affinity for PDE1 over PDE5, which it also inhibits. 
Vinpocetine is a Food and Drug Administration (FDA)-approved nutraceutical and a 
registered drug in Eastern Europe, used to enhance cerebral blood-flow and improve 
memory.46, 47 It inhibits injury-induced hypertrophy in human and rodent vessels, and 
decreases atherosclerosis in ApoE knockout mice.7, 8 From our results we anticipate that 
PDE inhibition, particularly PDE1-specific inhibition, might also be interesting as a po-
tential pathway subject to modification to chronically improve genomic stability-related 
vascular dysfunction by increasing signaling through the NO/sGC/cGMP axis.
In summary, we have identified PDE1 as a genetic risk factor and a potential treat-
ment target in age-related vascular disease, where it concerns disturbed NO-cGMP sig-
naling in VSMCs. This is specifically important for blood pressure regulation and vascular 
hypertrophy and possibly also in regulation of VSMC senescence. Our study warrants 
further exploration of PDE1 inhibitors as drugs to improve healthy cardiovascular aging 
in the general population.
Clinical Perspectives
After the failure of several clinical trials to show effectiveness of PDE5 inhibitors in 
chronic cardiovascular disease, our result underpin the previously suggested impor-
tance to further evaluate the potential of PDE1 as a treatment target. Our current study 
suggests that vascular aging related to genomic instability might be a major focus in this 
endeavor. Inhibition of specific PDE sub-types is an attractive option because their strict 
localization-function relationship, which was explained above for PDE1A, theoretically 
allows very specific pharmacological interventions. Unfortunately, the PDE1-specific 
inhibitor IC86340 has been discontinued, and a search for new inhibitors is required. 
Stimulators or activators of sGC might be an alternative drug group, although it might 
not provide the same specificity.
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ABSTRACT
We have identified genomic instability as a causative factor in vascular aging, a major 
contributor to cardiovascular disease and death. Loss of endothelium-dependent 
and -independent vasorelaxation, a major hallmark of age-related vascular disease, is 
accelerated in mice with a DNA repair defect in all cells of the organism. Also blood 
pressure and vascular stiffness is increased. It is not known if these changes are due to 
local or systemic DNA damage. We here investigated cardiovascular function in a mouse 
model with specific loss of Ercc1 in vascular endothelial cells (EC-KO) at the age of 3 and 
5 months, and identified the endothelium-derived factor that play a role. In vivo mea-
surements of vascular function revealed decreased microvascular vasodilation in the 
skin, decreased lung perfusion, decreased aortic distensibility, and decreased cardiac 
stroke volume and output at the age of 5 months in EC-KO vs. wildtype controls. This 
was absent at 3 months. At the age of 5.5 – 6 months EC-KO suddenly died, which was 
associated with renal papillary and tubular necrosis. This was preceded by extravasation 
of red blood cells in medular microvessels surrounding the tubuli at 5 months. Ex vivo 
vasodilatory function in aorta and iliac artery were normal at 3 months but decreased 
at 5 months after birth. Coronary artery dilator function was decreased at 3 months 
and to a higher degree at 5 months of age. Vasodilation to endothelium-derived nitric 
oxide was abolished in aorta and coronary artery, whereas endothelium-derived hyper-
polarization and responses to nitric oxide donor sodium nitroprusside were completely 
intact. Expression of eNOS mRNA and protein was decreased in EC-KO. Carotid arteries 
showed no difference in stiffness. Blood pressure was increased at 3 months, but normal 
at 5 months. Scanning electron microscope showed no endothelial denudation and 
aortic von Willebrand factor expression levels were normal in EC-KO. Expression levels 
of senescence markers were unchanged. In summary, DNA damage in the endothe-
lium leads to very specific, non-congenital disturbance of nitric oxide signaling in the 
endothelium, leaving endothelium-derived hyperpolarization and smooth muscle cell 
responses to nitric oxide intact. The phenotypic changes resemble those reported for 
eNOS knockout mice, including mild, temporarily increased blood pressure and gradual 
decrease of cardiac output. Thus, the effects of local endothelial DNA damage might be 
largely attributed to loss of nitric oxide signaling.
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INTRODuCTION
Despite the currently available prevention and treatment options, cardiovascular dis-
eases (CVD) continue to be a main cause of morbidity and mortality worldwide. Even 
when traditional risk factors, such as smoking, high cholesterol, diabetes or a sedentary 
lifestyle, are absent or controlled, cardiovascular problems remain a major health issue 
due to the independent risk factor age.1 Aging, which is not synonymous to age, is a 
natural but very complex process leading to the decline and ensuing loss of organ func-
tion. The accumulation of damaged DNA is considered as one of the primary causes 
driving the process of aging, and this involves various processes.2 Firstly, cells with unre-
paired damaged DNA enter into apoptosis or senescence; apoptosis can lead to organ 
function decline due to the loss of cells or tissue, and senescent cells acquire and secrete 
a senescence-associated secretory phenotype (SASP) that affects surrounding cells and 
ultimately renders the organism more susceptible to age-associated diseases.3 This 
principle is thought to be applicable for both cancer as well as cardiovascular disease. 
Further, DNA damage might simply lead to mutated gene products. Last, but perhaps 
most importantly, accumulating DNA damage leads to a so-called ‘survival response’ 
that switches the organism’s physiological status from one that promotes growth to one 
that suppresses growth and focuses on maintenance.4 The contribution of these moduli 
to age-related disease putatively depends on classical disease risk factors and yet un-
charted DNA damage sources. In all likelihood, in human populations this is subjected 
to individual genetic and environmental variations, explaining individual differences in 
the rate of aging. Also, this process potentially leads to variation in the rate of aging 
between organs. This so-called segmental aging is clearly observed in mouse models of 
accelerated aging.4 
Several mouse models of accelerated aging due to the accumulation of damaged 
DNA repair have been generated.4 One of the models that shows many features of 
human-like aging is the Ercc1Δ/− mouse. In these heterozygous mice the function of the 
Excision Repair Cross Complementation group 1 (ERCC1) protein is impaired because of 
one null-allele and one N-terminal protein truncation due to a deletion mutation in exon 
7 of the Ercc1 gene.5 The ERCC1 protein is important for several DNA repair mechanisms 
including global genome-and transcription-coupled nucleotide excision repair and 
interstrand crosslink repair; therefore, in Ercc1Δ/− mice there is an overt accumulation of 
DNA damage.6 Ercc1Δ/− mice live an average of 24-28 weeks and within 12 weeks of age 
develop many human-like features of accelerated aging like neurodegeneration and 
osteoporosis, and also display increased blood pressure, increased vascular stiffness and 
loss of macro- and microvascular dilator function.7 Like in humans and aging wildtype 
rodents, the vasodilator dysfunction in Ercc1Δ/− mice is explained by reduced NO-cGMP 
signaling, which was due to decreased endothelial nitric oxide synthase (eNOS) expres-
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sion and activation and increased metabolism of cGMP by phosphodiesterase (PDE) 1 
and PDE5.7, 8
Ercc1 Δ/− mice display segmental progeria, leaving some processes, like the oc-
currence of brain or spinal cord vacuolization, and tumor development, unaffected.5 
Conversely, this implies that affected organs might suffer from the impact of local rather 
than systemic DNA damage. Thus, the observed accelerated decline of endothelium-
dependent vasodilation in Ercc1Δ/− mice might arise from defective endothelial DNA 
repair. To address if local endothelial DNA repair leads to specific changes as observed 
in Ercc1Δ/− mice we investigated cardiovascular function in a mouse model with specific 
loss of Ercc1 in vascular endothelial cells.
METhODS
Animals
We evaluated the effect of endothelial genomic instability on cardiovascular function 
in a mouse model of endothelium-specific DNA repair defectiveness (Tie2Cre+ Ercc1fl/- 
mouse model).
The Cre-loxP system was used to generate a conditional mouse model expressing 
Cre-recombinase under the control of the vascular endothelial cell receptor tyrosine 
kinase (Tie2) promoter (Tie2Cre). Tie2Cre+/- female mice were crossed with Ercc1+/- male 
mice to generate Tie2Cre+/- Ercc1+/- mice in a C57BL/6J background. The females were 
then crossed with Ercc1fl/fl male mice in a FVB/N background to produce Tie2Cre+ Erc-
c1fl/- mice in a C57BL6/FVB F1 hybrid background 9. These Tie2Cre+ Ercc1fl/- mice were 
homozygous for Ercc1, after deletion of the floxed allele in endothelial cells expressing 
Cre-recombinase. These mice are referred throughout this manuscript as endothelial 
cell-knock out mice (EC-KO). Littermates (genotypes: Tie2Cre+ Ercc1fl/+, Tie2Cre- Ercc1fl/+, 
Tie2Cre- Ercc1fl/-) were used as controls. These mice are referred to as control mice in the 
manuscript.
Mice were kept in individually ventilated cages, in a 12 h light/dark cycle and fed 
normal chow and water ad libitum. All animal studies were approved by the Animal Care 
Committee of Erasmus University Medical Center Rotterdam (protocol number 118-13-
03).
EC-KO mice were dying suddenly when they were around 5.5-6 months-old, because 
of this measurements were performed at 3 and 5 months.
Pathological examination, tissue collection and blood analysis
One of the EC-KO mice unexpectedly died prematurely during daytime, and was sub-
mitted to whole body fixation in formalin for 48 hours and pathological examination. 
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Tissues were processed by paraffin embedding technique, sectioned by the microtome, 
and then stained with Hematoxiline Eosin. Slides were examined by a board-certified 
veterinary pathologist.
Before sacrifice, blood was collected from the vena porta and analyzed for cell 
counts. Immediately after sacrifice we collected vascular tissue, lungs, kidneys and heart.
Cardiac function
 Cardiac geometry and function were measured by performing 2-D guided short axis 
M-mode transthoracic echocardiography (Vevo770 High-Resolution Imaging System, 
VisualSonics) equipped with a 35-MHz probe. Left ventricular (LV) external and lu-
men diameters were traced, and heart rate, LV mass and fractional shortening were 
subsequently calculated using the VisualSonics Cardiac Measurements Package. Mice 
were under anesthesia with 2.5% isoflurane, intubated and connected to a pressure-
controlled ventilator, and body temperature was kept at 37°C.
Blood pressure measurement
Blood pressure (BP) was measured non-invasively in conscious mice using the tail cuff 
technique (CODA High-Throughput device, Kent Scientific). BP was measured on 5 con-
secutive days and each session consisted of 30 measurement cycles for each mouse. The 
first 4 days were taken as acclimatization sessions to minimize stress-induced changes 
in the measurements. A measurement was considered invalid if the minimum blood 
volume required for a blood pressure reading to be made was not reached. BP values 
reported here correspond to the average of all valid measurements recorded at day 5.
Aortic stiffness
Using the data on systolic and diastolic aortic diameters acquired by transthoracic echo-
cardiography we calculated aortic dilatation by subtracting the diastolic aortic diameter 
from the systolic aortic diameter.
Microvascular vasodilator function and lung perfusion in vivo
Three to seven days after blood pressure measurement we assessed in vivo vasodila-
tor function using Laser Doppler perfusion imaging. Reactive hyperemia, defined as 
the increase of the hindleg perfusion after temporary occlusion of the blood flow, was 
calculated. Blood flow was measured in the left hindleg one day after removing the 
leg’s hair using a hair removal cream. The hindleg was kept still with help of a fixation 
device. After recording baseline perfusion for 5 minutes, blood flow was occluded for 2 
minutes with a tourniquet. To record hyperemia and the return of the blood flow to the 
post-occlusion baseline, blood flow was monitored for 10 minutes after releasing the 
tourniquet. During all measurements mice were under 2.8% isoflurane anesthesia, and 
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temperature was constantly monitored and maintained between 36.4-37.0 °C. For each 
mouse we calculated the maximum response to occlusion and the area under the curve 
relative to the post-occlusion baseline. Only the area above the baseline was considered. 
Values below the baseline were set at 0.
In a separate set of 5 months-old control vs. EC-KO mice (n= 3 vs 3) lung perfusion 
was measured by microCT imaging. Mice were anesthesized with 2.5% isoflurane in O2 
and received IV injection with eXIA160 (Binitio Biomedical Inc., Canada) contrast agent. 
The mice were placed in a imaging cassette and restrained to prevent movement. Mice 
were scanned using intrinsic cardiac respiratory gating to reduce artifacts caused by 
irregular breathing. Blood flow was assessed during diastole.
Ex vivo vascular assessment
Immediately after sacrifice thoracic aorta, iliac and left anterior descending coronary 
arteries were carefully dissected from mice and kept in cold Krebs-Henseleit buffer (in 
mmol/L: NaCl 118, KCl 4.7,CaCl2 2.5, MgSO4 1.2 , KH2PO4 1.2, NaHCO3 25 and glucose 8.3 
in distilled water; pH 7.4). Vessel rings of 1.5-2 mm length were mounted in small wire 
myograph organ baths (Danish Myograph Technology, Aarhus, Denmark) containing 6 
mL of Krebs-Henseleit buffer oxygenated with 95% O2 and 5% CO2. After warming, the 
tension was normalized by stretching the vessels in steps until 90% of the estimated 
diameter at which the effective transmural pressure of 100 mmHg is reached. Thereafter 
the viability of the vessels was tested by inducing contractions with 30 and 100 mmol/L 
KCl. After the maximum response to KCl had been reached vessels were washed.
To evaluate vasodilatory responses, aortic and iliac segments were first pre-
constricted with 30 nmol/L of the thromboxane A2 analogue U46619, resulting in a 
preconstriction corresponding with 50-100% of the response to 100 mmol/L KCl. After 
this, concentration-response curves (CRCs) to the endothelium-dependent vasodilator 
acetylcholine (ACh) were constructed by adding cumulative doses (10-10-10-5 mol/L). 
When the CRC to ACh was completed, the vessel segments were exposed to the 
endothelium-independent vasodilator sodium nitroprusside (SNP, 10-4 mol/L). Complete 
CRCs to SNP (10-10-10-4 mol/L) were performed in parallel rings preconstricted with 30 
nmol/L U46619.
The contribution of nitric oxide (NO) and prostaglandins in the aortic ACh responses 
was explored by performing the experiments in the presence of the endothelial nitric 
oxide synthase inhibitor NG-nitro-L-arginine methyl ester salt (L-NAME, 10-4 mol/L) and 
the cyclo-oxygenase (COX) inhibitor indomethacin (INDO, 10-5 mol/L). Inhibitors were 
added to the organ bath 20 minutes prior to U46619.
In coronary arteries we investigated endothelium-dependent vasodilation by per-
forming CRCs to ACh and to the nucleotides adenosine diphosphate (ADP) and uridine 
triphosphate (UTP). The intracellular signalling activation caused by ADP and UTP, has 
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not been studied in detail in the mouse heart. However, studies on blood pressure and 
cerebral arterioles in the eNOS-/- mice have shown that the two nucleotides do not cause 
vasodilation through the same mechanisms. It is thought that UTP-induced vasodilation 
exclusively involves endothelium-dependent hyperpolarization (EDH) 10, while ADP acts 
through both NO and EDH on a 50%/50% basis.11 CRCs to ADP and UTP were performed 
in coronary arteries precontracted with U46619 and then in coronary segments pre-
contracted with 30 mM KCl. The latter was done to elucidate the contribution of EDH in 
ADP- and UTP-induced vasodilation because when arteries are precontracted with 30 
mmol/L KCl, EDH cannot occur because the artery is too strongly depolarized.12-14 VSMC 
dilatory function was tested by constructing CRCs to the NO donor SNP.
In iliac rings, after washing out KCl 100 mmol/L, we investigated contractile re-
sponses to angiotensin II (AngII, 10-10-10-7 mol/L), endothelin-1 (ET-1 10-10-10-6 mol/L) and 
phenylephrine (PE, 10-9-10-5 mol/L). The involvement of Ang II type 2 (AT2) receptors in 
AngII responses was tested by adding PD123319 (10-7 mol/L) 30 minutes prior to starting 
the CRCs.
Mechanical properties of the vascular wall
Carotid arteries explanted from 5 months old mice were mounted in the pressure 
myograph (Danish Myograph Technology, Aarhus, Denmark) in calcium free buffer (in 
mmol/L: NaCl 120, KCl 5.9, EGTA 2, MgCl2 3.6, NaH2PO4 1.2, glucose 11.4, NaHCO3 26.3; 
pH 7.4) to investigate the passive properties of the vessel. The intraluminal pressure of 
the carotid artery was increased stepwise by 10 mm Hg starting at 0 mm Hg and reach-
ing 120 mm Hg. Following each 10 mm Hg step the vessel was allowed to equilibrate for 
3 minutes and then, lumen and vessel diameter were measured and used to calculate 
mediastrain and mediastress. Mediastrain, calculated as pressure-induced increases in 
lumen diameter, relates to the elasticity of the vessel. Mediastress indicates distending 
force on the vessel wall or wall tension, and was calculated as described by Resch et al.15
eNOS activation
Freshly isolated lungs were cut in portions of about 0.5 x 0.5 mm, which were carefully 
incised with cuts made with microsurgical scissors to allow rapid, free entry of buffer 
and its contents into the lung vasculature. The portions were allowed to equilibrate for 
1 hour in Krebs-Henseleit buffer oxygenated with 95% O2 and 5% CO2 at 37ºC, freely 
hanging in the center of 10 ml-organ baths. After this, half of the lung portions were 
stimulated with 10 μmol/L acetylcholine for 10 minutes, and the other half remained 
unexposed. The lung portions were then removed and snap-frozen in liquid nitrogen to 
be stored at -80ºC until use for determination of eNOS phosphorylation levels applying 
Western blotting.
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Quantitative real-time PCR
Total RNA was isolated from aortic tissue and cDNA was prepared, which was amplified by 
Real-time PCR on a StepOne thermocycler (Applied Biosystems). Each reaction was performed 
in duplicate with SYBR Green PCR Master Mix (Applied Biosystems). β-actin and HPRT-1 were 
used for normalization. Results from unreliable duplicates or melting-curves were discarded 
(values were excluded of Ct ≥ 31). The relative amount of genomic DNA in DNA samples was 
determined as follows: RQ = 2(-∆∆Ct). Sequences of the primers used are provided in Table 1.
Table 1. Sequences of the primers used for qPCR analyses.
Gene name forward primer Reverse primer
p16 CCCAACGCCCCGAACT GCAGAAGAGCTGCTACGTGAA
p19 GCCGCACCGGAATCCT TTGAGCAGAAGAGCTGCTACGT
p21 GTCCAATCCTGGTGATGTCC GTTTTCGGCCCTGAGATGT
TNFα AGGGTCTGGGCCATAGAACT CAGCCTCTTCTCATTCCT
IL-1α TCAACCAAACTATATATATCAGGATGTGG CGAGTAGGCATACATGTCAAATTTTAC
IL-6 GACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTG
MMP13 ACTTCTACCCATTTGATGGACCTT AAGCTCATGGGCAGCAACA
GAPDH TGCACCACCAACTGCTTA TGGATGCAGGGATGATGTTC
Western blots
Frozen tissues were homogenized in ice cold RIPA buffer (50 mmol/L HCl pH 7.4, 150 
mmol/L NaCl, 1% NP-40, 0.25% Na-deoxycholate and 1 mmol/L EDTA) containing protease 
and phosphatase inhibitors (1 mmol/L PMSF, 1 mmol/L NaVO4, 1 mmol/L NaF, 1 μg/mL 
aprotinin, 1 μg/mL pepstatin and 1 μg/mL leupeptin) using a stainless-steel ultraturrax 
(Polytron). Homogenized tissues were centrifuged and protein concentration was mea-
sured in the supernatants using the BCA method (Thermo Scientific, USA). The samples 
were run on a criterion bis/tris gradient gel, and blotted to nitrocellulose membranes.
For eNOS, membranes were blocked with 5% milk TBS-T; for pSer1177- eNOS mem-
branes were blocked with 5% BSA TBS-T. After blocking, membranes were incubated 
overnight with the primary antibodies as follows: eNOS (Santa Cruz, SC-654 1:500 in 5% 
milk TBS-T) and pSer1177- eNOS (Santa Cruz, SC-21871-R 1:500 in 5% BSA TBS-T).
We used an HRP- conjugated antibody (Bio-Rad 1:2000 in 1% milk-TBS-T) to detect 
the primary antibodies. For visualization we used an enhanced chemiluminiscent sub-
strate for detection of HRP (Pierce ECL Western Blotting Substrate, Thermo Scientific). All 
protein expression levels were normalized to actin.
Statistical methods 
Data are presented as mean and SD. Statistical analysis between the groups of single 
values was performed by two-sided t-test. Differences in dose-response curves were 
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tested by ANOVA for repeated measures (sphericity assumed). Differences were consid-
ered significant at p <0.05.
RESulTS
General health features
Tie2Cre Ercc1f/- mice had a reduced lifespan, with a median of 24.6 weeks (Figure 1A). Up 
until several hours before death occurred EC-KO mice did not show any signs of discom-
fort or morbidity and body weights were normal (Figure 1B). However, shortly before 
death, immobility and rapid breathing was observed in 2 of the EC-KO mice. These mice 
died quickly during daytime. All other mice died during night-time when they were not 
observed. Blood cell analyses showed no significant changes (Table 2). One of the mice 
that died at the age of 22.6 weeks during daytime was collected timely enough to be 
submitted to whole body fixation in formalin for 48 hours and pathological examina-
tion. Organs included were brain, heart, skeletal muscle, aorta, sciatic nerve, liver, spleen, 
lung and kidney. The spleen showed moderate lymphopenia and lymphocyte apoptosis 
(Figure 1C), however this was not an obvious potential death cause. The kidney was 
showing severe necrosis spreading from the papilla to the medulla (Figure 1D-E). Since 
this a potential cause of death, e.g. by rapidly causing severe electrolyte disturbances, we 
investigated if 5 months old EC-KO mice showed aberrations in the kidney. Kidney micro-
sections were stained with Mason’s trichrome for microscopic examination. 5 Months-old 
EC-KO mice displayed extravasation of red blood cells in the proximity of the tubules 
(Figures 1F-G). The data suggest that endothelial DNA damage strongly affects the renal 
medullary microvasculature, and that this is a potential mechanism of mortality.
Table 2. Blood cell counts at 3 and 5 months
Parameter
3 months 5 months
KO (n=10) Control (n=17) p-value KO (n=8) Control (n=17-19) p-value
Leucocytes 7 (3.0) 6 (2.9) 0.70 7 (2.8) 9 (5.2) 0.22
% Lymphocytes 63 (7.6) 60 (8.0) 0.43 63 (6.5) 56 (16.6) 0.30
% Monocytes 4 (0.5) 4 (0.8) 0.10 4 (1.1) 4 (1.1) 0.24
% Granulocytes 33 (7.5) 36 (7.5) 0.33 34 (5.7) 35 (12.0) 0.80
Erythrocytes 10 (0.8) 10 (0.7) 0.35 10 (0.6) 10 (0.5) 0.71
Hemoglobin 9 (0.8) 9 (0.6) 0.87 10 (0.6) 9 (0.6) 0.15
Hematocrit 0.5 (0.04) 0.5 (0.03) 0.77 0.5 (0.03) 0.5 (0.03) 0.20
Platelets 383 (217) 343 (250) 0.67 451 (325) 497 (313) 0.74
Values are Mean (SD).
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In vivo microvascular function
At 3 months we did not observe significant differences between EC-KO and control mice 
in reactive hyperemia after 2-min occlusion of blood flow (Figures 2A, B, E, F). However, 
when measured at 5 months, EC-KO mice showed decreased reactive hyperemia in 
	     
	






!  !	
 !
! 

*-'( +-*

-&


	
.
/%
#-
,1
/!
#1)
-,
	     
	






!  !
 !

! 	


*-'( +-*

-&


	
.
/%
#-
,1
/!
#1)
-,
	     
	






!  !
 !
! 


*-' +-*

-&


	
.
/%
#-
,1
/!
#1)
-,
	      
	





 !  !
 !
! 	

*-' +-*

-&


	
.
/%
#-
,1
/!
#1)
-,
 
 
 
+-,1(0 +-,1(0
-,1/-*+)#%
	     
	






! 
! 
! 

*-'( +-*

-&


	
.
/%
#-
,1
/!
#1)
-,

	     
	









*-'( +-*

-&


	
.
/%
#-
,1
/!
#1)
-,
-,1/)"21)-,-&!,$./-01!'*!$),01-%,$-1(%*)2+$%.%,$%,13!0-$)*!1)-,0
figure 3. Endothelium-dependent and independent relaxations in isolated aortic and iliac rings measured 
ex vivo in small wire organ bath set-ups. ACh-induced vasodilation of KO and control mice in aorta and iliac 
artery at 3 months (A), and at 5 months (B). Endothelial-independent relaxations induced by SNP in aortic 
and iliac rings at 3 months (C) and at 5 months (D). Contribution of NO and prostaglandins to ACh-induced 
vasodilation in control (E) and KO mice (F). **P<0.001; ***P<0.0001 (GLM-RM).
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hindlimbs (Figures 2C-F). Of note, when passing from the age of 3 to 5 months WT mice 
tended to show increased reactive hyperemia, whereas this tended to decrease in EC-KO 
mice. Lung perfusion was successfully measured in only 1 pair of control vs. EC-KO mice 
and results suggest that blood supply to the lung is decreased in EC-KO mice (Figure 2G); 
however, this experiment will have to be repeated in a representative sample of mice to 
draw definitive conclusions.
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figure 4. Vasodilation in coronary arteries measured ex vivo in small wire organ bath set-ups. Relaxations to 
ACh (A), ADP (B) and UTP (C) in coronary rings precontracted with U46619. Relaxations to ADP (D) and UTP 
(E) in coronary rings precontracted with KCl 30mM. SNP induced vasodilation (F). ***P<0.0001 (GLM-RM).
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Ex vivo vasodilator function
Loss of vasodilator capacity is an important feature in the pathogenesis of aging-related 
cardiovascular disease. Therefore, vasodilator responses were measured. Arterial tissue 
from diverse embryonic origin, i.e. descending aorta vs. iliac artery vs. coronary artery, 
were included, since it is known that this origin creates differential pathogenic changes.16 
Vasodilator responses in aorta and iliac arteries 
Ex vivo vascular function tests revealed an age-dependent decrease in endothelium-
dependent relaxations to acetylcholine in EC-KO mice in aortic and iliac artery, being 
absent at 3 months (Figure 3A) but present at 5 months (Figures 3B). Vascular smooth 
muscle dilatory function to the NO donor SNP was intact in both aorta and iliac arteries 
at 3 and 5 months (Figures 3C-D).
To investigate which vasodilator pathways were involved in the decreased endo-
thelium-dependent relaxations to ACh in aorta at 5 months we performed the CRCs in 
the presence of the eNOS inhibitor L-NAME and the COX inhibitor INDO. In control mice, 
approximately half of the ACh responses were mediated by NO (responses to ACh were 
reduced by ~50% in the presence of the eNOS inhibitor L-NAME) (Figure 3E). No appar-
ent contribution of prostaglandins was observed since adding the COX inhibitor did not 
cause further reductions in the vasodilator responses (Figure 3E). Compared to control 
mice, in EC-KO mice there was no contribution of the NO or prostaglandins pathways 
to the ACh vasodilatory responses (Figure 3F). In both WT and KO mice a residual ACh 
response was observed, suggesting that the contribution of EDH is intact.
Vasodilator responses in coronary arteries 
In coronary arteries endothelial dysfunction was already present at 3 months (Figure 4). 
Endothelium-dependent relaxation to ACh was significantly decreased in EC-KO mice at 
3 months and more pronounced at 5 months (Figure 4A).
At 5 months we evaluated responses to the nucleotides ADP and UTP. Relaxations to 
ADP were found to be partly reduced in EC-KO mice (Figure 4B) while responses to UTP 
were similar in EC-KO and control mice (Figure 4C). Figures 4D and 4E show the responses 
to ADP and UTP in arteries precontracted with 30 mmol/L KCl instead of U46619. In such 
arteries, EDH cannot occur because the artery is too strongly depolarized; 12-14 therefore 
the relaxation responses seen in Figure 4D are mediated by NO, confirming that in 
EC-KO mice NO signaling is affected and that ADP causes relaxation via mixed NO-EDH 
signaling. In Figure 4E no relaxation responses are observed (either in EC-KO or control 
mice), indicating that the relaxations responses induced by UTP (shown in Figure 4C) are 
entirely dependent on EDH. Therefore, gathering the results from Figures 4A-4E and as 
expected from the results in aorta we conclude that in EC-KO mice NO signaling is nearly 
abolished while EDH signaling is preserved. In agreement with the results in aorta and 
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iliac arteries, vascular smooth muscle dilatory function to NO in coronary arteries was 
intact at 3 and 5 months (Figure 4F).
levels of eNOS, expression of endothelial vs. VSMC components, and scanning 
electron microscopy
Western blot analysis showed a tendency towards reduced baseline eNOS protein level, 
corrected for β-actin, in EC-KO vs. WT (Figure 5A). The ratio of eNOS-activating phos-
phorylation of the serine residue at position 1177 (pSer1177-eNOS) to total eNOS protein 
was not different at baseline. (Figure 5A). Expression of eNOS mRNA also appeared to be 
suppressed in EC-KO, further explaining the loss of eNOS protein and signaling (Figure 
5B). To elucidate vascular cell-specific effects of the parallel presence of Tie2-driven Cre 
expression with Plox sites in the mouse genome, we measured the expression of Ercc1 
mRNA, endothelium-specific (von Willebrand factor, vWF) and VSMC-specific (SM22α ac-
tin) markers in aortic tissue of EC-KO vs. control mice (Figure 5B). We selected 3 samples 
representing EC-KO mice and 5 samples representing control mice; however, one of the 
EC-KO samples did not contain sufficient RNA to successfully perform PCR.
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figure 5. Levels of eNOS, expression of endothelial vs. VSMC components, and scanning electron micros-
copy. Protein expression levels in lung of eNOS and p-eNOS (A), mRNA expression of eNOS, ercc1, von 
Willebrand factor and SM22α actin (B). Representative scanning electron microscopy images of the endo-
thelium (C). Wall thickness measured in HE-stained aortic microsections (D).
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Although statistical analyses could not be performed, in EC-KO mice there was a 
striking decrease in Ercc1, whereas vWF and SM22α actin expression remained similar to 
expression in control mice. The data suggest that Ercc1 was suppressed but did not lead 
to loss of ECs or VSMCs. To examine the integrity of the endothelial cell layer distal parts 
of the abdominal aorta from 5 months-old animals (5 control vs. 5 EC-KO mice) were 
fixated in glutaraldehyde 2% and used for scanning electron microscopy after platinum 
sputtering. Scanning Electron Microscopy of the luminal surface also did not reveal a 
loss of endothelial cells (Figure 5C). Also, wall thickness measured microscopically in HE-
stained aortic microsections was similar between EC-KO and control mice (Figure 5D).
Blood pressure
Since endothelium-dependent vasodilations were altered we explored if this had conse-
quences for blood pressure. Systolic blood pressure was higher in EC-KO mice at 3 months 
(138 mm Hg in EC-KO vs 125 mm Hg in control mice) but no differences were observed at 5 
months. No differences were observed in diastolic blood pressure at 3 or 5 months (Table 3).
Table 3. Cardiac function, blood pressure and aorta distensibility at 3 and 5 months.
Parameter
3 months 5 months
KO 
(n=10-19)
Control 
(n=11-21)
p-value
KO 
(n=11-17)
Control
 (n=12-31)
p-value
SV (uL)* 30 (4.5) 31 (4.1) 0.56 25 (5.2) 29 (3.5) 0.03
FS (%) 34 (5.1) 34 (5.7) 0.71 33 (6.5) 33 (6.0) 0.94
HR (bpm) 502 (37.4) 492 (37.0) 0.38 494 (40.1) 498 (49.2) 0.78
CO (ml/min)* 15 (2.3) 15 (2.6) 0.92 13 (2.4) 14 (1.7) 0.06
SBP (mmHg) 138 (14.6) 125 (11.9) 0.04 128 (22.8) 125 (20.6) 0.72
DBP (mmHg) 94 (15.2) 89 (15.6) 0.46 88 (19.3) 86 (20.7) 0.86
Aorta distensibility (mm) 0.3 (0.1) 0.3 (0.04) 0.69 0.2 (0.1) 0.3 (0.1) 0.05
Values are Mean (SD). SV, stroke volume; FS, fractional shortening; HR, heart rate; bpm, beats per minute; 
CO, cardiac output; SBP, systolic blood pressure; DBP, diastolic blood pressure. * Values are corrected for 
heart weight, expressed as per 100 mg of heart weight.
Cardiac function
The change in blood pressure followed an unexpected course, as it is slightly elevated at 
an age that vasodilation only started to develop (3 months), and becomes normal again 
when endothelium-dependent vasodilation is strongly decreased (5 months). Cardiac 
function was explored as a possible explanation. Since we included female and male 
mice, we corrected the values where applicable for heart weight No differences between 
EC-KO and control mice were observed in heart rate, stroke volume (SV), cardiac output 
(CO) and fractional shortening at 3 months. However, stroke volume was significantly 
decreased in 5 month-old EC-KO compared to control mice (Table 3). Also, SV and CO 
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significantly decreased in the EC-KO mice at 5 months compared with measurements 
performed when they were 3 months old.
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figure 6. Constrictor responses at 3 and 5 months in aorta and iliac arteries. Contractile responses (in milli 
Newtons) to KCl 100 mM in aorta and iliac arteries (A, E), and to angiotensin II (B, F), endothelin-1 (C, G) and 
phenylephrine (D, H) in iliac arteries at 3 and 5 months. *P<0.05 (GLM-RM).
Chapter 3
92
Ex vivo vasoconstrictor responses 
Another possibility to explain the course of blood pressure change is adaptation of 
contractile responses. Hence, we tested receptor-independent constriction due to 
hyperpolarization with KCl, and receptor-mediated constriction to the central nerve 
system-regulated neurotransmitter PE, the both locally and systemically regulated 
hormone Ang II, and the locally regulated endothelium-derived constricting peptide 
ET-1. At 3 months, no differences were observed between EC-KO and control mice in the 
responses to KCl, Ang II, ET-1 or PE (Figures 6A-D). At 5 months, EC-KO mice exhibited 
significantly weaker contractions to KCl in aorta and iliac arteries (Figure 6E). In iliac ar-
tery, constrictor responses to Ang II and ET-1 (Figures 6F-G) remained normal, but those 
to PE were significantly decreased (p-value = 0.016) (Figure 6H).
Mechanical properties of the vascular wall
Increase of vascular stiffness is another factor contributing to increased blood pres-
sure. Since we previously found that arterial stiffness was increased in Ercc1Δ/- mice,7 
we measured aortic wall movement during cardiothoracic echography, and calculated 
distensibility of the aorta by subtracting the diastolic aortic diameter from the systolic 
aortic diameter.
At 3 months no differences were found between EC-KO and control mice but at 5 
months distensibility was decreased in EC-KO (Table 3).
Since the decreased distensibility might be an indicator of increased wall stiffness 
we evaluated the mechanical properties of carotid arteries (Figure 7). No significant 
differences in lumen diameter or wall thickness under similar perfusion pressure incre-
ments were observed between EC-KO and control mice (Figures 7A-B). No differences in 
mediastrain (indicating elasticity) or mediastress (which indicates distending force on 
the vessel wall) were observed (Figures 7C-D).
mRNA expression of SASP components
Since we previously found an increase of p53, p21 and senescence-associated 
β-galactosidase staining in Ercc1Δ/- mice, a role of cellular senescence in the observed 
endothelial function differences was suggested 7. Although our previous report could 
detect only few senescent cells in the medial layer, and we only expect EC senescence in 
our EC-KO, which should be difficult to detect, we decided to perform qPCR for several 
SASP components. We found no significant differences in aortic mRNA levels of p16, 
p19, p21, TNFα, IL-1α, IL-6 and MMP13 (Figure 8).
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figure 7. Mechanical properties of the carotid artery measured in a vascular perfusion set-up at 5 months. 
Lumen diameter (A), wall thickness (B), mediastrain (C) and mediastress (D) measured at increasing intra-
luminal pressures.
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figure 8. mRNA expression of several SASP components measured in aorta. aortic mRNA levels of p16, p19, 
p21, TNFα, IL-1α, IL-6 and MMP13 in 5 months-old Control vs KO mice.
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DISCuSSION
We investigated the role of local endothelial genomic instability on cardiovascular func-
tion in a mouse model with specific loss of Ercc1 in vascular endothelial cells. We found 
that local endothelial genomic instability causes macrovascular and microvascular va-
sodilator dysfunction due to specific loss of endothelium-dependent NO signaling, i.e., 
not EDH or prostaglandins. Likely, there is a reduced NO availability, taken the decreased 
eNOS expression, and the normal responses of VSMC to exogenously administered NO. 
The preserved endothelial cell layer, as confirmed by SEM, intact vWF levels and normal 
EDH excludes the loss of NO through reduced EC numbers. Notably, the rate of develop-
ment of vasodilator function is vessel-specific, at 3 months of age being observed in 
coronary arteries only but not in iliac artery, aorta, or the skin microvasculature. This 
suggests a non-congenital origin of the vasomotor dysfunction and a non-homogenous 
regulation of eNOS over the vascular bed under otherwise healthy conditions. The 
reduction of vasodilator response was only associated with a temporary blood pressure 
increase. Apart from vasodilator dysfunction, EC-KO mice showed a severely compro-
mised microvascular barrier function in the kidney, potentially leading to premature 
death. Furthermore, cardiac output was affected at 5 months of age. In addition, aortic 
distensibility measured by echography was reduced, suggesting increased vascular stiff-
ness, but this was not observed by stress and strain measurements in carotid arteries. 
In summary, local endothelial DNA damage leads to very specific loss of NO signaling, 
affecting organ function and potentially also blood pressure under otherwise healthy 
conditions. The impact on vascular stiffness remains to be further explored.
Our present study shows that the effect of DNA damage on NO signaling is very spe-
cifically evoked within the endothelium, possibly even cell-autonomously. This answers 
an important question remaining from our previous study in the Ercc1Δ/− mouse model, 
showing that NO signaling was disturbed both in EC and VSMC.7, 8 Hence, the endothelial 
effect of DNA damage is not dependent on genomic lesions elsewhere. Nevertheless, 
the endothelium being important in all organs, Ercc1 KO mice share some features, 
including a worsened renal morphology and a shortened lifespan.5 While Ercc1Δ/− live an 
average of 24-28 weeks, endothelial-specific KO live until an average age of 25 weeks. 
However, in endothelial-specific KO mice death is sudden, without preceding weight 
loss or obvious behavioral changes, whereas Ercc1Δ/− mice start deteriorating at an early 
age, showing consistent weight loss and problems of neuronal origin.5 Renal tubular 
malfunction leading to sudden death caused by severe electrolyte disturbances was 
proposed as one of the possible causes of death in the endothelial KO mice, whereas 
in Ercc1Δ/- mice the neurodegeneration and general frailty are very prominent and 
considered as possible cause of death. Nevertheless, one cannot entirely exclude that 
renal dysfunction contributes in both models. Indeed, cellular senescence and DNA 
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damage response markers are associated with reduced viability of the kidney when 
transplanted.17, 18 More attention is needed for further exploration of the role of DNA 
damage in renal aging and chronic kidney disease, where knowledge is lacking.
On the basis of the present study we cannot entirely rule out that sudden death 
arose from effects on the circulation in other organs. Indeed, the coronary circulation 
was affected relatively early. Lowered cardiac output was observed at the age of 5 
months. Several hours before death at least a part of the animals were showing respi-
rational problems, which might relate to cardiac events. Alternatively, lung perfusion 
might be severely undermined, as was suggested by the observation employing tho-
racic uCT flowmetry. A close monitoring of cardiac function, both left and right ventricle 
as wells as electrocardiograms, pO2, and thrombotic status, which is also regulated by 
EC and NO, would be needed to further elucidate the cause of death. Nevertheless, the 
current findings point out that local endothelial DNA damage has very specific and 
clinically relevant consequences independently from accelerated aging in other organs. 
This underlines the potential of the present model as a model to explore the role of 
endothelial-specific aging on health.
A striking finding was the temporary presence of increased blood pressure, be-
ing increased at 3 months, which is in line with increased blood pressure in 8 weeks 
old Ercc1Δ/- mice found previously,7 but normal again at 5 months. The normalization 
of blood pressure is associated with a lower left ventricular stroke volume and cardiac 
output. Also, vasoconstrictive responses to KCl and phenylephrine were decreased. 
Thus the blood pressure rise might be lost in EC-KO at the age of 5 months because of 
reduced vasoconstrictor responses. Whether this is an adaption response or a patho-
logical consequence of DNA damage is unclear. On the one hand, the specific reduction 
of PE vs. ET-1 and Ang II responses might point at an adaptation, since the adrenergic 
receptors acted upon by PE are part of the acute, vasomotoric blood pressure regulation 
by the sympathetic nervous system, whereas Ang II and ET-1 are more associated to 
chronic vascular remodeling. On the other hand, the altered cardiac function might be 
a consequence of reduced coronary vasodilator capacity. Whether it be the one, the 
other or a combination of both processes, at least the almost total loss of NO signal-
ing does not immediately lead to dramatic consequences for blood pressure or cardiac 
function at the age studied. This is in striking resemblance with earlier findings in eNOS 
knockout mice, where it was shown that blood pressure increase was also biphasic, and 
that cardiac hypertrophy only develops much later, at 21 months of age.19 Of course, 
the presence of compensatory mechanism in an otherwise healthy animal, which holds 
for both our EC-KO as well as eNOS KO mice, will enable the animals to maintain blood 
pressure homeostasis. Although prematurely dying, aging eNOS KO mice live on aver-
age 4 times longer than EC-KO, and therefore the sudden death observed here cannot 
be explained by lack of eNOS function alone.
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Increased vascular stiffness is an important hallmark of vascular aging. We showed 
previously that DNA damage accelerates the increase of vascular stiffness. The origin of 
this increase, either in humans or in our model of accelerated aging, is not completely 
understood. Here we show that EC-KO mice display reduced aortic distensibility at 5 
months of age. However since increased stiffness could not be confirmed in carotid 
arteries, the change observed in aorta might be due to the reduced stroke volume of the 
heart. On the other hand, compliance is normally calculated correcting vascular disten-
sion for blood pressure, and the latter is unchanged in 5 month-old EC-KO. Regretfully, 
blood pressure was not measured in parallel with compliance. Again in agreement, eNOS 
KO mice of similar age as our EC-KO show decreased aortic compliance. However, their 
carotid compliance is higher, albeit marginally.20 Since eNOS decrease is only partial in 
our model, a slower development of increased vascular stiffness might be expected, 
and the reduced aortic distensibility might be an early sign of such aberration. Further 
scrutiny with more exact measurements, combining distensibility, pulse wave velocity 
and blood pressure is warranted.
Our results could not be correlated to cellular senescence. This could be because 
cellular senescence might not be required for induction of vasodilator dysfunction. 
Alternatively, our analysis might not allow detection of EC-specific changes, ECs being in 
strong minority compared to VSMC in aortic tissue causing signal dilution. In a previous 
study we showed that in Ercc1Δ/- mice senescent cells were VSMC, whereas senescent 
EC were not observed. Senescent cells were only very few, increasing the chance for 
senescent EC to remain undetected. Nevertheless, one has to question how senescence 
in very few cells could lead to the presently observed, strong effects on vasodilation. 
Hypothetically, the SASP signal might be conveyed through cell-cell communication 
within the endothelium, but until now only the reverse, i.e. the rescue from senescence 
of endothelial cells by endothelial progenitor cells, has been reported.21 Alternatively, 
a strongly localized paracrine pro-inflammatory process could take place. Indeed, this 
would not be detected with our present analysis. In general, the knowledge regarding 
this question is rather minimal, which can be attributed to the complicated detection 
of cell senescence and local inflammation in the endothelium, and the lack of studies 
regarding cell-cell communication in senescent EC. Nevertheless, it has been suggested 
previously that SASP in few EC might cause a more generalized dysfunction of circu-
latory function, much in a way that SASP of tumor fibroblasts might promote cancer 
progression.3 
In summary, we found that local endothelial genomic instability causes sudden 
death, clear microvascular complications in the skin, kidney and possibly also in the 
lung, coronary vasodilator dysfunction associated with lower cardiac stroke volume, and 
macrovascular dilation problems. Potentially, early sign of increased vascular stiffness 
are present. Measurement of NO signaling and the striking resemblance with eNOS 
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knockout mice indicate that the loss of this signaling pathway might play a major role 
in the observed phenotype. Interventions that normalize this signaling pathways, such 
as pharmacotherapy with guanylyl cyclase stimulators or activators and specific phos-
phodiesterase inhibitors are indicated. Further, diet restriction is a potential treatment 
option. This has already been shown to be effective in Ercc1Δ/- mice 6, 8, 22, in accordance 
with its generally known anti-vascular aging effect in humans.
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ABSTRACT
DNA damage is a leading causal factor in aging, and has been implicated in aging-
related cardiovascular disease. Amongst others it contributes to decreased vasodilator 
responses, increased vascular stiffness and increased blood pressure. Recently, we 
showed that genetic ablation of the DNA repair in endothelial cells in mice specifically 
undermines endothelium-derived nitric oxide-induced vasodilation. Since this does not 
represent the full array of functional changes when compared to whole body DNA repair 
mutant mice we hypothesized that local DNA damage in vascular smooth muscle cells 
(VSMC) is also contributing to vascular aging, and that this would cause cell autono-
mous, i.e. VSMC-specific changes. To this end we removed the Zmpste24 gene, which 
is pivotal in the maturation of the genome maintenance protein lamin A, specifically in 
smooth muscle. The smooth muscle-specific DNA mutant mice had a shortened longev-
ity, living on average 26 weeks, morbidity and subsequent death developing rapidly. 
Half of the mice developed dilated proximal aortic arches, which was accompanied by 
aortic regurgitation. Despite a modest decrease of ejection fraction in both mice with 
and without aortic regurgitation (~18% relative to wildtype mice) there were no signs 
of heart failure. Systolic blood pressure was increased by ~10 mmHg, but was normal in 
the mice with aortic regurgitation. Smooth muscle-specific vasodilation to nitric oxide 
was decreased, whereas endothelium-dependent dilations were normal by virtue of 
replacement of nitric oxide responses by increased prostaglandin and endothelium-
dependent hyperpolarization. Carotid arteries showed less compliance to increasing 
intraluminal pressure. The lamina media showed less cellularity, and contracted less 
to Ca2+. There was a trend towards loss of AT2 receptor-mediated vasoconstrictions, a 
hallmark of aging-related vascular disease and hypertension. Markers of DNA damage 
and senescence were increased in the knockout mice. Most of the changes were already 
present in animals of 3 months of age, except for increased SBP and aortic dilatation / 
regurgitation. In summary, a defective DNA repair specifically in smooth muscle cells 
leads to a rapid development of a broad array of aging-related vascular problems, but 
all related to smooth muscle-specific defects. Thus, the effect of DNA damage appears 
to be cell-autonomous. This mouse represents a possible model for type A aortic dissec-
tion, a life threatening condition.
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INTRODuCTION
Age is the most important risk factor for cardiovascular diseases, as age-induced changes 
in vascular structure and function lead to impaired arterial compliance, allowing disease 
to progress.1, 2 Hallmarks of vascular ageing in the clinic include decreases in vasodila-
tory capacity, organ perfusion and angiogenesis, and increases in wall thickness, blood 
pressure (BP) and atherogenesis. Underlying pathogenic processes can be retraced to 
dysfunction of the endothelium, and involve reduced levels of endothelium-derived 
relaxing factors, a pro-inflammatory (‘activated’) state of the endothelial cells (EC), leaki-
ness of the cell-cell contacts, and a disbalance in cell fate (apoptosis vs. senescence vs. 
proliferation).3-6 In Chapter 3 we showed that DNA damage, a causative factor in general 
ageing, forces EC to assume a state of dysfunction that promotes the above-mentioned 
pathogenic processes. Comparison of the vascular phenotype of mice with EC-specific 
knockout of the endonuclease ERCC1 (Tie2Cre:Ercc1f/- mice, or EC-KO) with whole body 
Ercc1 gene mutants (Ercc1Δ/-) revealed that both mice display reduced endothelium-
dependent vasodilation, whereas in Ercc1Δ/- the vascular smooth muscle cells (VSMC) re-
sponsiveness to nitric oxide (NO) is additionally disturbed. Furthermore, in Ercc1Δ/- mice 
there is a quick development of carotid artery stiffness, which is absent in EC-KO, and 
BP increase appears to be more pronounced in Ercc1Δ/- mice. Senescence markers were 
observed only in the aorta of Ercc1Δ/- mice. This suggests that DNA damage effects are 
cell(-type)-autonomous, and that damage in >1 cell type is required to induce the full ar-
ray of changes observed in the aging (human) vasculature. Indeed, multiple studies sup-
port the hypothesis that DNA damage is a major driver of (vascular) ageing by inducing 
cellular apoptosis and senescence.7-9 This not only impairs tissue regeneration, but also 
results in the secretion of various cytokines and growth factors, leading to pathological 
remodeling of the extracellular matrix (ECM), and ultimately causing changes in arterial 
structure and function.6 Structural remodeling in aged arteries includes an increase 
in lumen diameter, diffuse medial thickening, and obvious ECM remodeling.4, 6, 10 This 
contributes to clinical symptoms, in particular systolic hypertension, increased arterial 
stiffness and increased pulse wave velocity (PWV).11, 12 Our observations in Ercc1Δ/- and 
EC-KO point at a role of DNA damage in these processes, at least in EC. The contribution 
of DNA damage in VSMC is still unknown.
One of the leading observations that demonstrates the putative importance of DNA 
damage in humans is the association between lamin A dysfunction and vascular aging. 
Lamin A has an important structural role in nuclear scaffolding and is involved in the regu-
lation of nuclear pore formation and chromatin organization.13, 14 Defective maturation 
of lamin A results in the accumulation of prelamin A. Prelamin A (like progerin) induces 
DNA damage, apoptosis and senescence, e.g. in cells from patients with Hutchinson-
Gilford Progeria Syndrome (HGPS), in cells from aged humans, and in cells from transgenic 
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animals that display premature ageing.14-19 This is due to the fact that prelamin A impairs 
the recruitment of DNA damage repair proteins and checkpoint activation, thus resulting 
in defective DNA damage repair.15, 17, 19-22 HGPS patients and mice with defective lamin 
A maturation show an array of aging features at young age, such as (premature) death, 
weight loss, alopecia, growth retardation, lipodystrophy, and, most importantly, cardio-
vascular disease.16, 23-27 The latter is featured by myocardial infarction or cerebrovascular 
events, and a major loss of VSMCs in both big and small arteries.28 Thus, prelamin A ac-
cumulation is expected to produce a large array of vascular aging features observed in the 
general population in humans. VSMC DNA damage due to prelamin A accumulation, like 
such damage in Ercc1-defective mice (Chapter 2), may disturb VSMC relaxation.
The aim of this study was to determine how prelamin A accumulation in VSMCs 
affects the physiology and function of the cardiovascular system. To this end, the SMC-
specific Zmpste24 KO mouse was used. This is a novel model where the accumulation 
of prelamin A is restricted to SMC in the vasculature and/or other SM22α-expressing 
tissues, i.e. SMC outside the vasculature.
METhODS
Animals 
The SMC-specific Zmpste24 KO mouse model that was used in this study is a novel model 
that has not been used before to study the effects of prelamin A accumulation in vivo. 
This model, unlike the other Zmpste24 KO mouse models, restricts the accumulation of 
prelamin A to the vasculature and/or tissues with cell types that express the SMC marker 
SM22α.The mice used in this study were Zmpste24fl/fl Cre-/- and Zmpste24fl/fl Cre+/-. Ear DNA 
was amplified by PCR and resolved by agarose gel to determine mouse genotypes. In 
this study, Zmpste24fl/fl Cre-/- and Zmpste24fl/fl Cre+/- mice will be referred to as WT and 
Zmpste24 SMC-KO mice respectively.
Mice were kept in individually ventilated cages, in a 12 h light/dark cycle and fed 
normal chow and water ad libitum. All animal studies were approved by the Animal Care 
Committee of the King’s College of London and Erasmus MC.
Cardiac function
Left ventricular functions were assessed using M-mode, or motion mode, from the 
parasternal long axis, which gives a view of the left ventricle and atrium and the aorta 
(Vevo2100 High-Resolution Imaging System, VisualSonics). M-mode imaging modality 
was used to determine the ejection fraction and left ventricle dimensions. Mice were un-
der anesthesia with 2.5% isoflurane, intubated and connected to a pressure-controlled 
ventilator, and body temperature was kept at 37°C.
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Blood pressure measurement
We measured BP non-invasively in conscious mice using the tail cuff technique (MK-
2000ST NP-NIBP monitor, Muromachi, Japan). Mice were trained for 4 days to minimize 
stress-induced changes in the measurements, and measurements were then taken on 
the 5th day.
Ex vivo vascular function
Thoracic aorta, iliac and left anterior descending coronary arteries were collected from 
mice within 5 minutes after sacrifice and kept in cold Krebs-Henseleit buffer (in mmol/L: 
NaCl 118, KCl 4.7,CaCl2 2.5, MgSO4 1.2 , KH2PO4 1.2, NaHCO3 25 and glucose 8.3 in distilled 
water; pH 7.4). Vessel segments of maximum 2 mm length were mounted in small wire 
myograph organ baths (Danish Myograph Technology, Aarhus, Denmark) containing 
Krebs-Henseleit buffer oxygenated with 95% O2 and 5% CO2. The tension was normal-
ized to 90% of the estimated diameter at which the effective transmural pressure is 100 
mmHg. We tested the viability of the vessel segments by inducing contractions with 30 
and 100 mmol/L KCl.
Vasodilator responses
After washout of KCl, coronary and aortic segments were pre-constricted with 30 nmol/L 
U46619, a thromboxane A2 analogue, resulting in 50-100% of the previously obtained 
contraction to 100 mmol/L KCl. Following pre-constriction, concentration-response 
curves (CRCs) to the endothelium-dependent vasodilator acetylcholine (ACh) were 
constructed by adding cumulative doses (10-10-10-5 mol/L). After the CRC to ACh was 
finished, the vessel segments were exposed to the endothelium-independent vasodila-
tor sodium nitroprusside (SNP, 10-4 mol/L). Complete CRCs to SNP (10-10-10-4 mol/L) were 
done in parallel rings preconstricted with 30 nmol/L U46619.
The involvement of nitric oxide (NO), prostaglandins and the endothelium-depen-
dent hyperpolarization (EDH) in ACh responses was investigated in aortic segments by 
performing the experiments in the presence of the endothelial nitric oxide synthase 
inhibitor NG-nitro-L-arginine methyl ester salt (L-NAME, 10-4 mol/L), the cyclo-oxygenase 
(COX) inhibitor indomethacin (10-5 mol/L) and the intermediate and small conductance 
Ca2+-dependent K+ channel (IKCa/SKCa) blockers TRAM34 (10-5 mol/L) and apamin (10-7 
mol/L). The involvement of phosphodiesterase (PDE) in SNP vasodilation was investi-
gated by performing the experiments in the presence of the PDE inhibitor sildenafil 
(10-7 mol/L). At this concentration the inhibitor is expected to predominantly block PDE5 
and to a lesser degree possibly also PDE1. Inhibitors were added to the organ bath 20 
minutes prior to U46619.
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Constrictor responses 
In aorta arteries, we assessed contractile responses to phenylephine (PE, 10-9-10-5 mol/L) 
after washing out KCl 100 mmol/L. In coronary arteries, we evaluated contractile re-
sponses to KCl, calcium and endothelin-1 (ET-1). In iliac arteries, we assessed contractile 
responses to angiotensin II (Ang II, 10-10-10-7.5 mol/L), ET-1 (10-10-10-6 mol/L) and the 
calcium ionophore ionomycin (10-10-10-5 mol/L). Irbesartan (10-7 mol/L) was used to test 
the involvement of Ang II type 1 (AT1) receptors and PD123319 (10-7 mol/L) to test the in-
volvement of Ang II type 2 (AT2) receptors. CRCs to ET-1 were also performed in the pres-
ence of the ETA receptor antagonist BQ123 (10-6 mol/L) and the ETB receptor antagonist 
BQ788 (10-6 mol/L). The CRC to ionomycin was also done under RhoA-kinase inhibition 
(Y27632, 10-5 mol/L). Inhibitors were added 30 minutes prior starting the CRCs.
Mechanical properties of the vascular wall
Passive properties of the vessel were measured in the carotid artery mounted in pres-
sure myograph (Danish Myograph Technology, Aarhus, Denmark) in calcium free buffer 
(in mmol/L: NaCl 120, KCl 5.9, EGTA 2, MgCl2 3.6, NaH2PO4 1.2, glucose 11.4, NaHCO3 26.3; 
pH 7.4). The intraluminal pressure of the carotid artery was increased stepwise by 10 
mm Hg starting at 0 mm Hg and reaching 120 mm Hg. After each 10 mm Hg increment 
the vessel was allowed to equilibrate for 3 minutes and then, lumen and vessel diameter 
were measured. With these data, mediastress and mediastrain were calculated.
Genetic association studies
We investigated the association of single-nucleotide polymorphisms (SNPs) in the 
LMNA and ZMPSTE24 genes with systolic and diastolic BP (SBP, DBP) and carotid-femoral 
pulse wave velocity (CFPWV) using data from different consortia with large population 
samples. The look-up for the association between the LMNA and ZMPSTE24 SNPs and BP 
was done in the International Consortium of Blood Pressure Genome-Wide Association 
Studies (ICBP-GWAS).29 ICBP-GWAS includes data from approximately 200,000 partici-
pants of European ancestry from 35 studies. Linear regression analyses were adjusted for 
sex, age, age squared, body mass index and ancestry principal components. Individuals 
who had received treatment for hypertension were imputed to have 15 mm Hg higher 
SBP and 10 mm Hg higher DBP than the observed measurements. Associations with 
CFPWV were tested using data from the AortaGen Consortium which comprises around 
20,000 individuals of European ancestry from 9 cohort studies.30 Since CFPWV has a right 
skewed distribution due to nonlinear increases and high variance with advancing age, 
together with differences due to the method used by the different cohorts, association 
analyses were performed using a sex-specific standardized residual based on the inverse 
of CFPWV, this normalizes the distribution. The standardized residual was adjusted for 
age, age squared, height, and weight.
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Statistical analysis
Data are presented as mean and SEM. Statistical analysis between the groups of single 
values was performed by two-sided t-test, 1-way or 2-way ANOVA as appropriate. Differ-
ences in dose-response curves were tested by ANOVA for repeated measures (sphericity 
assumed). Differences were considered significant at P<0.05. For the genetic association 
studies 35 SNPs were selected: 17 inside the LMNA gene and 18 in the ZMPSTE24 gene. 
The significance threshold was calculated using Bonferroni correction for multiple test-
ing. P-values <1.43x10-3 (=0.05/35) were considered significant.
RESulTS
lifespan and body weight
Figure 1A shows the Kaplan-Meier analysis comparing the survival rates between WT 
and SMC-KO mice. SMC-KO mice had a median survival of 26 weeks, whereas WT mice 
lived beyond 52 weeks. WT and SMC-KO mice body weights were measured from a 
period of 1 to 6 months before early death for both males and females. Figure 1B shows 
that Zmpste24 SMC-KO mice gained weight normally from birth as their WT counterparts 
until about 5 months when the weight started to decrease. SMC-KO mice showed signifi-
cant weight loss at 6 months when they weighed 27.61±1.06 g compared with WT mice 
31.62±1.47 g (2-way ANOVA p<0.05). At this age the SMC-KO mice developed dilated 
bowels, which might relate to SMC DNA repair knockout and the observed weight loss. 
The gastrointestinal tract remains to be further explored in relation to SMC apoptosis.
DNA damage and senescence markers in SMC-KO mice at 6 months
Deletion of Zmpste24 in SMC is expected to increase DNA damage and cause cellular 
senescence in the medial layer of arterial tissue. Ascending aorta sections from 6 
months-old WT and SMC-KO mice were stained with a γH2AX antibody. As shown in 
Figure 1C-J, SMC-KO mice displayed cell loss in the media layer and extensive DNA dam-
age in the medial layer compared with WT mice. In agreement with this finding, mRNA 
expression of the senescence markers p16 and p21 was significantly increased in aorta 
from 6 months-old SMC-KO mice (Figure 1K-L).
Cardiac function and blood pressure
Echocardiography was used to assess the cardiac function in WT and SMC-KO mice at 
3 and 6 months. Using color Doppler imaging to visualize blood flow from the left ven-
tricle to the aorta, it was discovered that SMC-KO mice exhibit aortic insufficiency, also 
known as aortic regurgitation. There was normal flow of blood from the left ventricle 
to the aorta in WT mice; however, in SMC-KO mice, this was very quickly followed by a 
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figure 1. Lifespan, body weights, DNA damage and senescence markers. Kaplan-Meier survival analysis 
of Zmpste24 WT and SMC-KO mice (A) and body weights from 1 to 6 months (B); n= 9-25 mice per group, 
*P<0.05 (2-way ANOVA). DAPI staining of 6 months-old WT and KO mice ascending aorta showing cell loss 
in the media of KO mice (C-D). Positive smooth muscle actin staining in WT and SMC-KO aortic sections 
(E-F). Positive DNA damage (γH2A) stain in KO mice ascending aorta sections (G-H). Merged DAPI, SMA and 
γH2A stains (I-J). n=4-5. mRNA expression of p16 (K) and p21 (L) in aorta; n= 8-9 mice per group, *P<0.05; 
**P<0.01 (t-test).
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jet of flow back into the left ventricle from the aorta. Of the 23 SMC-KO mice scanned 
at 3 and 6 months over half (52%) had aortic regurgitation (AR). AR is often associated 
to proximal aortic dilation. Echography indeed revealed dilation of the aortic root and 
ascending aorta in SMC-KO mice with AR at 6 months (Figure 2A and B). In SMC-KO mice 
without AR aortic root, diameter was wider than in WT mice and no differences in the 
ascending aorta diameter were observed.
From the age of 3 months fractional shortening (FS) and, thus, ejection fraction (EF), 
started to decrease in SMC-KO compared to WT, which became significant at the age of 
6 months (Figures 2C and 2D, 2-way ANOVA, P<0.05). There was no difference in EF and 
FS between SMC-KO mice with AR vs without AR at both time points (not shown). The 
difference in FS and EF remained small, and accordingly left ventricular diastolic and sys-
tolic diameter were not different between WT and SMC-KO mice at both ages (Figures 2E 
and 2F). To explore if there were any further hemodynamic consequences, BP and heart 
rate measurements were performed at the age of 4, 5 and 6 months. SBP was increased 
in SMC-KO mice vs. WT at 6 months of age (Figure 3A), whereas DBP (Figure 3B), pulse 
pressure (not shown) and heart rate (Figure 3C) were unchanged. When separating SMC-
KO without AR from those with AR, only mice without AR displayed increased SBP, and 
also increased DBP (Figure 3D and 3E). No differences were observed at the age of 4 and 
5 months in BP or heart rate (not shown). Post-mortem histological analyses revealed 
no differences in heart weight corrected for tibia length or in left ventricular posterior 
wall thickness at the age of 6 months (not shown). Thus, despite the small change in FS, 
and as a consequence EF, there were no signs of heart failure yet, nor of the typical BP 
changes one can expect in AR (decreased DBP and increased PP, normal or increased 
SBP). Moreover, increased SBP was only observed in animals without AR.
Ex vivo vascular function
To find an explanation for the (AR-independent) cardiac dysfunction and high SBP 
observed in SMC-KO mice, we investigated vasodilator and vasoconstrictor responses.
Vasodilator responses
The aortic responses to the endothelium-dependent vasodilator ACh at the age of 5 
months were similar in SMC-KO and WT mice (Figure 4A). Yet, the response to the NO 
donor SNP was disturbed in SMC-KO mice (Figure 4B). Findings at an earlier age (3 
months) were identical (Figures 4A and 4B). These findings are suggestive for an upregu-
lation of non-NO endothelium-derived relaxing factors employed by ACh. Therefore, in 
5 months-old mice we evaluated the contribution of NO, prostaglandins and EDH to 
the ACh relaxation responses. In WT mice, approximately half of the ACh response was 
mediated by NO (responses to ACh were reduced by ~50% in the presence of the NOS 
inhibitor L-NAME). Of the remaining half, a small fraction was due to prostaglandins 
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figure 2. Aortic diameters and changes in cardiac function following a 3-month period. Diameters of the 
aortic root (A) and ascending aorta (B) measured using images obtained from echocardiography scans at 
6 months in WT and Zmpste24 SMC-KO mice with or without aortic regurgitation (AR). n= 8-13 mice per 
group. *P<0.05; **P<0.01; ***P≤0.0001 (1-way ANOVA); #P<0.05 (t-test). Fractional shortening (C), ejection 
fraction (D), left ventricular diastolic (E) and systolic volume (F). n=8-9 mice per group. * P<0.05 (2-way 
ANOVA).
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(i.e., blocked by indomethacin), while there appeared to be no role for EDH (Figure 4C). 
Compared to WT, the NO contribution to the ACh response in SMC-KO was diminished, 
while the contributions of prostaglandins and EDH were upregulated (Figure 4D). Thus, 
non-NO-mediated responses compensate for the diminished role of NO in the ACh-
mediated relaxation of the aorta of SMC-KO.
To investigate whether increased PDE1 or 5 activity underlies the diminished re-
sponse to SNP, the SNP effect was studied in the presence of the PDE inhibitor sildenafil 
and L-NAME. This combination abolished the difference between WT and SMC-KO (Fig-
ure 4E), confirming that enhanced NO degradation by PDE is indeed responsible for the 
decreased SNP response in SMC-KO.
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figure 3. Blood pressure and heart rate mea-
sured at 4, 5 and 6 months. Systolic blood pres-
sure (A), diastolic blood pressure (B) and heart 
rate (C) at 6 months in WT and Zmpste24 SMC-
KO mice. Systolic (D) and diastolic blood pres-
sure (E) in SMC-KO with and without aortic re-
gurgitation (AR) and WT mice. n= 7-15 mice per 
group. *P<0.05 (2-way ANOVA); #P<0.05 (t-test)
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figure 4. Vasodilation in aorta and coronary arteries. Endothelium-dependent relaxations to acetylcholine 
(ACh) in aortic rings at 3 and 5 months (A) in WT and Zmpste24 SMC-KO mice. Endothelium-independent 
relaxations to sodium nitroprusside (SNP) in aorta at 3 and 5 months (B). Contribution of NO, prostaglandins 
and endothelium-dependent hyperpolarization to ACh-induced vasodilation in WT (C) and SMC-KO mice 
(D) at 5 months. SNP-induced vasodilation in the presence of L-NAME and sildenafil in WT and SMC-KO mice 
at 5 months (E). Relaxations to ACh (F) and SNP (G) in coronary artery at 5 months. **P<0.001; ***P<0.0001 
(GLM-RM).
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Given the compromised cardiac function in SMC-KO mice, we also evaluated coro-
nary vasodilatory function in 5 months-old mice. In this preparation, both the endothe-
lium-dependent relaxation to ACh (P<0.0001) and the response to SNP (P=0.06) were 
diminished in SMC-KO mice vs. WT mice (Figures 4F and 4G).
Morphological and mechanical properties of the vascular wall
Increased vascular stiffness can contribute to increased BP. Hence, at 5 months we evalu-
ated the mechanical properties of carotid arteries (Figure 5). SMC-KO mice exhibited 
less increases in lumen diameter with stepwise increments in intraluminal pressure 
compared to WT mice (Figure 5A), while no differences were observed in wall thickness 
(Figure 5B). Strain (calculated as pressure-induced increases in lumen diameter and 
indicating compliance) tended to be lower, although not statistically significant, in SMC-
KO mice (Figure 5C). Stress, which indicates distending force on the vessel wall, was 
significantly reduced in SMC-KO mice (Figure 5D).
Changes in stiffness of aorta and arteries in aging mice and humans are associated 
with increased wall thickness and decreased cellularity 31. Wall thickness did not appear 
to change in carotids. Histological examination revealed increased wall thickness in the 
aorta of SMC-KO mice as well (Figure 5E), combined with decreased cellularity based on 
nuclei counting (Figure 5F).
Constrictor responses 
Decreased cellularity and increased wall stiffness are associated with decreased KCl-
induced vasoconstriction in aged mice and humans.31,32 Such changes might affect BP 
regulation, and we therefore measured responses to various vasoconstrictors in iliac and 
coronary arteries. The former are known to display an increased response to Ang II in 
Ercc1Δ/- mice, most likely due to the loss of loss of AT2 receptor-mediated counterregula-
tion of AT1 receptor signaling.33 
KCl was given to induce vasoconstriction independently of receptors. At 5 months, 
but not at 3 months of age, SMC-KO mice displayed lower iliac responses to KCl than WT 
mice (Figure 6A). To explore if calcium responsiveness could explain the differences in 
KCl response, CRCs to the calcium ionophore ionomycin were constructed in iliac arter-
ies of 3 and 5 months- old mice (Figure 6B). Indeed, iliac arteries of 3 months-old WT and 
SMC-KO mice showed no difference in their response to ionomycin, whereas at 5 months 
ionomycin induced smaller constrictions in SMC-KO iliac arteries. RhoA kinase is known 
to be activated in the aging artery and contributes to vasoconstriction.34 Blockade of the 
effect of ionomycin by the RhoA kinase inhibitor Y27632 was significant in iliac arteries 
of SMC-KO mice only (Figures 6C and 6D). Coronary constrictor responses to both KCl 
and calcium were also diminished in 5 months-old SMC-KO mice (Figures 6E and 6F), 
and the same was true for the KCl-induced constriction of the aorta (data not shown).
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figure 5. Mechanical properties of the carotid artery measured in a vascular perfusion set-up. Lumen diam-
eter (A), wall thickness (B), strain (C) and stress (D) at increasing intraluminal pressures in WT and Zmpste24 
SMC-KO mice. **P<0.001 (GLM-RM). Aortic wall thickness (E) and representative images showing ascending 
aorta sections of WT and SMC-KO mice at 6 months stained with HE (F). ***P≤0.0001 (t-test).
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figure 6. Receptor-independent constrictor responses in iliac and coronary arteries. Contractile responses 
to 100 mM KCl (A) and to the calcium ionophore ionomycin in iliac arteries of WT and Zmpste24 SMC-KO 
mice at 3 and 5 months (B). Contribution of the RhoA kinase to the ionomycin response at 5 months in 
WT (C) and SMC-KO mice (D). Contractile responses to increasing concentrations of KCl (E) and to increas-
ing concentrations of calcium in coronary arteries at 5 months (F). #P<0.05 (t test); *P<0.05, **P<0.001; 
***P<0.0001 (GLM-RM).
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Ang II responses were studied in iliac arteries in the presence or absence of the 
receptor antagonists PD123319 (AT2 receptor) and irbesartan (AT1 receptor). Given the 
general decrease of contractility in SMC-KO mice, the Ang II-induced responses of iliac 
arteries of WT and SMC-KO mice at the age of 5 months (Emax 1.2±0.40 mN vs. 0.35±0.09 
mN, P<0.05) were corrected for the difference in response to 100 mM KCl. After this cor-
rection, Ang II responses were identical in both strains. Irbesartan almost totally blocked 
these responses (Figure 7A), while PD123319 tended to increase the Ang II response in 
WT mice, but not in SMC-KO mice (Figure 7B). To explore if this change in receptor func-
tion was specific for Ang II, we also investigated responses to ET-1. ETA and ETB receptors, 
similarly to AT1 and AT2 receptors, show opposite functions, and this difference is lost in 
hypertensive conditions.35 At 5 months of age, the ET-1 responses were stronger in WT 
than in SMC-KO mice (Emax 7.3±1.3 mN vs. 2.6±0.7 mN, P<0.05), but correction for KCl 
responses abolished this difference (Figure 7C). Antagonism of the ETA and ETB receptors 
with BQ123 and BQ788, respectively, led to similar responses in SMC-KO and WT mice. 
ETA receptor antagonism decreased the constrictor responses to ET-1 whereas ETB recep-
tor antagonism did not affect the responses to ET-1 (Figures 7D and 7E).
Genetic association studies
We found 6 SNPs in the LMNA gene to be significantly associated with CFPWV (Table 1). 
Four SNPs were associated with increased CFPWV and 2 with decreased CFPWV. SNP 
rs2485668 showed the lowest P value (β= 0.074, P=7.1x10-4). No significant associations 
were found with SBP or DBP.
Table 1. Single nucleotide polymorphism in the LMNA gene associated with pulse wave velocity
SNP ID
chromosome Allele
Beta Standard error p-value
nr Position
Effect
allele
frequency
rs2485668 1 154368173 C 0.080015 0.075 0.022 0.000707
rs582690 1 154354880 C 0.919953 -0.075 0.022 0.000722
rs509551 1 154366673 C 0.920109 -0.077 0.022 0.000798
rs584025 1 154355150 C 0.921043 -0.074 0.022 0.000825
rs9427236 1 154360030 C 0.920747 -0.072 0.022 0.001034
rs2485676 1 154361496 G 0.079207 0.071 0.022 0.001401
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DISCuSSION 
In this study we explored whether genomic instability, caused by the presence of prelamin 
A, an accepted marker of vascular aging, would cause vasomotor disturbances and pos-
sible cardiac problems. Indeed, cardiac function was modestly altered, as characterized 
by a ≈16% decrease of FS and EF in SMC-KO mice vs. WT mice. SBP additionally increased 
by 11 mm Hg. A decreased NO-mediated VSMC relaxation and increased stiffness could 
underlie the increased SBP. The dilation of the ascending aorta, and the concomitant AR, 
might also affect BP. In fact, type A aortic dissection, for which the dilation in mice might 
model, can be accompanied by hypotension. Normally this is an ominous event possibly 
pointing at tamponade of the cardiac muscle or imminent rupture of the ascending 
aorta. The reduced EF and the normalized BP in AR vs. non-AR mice might be indicative 
for such a situation, but this could not be established in the current study. At least, there 
were no signs of dilated cardiomyopathy that could explain the cardiac function chang-
es, or indicate that chronic hypertension has caused aortic dilatation and AR. Therefore 
the remodeling of the aortic root most likely arises from local changes induced by DNA 
damage. DNA damage was indeed observed in the aorta of SMC-KO. We cannot exclude 
that the SMC-KO mice are either compensating for the loss of NO-mediated vasodilation 
by adaptation of cardiac function, or that changes in the digestive tract contribute to BP 
changes. Nevertheless, it is clear that local inhibition of DNA maintenance in SMC cause 
VSMC-specific decrease of NO-mediated vasodilation, which can be compensated by 
the endothelium by means of recruitment of prostaglandin and EDH. The endothelial 
compensation of NO loss is a well-known phenomenon, for example in models of heart 
failure, ischemia-reperfusion and hypercholesterolemia.36 Furthermore, constriction 
responses to KCl and Ca2+ were diminished, as occurs also in humans.32 This might be 
the result of increased stiffness and the loss of VSMC, an observation also made in aged 
WT mice.31 Thus, DNA damage is causing vasomotor and aortic morphological changes 
disturbance that are also observed in aging-related situations with clinical relevance.
The findings in SMC-KO mice contrast with those in mice with EC-KO of Chapter 3. 
EC-KO mice show a specific decrease of endothelium-dependent NO-mediated relaxation, 
whereas SMC-KO mice display specific decrease of endothelium-independent NO-mediat-
ed relaxation. EC-KO mice do not compensate for loss of ACh-induced dilations, whereas 
SMC-KO do, namely by increasing prostaglandin-induced dilatations and recruiting EDH, 
similar to observations in eNOS knockout mice.37-39 Apparently, local DNA damage in ECs 
undermines the compensatory function of the endothelium, while reduced NO respon-
siveness caused by local DNA damage in VSMCs can be compensated by the endothelium. 
This novel finding, with potential relevance for vascular disease, agrees with the observa-
tion in Chapter 5 that diet restriction allows Ercc1Δ/- mice to recruit dilator prostaglandins, 
and that dietary restriction conserves genomic integrity in various tissues.40 
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Another striking finding is that EC-KO mice do not show increased carotid stiffness 
whilst SMC-KO mice do. VSMC dysfunction may more rapidly result in increased stiff-
ness than endothelial dysfunction, because VSMC produce matrix and are expected 
to directly contribute to loss of compliance, as evidenced in isolated arteries under 
calcium-free conditions in both studies. In EC-KO mice, in-vivo aorta distensibility was 
decreased, perhaps heralding the initiation of vascular stiffness increase. However, since 
EC can actively contribute to changes in compliance through the release of relaxing 
and contracting factors, a more complete assessment of vascular stiffness is needed. 
This should include examination of matrix changes, elastic properties, in vivo autonomic 
regulation, and local regulation of hemodynamic function. This is particularly important 
because of the observation that stress is lower in SMC-KO mice compared to WT. There 
is a chance that the decrease in compliance is due to the relatively lower forces per area 
surface applied in the SMC-KO carotid arteries. The difference in stress is surprising, and 
might be explained by differential changes in radial vs. longitudinal elastic properties. To 
answer this question dedicated equipment for measurement of bidirectional elasticity 
is needed. Regardless of the present limitations the observations in SMC-KO mice are 
in agreement with observations in Ercc1Δ/- mice and suggest that DNA damage in VSMC 
contributes to the increase of vascular stiffness that is seen in aging. This is further sup-
ported by the findings from the genetic association look-up where polymorphisms in 
the LMNA gene were associated with PWV in a large population sample.
Apart from changes in vasodilation, also vasoconstriction was hampered in SMC-KO 
mice. This is due to lowered Ca2+-induced constriction, occurring independently from 
voltage-gated calcium channels. This might simply be a consequence of the increased 
vascular stiffness and loss of medial cellularity, as proposed recently.31 Alternatively, 
Ca2+ sensitivity might be decreased. This possibility is supported by the observation 
that both in EC-KO and SMC-KO mice KCl responses are decreased, while medial acel-
lularity and increased stiffness cannot have played a role in EC-KO mice. The loss of KCl 
responses was also observed in aging human coronary arteries,32 illustrating yet another 
common feature of human and mouse vascular aging.31, 41 In addition, RhoA kinase con-
tributed exclusively to Ca2+-induced vasoconstriction in SMC-KO mice; an increase of 
RhoA kinase in aging VSMC has been reported previously,34 supporting the concept that 
DNA damage closely resembles aging.42 However, it should be noted that responses in 
WT mice were more variable, therefore our current results are only suggestive and the 
upregulation of RhoA kinase in mouse models of accelerated vascular aging should be 
further studied.
Typically, receptor-mediated constrictions, when corrected for this loss of Ca2+ 
responsiveness, were not found to be altered in SMC-KO, both in the case of Ang II and 
ET-1. Dilator AT2 receptor responsiveness appeared to be lost, as has been seen before in 
disease conditions.33, 43 Yet, this did not lead to enhanced AT1 receptor-induced constric-
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tion, possibly because the AT1 receptor-induced effects were modest anyway due to 
the upregulated non-NO endothelial compensatory pathways in this model. Markers of 
DNA damage might help to determine which aged patients, if any, benefit from renin-
angiotensin system blockade.
A remaining issue in DNA repair defective mice is the lack of hypertrophy of the arte-
rial and aortic lamina media. This is often observed in human aging. The short longevity 
in combination with the medial cell loss might prevent hypertrophy from occurring in 
the mouse models. To explore this possibility the application of hypertrophic stimuli, 
such as dyslipidemia, strongly increased arterial pressure, endothelial removal at young 
age, luminal wire injury, peri-arterial cuff placement or chronic Ang II infusion in EC- and 
SMC-KO mice might provide better insight.
In summary, SMC-KO mice recapitulate aspects of aging-related human vascular 
problems such as increased SBP, decreased vasodilation to NO, dilation of the ascending 
aorta with concomitant aortic regurgitation, a potential increase in arterial stiffness, 
and, although with reservation, a loss of AT2 receptor function. These characteristics are 
complementary to the earlier observed aging-like changes in EC-KO mice. The sum of 
changes in EC-KO and SMC-KO mice well resembles the vascular phenotype in Ercc1Δ/- 
mice, albeit that SMC-KO mice uniquely shows aortic dilation. Thus both DNA damage 
in EC and VSMC, in a cell-autonomous way, lead to specific changes that are relevant for 
aging-related vascular disease. The present results refer to several clinical phenomena 
that are encountered in aging humans, such as type A aortic dissection, loss of coronary 
artery function and ejection fraction, hypertension and altered responsiveness to Ang 
II blocking drugs, Ca2+ channel blockers and associated medicines. Thus, the SMC-KO 
model, in complement to EC-KO and Ercc1Δ/- mice, can help to pinpoint the etiology 
of specific aging-related cardiovascular problems. The application of stress factors, e.g. 
those mimicking classical risk factors that contribute to DNA damage, may provide fur-
ther clinical relevant results. With the creation of cell-type specific DNA repair defective 
mice this has now become technically feasible.
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ABSTRACT
DNA damage is an important contributor to endothelial dysfunction and age-related 
vascular disease. Recently, we demonstrated in a DNA repair-deficient, prematurely ag-
ing mouse model (Ercc1∆/- mice) that dietary restriction (DR) strongly increases life- and 
health span, including ameliorating endothelial dysfunction, by preserving genomic 
integrity. In this mouse mutant displaying prominent accelerated, age-dependent 
endothelial dysfunction we investigated the signaling pathways involved in improved 
endothelium-mediated vasodilation by DR, and explore the potential role of the renin-
angiotensin system. Ercc1∆/- mice showed increased blood pressure and decreased aortic 
relaxations to acetylcholine in organ bath experiments. Nitric oxide (NO) signaling and 
phospho-Ser1177-eNOS were compromised in Ercc1Δ/- DR improved relaxations by increas-
ing prostaglandin-mediated responses. Increase of cyclo-oxygenase 2 and decrease 
of phosphodiesterase 4B were identified as potential mechanisms. DR also prevented 
loss of NO signaling in vascular smooth muscle cells and normalized angiotensin II 
vasoconstrictions, which were increased in Ercc1∆/- mice. Ercc1∆/- mutants showed a loss 
of Angiotensin II type 2 receptor-mediated counterregulation of Angiotensin II type 1 
receptor-induced vasoconstrictions. Chronic losartan treatment effectively decreased 
blood pressure, but did not improve endothelium-dependent relaxations. This result 
might relate to the aging-associated loss of treatment efficacy of renin-angiotensin sys-
tem blockade with respect to endothelial function improvement. In summary, dietary 
restriction effectively prevents endothelium-dependent vasodilator dysfunction by 
augmenting prostaglandin-mediated responses, whereas chronic Angiotensin type 1 
receptor blockade is ineffective.
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INTRODuCTION
Age is a major risk factor for the development of cardiovascular diseases (CVD), indepen-
dently from traditional risk factors.1 An important factor that contributes to organismal 
aging, including vascular aging, is genomic instability.2, 3 We recently demonstrated that 
mutation of the DNA repair endonuclease excision repair cross complementing 1 in mice 
(Ercc1∆/- mice) accelerates important characteristics of vascular aging-related vasomotor 
dysfunction.4, 5 In general, Ercc1∆/- mice rapidly and faithfully mimic natural human aging 
compared to aged wild-type (WT) mice.6 Accordingly, mouse models of accelerated vas-
cular aging due to genomic instability can be used as tools complementary to models 
representing the impact of classical risk factors, such as hypertension and dyslipidemia.
We demonstrated that dietary restriction (DR, 30% reduced food intake without 
malnutrition), a universal intervention extending lifespan in numerous species, 
tripled remaining lifespan and strongly improved health span in Ercc1∆/- animals, by 
far exceeding the relative lifespan extension in WT mice. We found that this dramatic 
anti-accelerated aging effect in the mutant was at least in part due to preserving ge-
nomic integrity by reducing DNA damage accumulation.2 The improvement of health 
span included prevention of endothelial dysfunction, which in humans is one of the 
major contributors to morbidity and mortality due to a decline in vascular function.1 
In humans, DR has a beneficial effect on cardiovascular risk, which is attributed to the 
reduction in diet-related risk factors such as dyslipidemia, high blood pressure (salt in-
take), and hyperglycemia.7 This in turn reduces oxidative stress and augments the nitric 
oxide (NO) – cGMP pathway, an important endothelial signaling axis involved in blood 
flow, blood pressure and cardiovascular growth regulation.7 Our results in Ercc1∆/- mice 
have added a novel paradigm, namely that DR preserves genomic integrity and thus in 
this manner protects against vascular aging.
In this new paradigm it is not known which vasodilatory signaling pathway is 
improved. In our previous studies we have shown that, comparable to human aging, 
Ercc1∆/- mice display a reduction of NO– cGMP signaling and increased oxidative stress.4, 5 
Therefore, we here set out to identify which vasodilatory signaling pathway is improved 
by DR in Ercc1∆/- mice. In addition, the impact of DR on endothelium-independent relax-
ation was investigated.
A potential mediator of blood pressure increase and decreased endothelium-
dependent relaxation caused by DNA damage is activation of the renin-angiotensin sys-
tem (RAS). Angiotensin (Ang) II, the main bioactive hormone of this system, is strongly 
involved in hypertension, arteriosclerosis, vascular DNA damage and cell senescence, 
inflammation, oxidative stress, longevity and health span.8 Also, Ang II inhibits eNOS - 
NO - cGMP signaling.9 Given that the RAS is sensitive to salt and LDL cholesterol, it may 
also respond to DR.10, 11 However, it is not known how genomic instability influences 
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RAS activity, let alone whether RAS activation would mediate its detrimental effects on 
the vascular wall. Therefore, we additionally studied the vasoconstrictor responses of 
the Ercc1∆/- mouse vasculature to Ang II under ad libitum (AL) feeding and DR. Also, we 
evaluated the effect of chronic AT1 receptor blockade on endothelial function and blood 
pressure in AL-fed Ercc1∆/- mice.
METhODS
Animals and interventions
Animal experiments were performed at RIVM and Erasmus MC in accordance with the 
Principles of Laboratory Animal Care and with the guidelines approved by the Dutch 
Ethical Committee in full accordance with European legislation.
Dietary restriction studies 
Ercc1∆/- mice and their wild-type littermates (WT) (Bl6/FVB F1 hybrids) underwent DR 
intervention from resp. 7 and 11 weeks after birth until sacrifice as described extensively 
in our previous publication, and in the Methods supplement.2 At the age of 16 weeks, 
AL-fed Ercc1∆/- weigh on average ~13 grams, whereas DR-fed Ercc1∆/- animals weigh ~10 
grams.2 
Losartan intervention study
From 5 weeks of age, Ercc1∆/- and WT mice (Bl6/FVB F1 hybrids) were divided into two 
groups per strain, which were either treated with losartan (100 mg/kg/day) in drinking 
water, or drinking water only until the age of 12 weeks when the animals were sacrificed. 
Blood pressure was measured by tail cuff at the age of 11 weeks. At the studied age, 
Ercc1∆/- mice weigh ~15 grams on average.2 The study rationale and animal numbers are 
described in the Methods supplement.
Organ bath experiments
Tissue harvesting and preparation procedures, and detailed description of the organ 
bath experiments can be found in the Methods supplement.
In short, thoracic aorta and iliac arteries were collected and tested in small wire 
organ bath setups. Vasodilations to cumulative concentrations of acetylcholine (ACh) 
and sodium nitroprusside (SNP) were measured in vessels preconstricted with U46619 
to construct concentration-response curves (CRCs). When sufficient aortic tissue was 
available, the involvement of nitric oxide (NO) and prostaglandins in ACh responses was 
investigated by performing the experiments in the presence of the endothelial nitric 
oxide synthase (eNOS) inhibitor NG-Methyl-L-Arginine acetate salt (L-NMMA, 10-5 mol/L), 
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the cyclo-oxygenase (COX) inhibitor indomethacin (INDO, 10-5 mol/L) or both inhibitors. 
In iliac arteries Ang II (10-10-10-7 mol/L) CRCs were constructed. PD123319 (10-7 mol/L) 
was used to test the involvement of Ang II type 2 (AT2) receptors, and the guanylyl cy-
clase inhibitor 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10-5 mol/L) to test the 
role of NO-cGMP signaling. Inhibitors were added 15 minutes prior to U46619 or Ang II.
Quantitative real-time PCR
Total RNA was isolated and cDNA was prepared, which was amplified by real-time PCR 
to perform ΔΔCT quantification, either with the use of SYBR green or Taqman analysis. 
Further details are found in the Supplementary information.
Western blots
Protein was isolated from lung tissue, run on bis/tris gradient gels, blotted to nitrocel-
lulose membranes and then incubated with primary antibodies. Details are provided in 
the Supplementary information.
Plasma renin concentration
Blood was collected from 12-wk-old WT and Ercc1∆/- mice by cardiac puncture and trans-
ferred to EDTA coagulation vials. Blood samples were centrifuged at 4600 rpm for 10 
minutes to collect plasma. Plasma renin concentration was determined by an enzyme-
kinetic assay as described previously.12
Statistical methods
Data are presented as mean±SEM. SNP-corrected ACh responses were calculated as fol-
lows: (response to ACh as % of U46619 preconstriction / response to 10-4 mol/L SNP as 
% of U46619) x 100 (to indicate as a percentage) x -1 (to indicate that it is a relaxation). 
Statistical testing for differences between single values expressed in bar graphs was 
performed by t-test or 1-way ANOVA followed by appropriate post-hoc tests. Differences 
in CRC were tested by general linear model for repeated measures (GLM-RM, sphericity 
assumed). Differences were considered significant at p<0.05.
RESulTS
The effect of DR on acetylcholine responses in WT and Ercc1∆/- mice 
We first investigated the effect of genomic instability and DR on the diminished ACh 
response at different ages in Ercc1∆/- and WT mice. As previously reported, AL-fed Ercc1∆/-
mutants showed a lifespan of 19 weeks (median age), which was extended by DR to a 
median age of 44 weeks 2. ACh responses in the Ercc1∆/- aorta of AL-fed animals age-
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dependently decreased between the age of 7 to 16 weeks (Figure 1A), and at the latter 
age were significantly decreased compared to 20-wk old WT. WT aortas did not show 
any change in ACh response between 11 to 20 weeks (data not shown). To explore if DR 
would protect against endothelial dysfunction until an age at which AL-fed Ercc1∆/- mice 
have already succumbed (predominantly occurring from neurodegeneration), we pro-
ceeded to an age of 30 weeks in DR-fed animals. In our initial publication on the effect 
of DR on general health 2 we demonstrated that DR improved the response to ACh in 
16-wk-old Ercc1∆/- mice. Here we show that the improvement of ACh responses persisted 
in 30-wk-old DR-fed Ercc1∆/- mutants (Figure 1B), well after the AL mice had died. In WT 
animals DR had no effect on ACh-induced relaxation (Figure 1B). Thus, Ercc1∆/- mice 
showed decreased aortic relaxations to ACh with increasing age, which could partly be 
prevented by DR.
Endothelial vs. non-endothelial responses
Ercc1∆/- aortas displays a pronounced decrease of endothelium-independent responses 
to NO.4, 5 We therefore investigated the effect of DR on responses to SNP, which entirely 
rely on direct release of NO and subsequent cGMP production in vascular smooth muscle 
cells (VSMC), as evidenced by the complete blockade of this response by the guanylyl 
cyclase inhibitor ODQ (data not shown). Dilatory responses to 10-4 mol/L SNP, which was 
given on top of ACh, progressively decreased in AL-fed Ercc1∆/- mice, reaching statistical 
significance in 16-wk-old mice as compared to 7-wk-old mice (Figure 1C, p<0.05 one-way 
ANOVA on 7-, 11- and 16-wk AL-fed mice with Dunnett post-hoc test). DR significantly 
prevented the age-dependent decline in dilator responses in 11- and 16-wk-old mice 
(Figure 1C, p<0.05, t-test). Even 30-wk-old DR-fed Ercc1∆/- mutants still displayed a better 
SNP response as compared to 16-wk AL-fed Ercc1∆/- mice (p<0.05, t-test). In WT animals 
no age- or diet-related changes were observed (Figure 1D, 11-wk animals not shown), 
and SNP responses were similar to those in 7-wk AL-fed and DR-fed Ercc1∆/- mice, which 
is expected as WT mice at 20 weeks of age do not (yet) display an aging-phenotype
To exclude any influence of ACh on SNP responses and to explore dose-related ef-
fects of SNP, we generated SNP CRCs in 16-wk-old Ercc1∆/- and in 20-wk-old WT animals 
(Figure 1E). The data confirmed that in AL-fed Ercc1∆/- mice SNP responses were strongly 
reduced, and that they were fully restored to the level of WT animals by DR. In WT ani-
mals no significant changes occurred.
The response to ACh depends on the amount of relaxing factors that is released 
from the endothelium as well as the responsiveness of the VSMC to these factors. The 
present observation that responses of VSMC to NO are fully restored by DR (Figure 1C, E) 
while the responses to ACh are not (Figure 1B), suggests that the release of endothelial-
derived relaxing factors is compromised. Therefore, we studied the contribution of these 
factors to vasodilation.
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figure 1. The effect of dietary restriction on endo-
thelial and non-endothelial vasodilations in Ercc1Δ/- 
and WT mice at different ages (A) Age-dependent 
acetylcholine (ACh)-induced vasodilation in aortic 
segments from ad libitum (AL) fed wildtype (WT) 
and Ercc1∆/- mice as measured ex vivo in small wire 
organ baths. (B) Effect of diet restrictions (DR) on 
the ACh responses. (C - E) age-dependent sodium 
nitroprusside (SNP)-induced vasodilations and the 
effect of diet restriction (DR). SNP was either given 
as a bolus concentration of 10-4 mol/L SNP after con-
structing ACh concentration response curves (C, D) 
or administered in cumulative concentrations im-
mediately after preconstriction (E). Responses are 
expressed as % relaxation of the U46619. Error bars: 
S.E.M. *P<0.05, GLM-RM. &P<0.05 16-week (16-wk) 
vs. 7-week (7-wk) Ercc1∆/-AL, one-way ANOVA, Dun-
nett post-hoc test, #P<0.05 t-test, †P<0.05, 16-wk 
Ercc1∆/-AL compared to all other groups, GLM-RM.
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The role of endothelial signaling compounds in genotype- and diet-related 
effects
Dilations in AL-fed vs. DR-fed WT mice did not differ and results were therefore pooled. 
ACh responses were almost completely dependent on NO in WT animals since adding 
the eNOS inhibitor L-NMMA blocked the response to ACh (Figure 2A). As expected 
from our previous study,4 NO also mediated a large part of the vasodilation to ACh in 
AL-fed Ercc1∆/- mice (Figure 2B). The residual response suggests the emergence of an 
endothelium-derived hyperpolarizing factor (EDHF), which did not appear to be COX-
dependent, since it was not affected by indomethacin (Figure 2B). This result, together 
with the observation that inhibition of vasodilation by L-NMMA was much more pro-
nounced in WT confirms the specific loss of NO signaling in Ercc1∆/- aorta’s. Remarkably, 
the DR-induced facilitation of the ACh response in Ercc1∆/- mice appeared to be due to 
an upregulation of a vasodilator prostaglandin pathway, since now indomethacin did 
further reduce the response of ACh on top of L-NMMA, while the effect of L-NMMA alone 
was unaltered (Figure 2C). We studied total eNOS and pSer1177-eNOS (eNOS-activating 
phosphorylation of the serine residue 1177) protein expression in lung tissue (Figure 
3A). No significant differences in eNOS levels were found between groups, although 
as observed in a previous publication,4 total eNOS protein tended to be lower in AL-
fed Ercc1Δ/- mice as compared to AL-fed WT. In contrast, DR significantly increased the 
pSer1177-eNOS/eNOS ratio in WT mice but not in Ercc1Δ/- (Figure 3A).
Prostaglandins are produced by COX-1 or 2, and exert their vasodilator effects 
through the IP receptor using adenylyl cyclase (AC) 5/6 – cAMP signaling as a second 
messenger system. cAMP is prone to degradation by phosphodiesterase type 4B/D 
(PDE4).13-15 To investigate which of these components could be responsible for the 
upregulated prostaglandin response we first quantified mRNA expression in blood 
vessel-rich lung tissue. Ct values for the IP receptor, PDE4D and AC6 mRNA levels were 
on average >34, and therefore we considered these levels too low for reliable detection. 
COX-1 expression was significantly increased, and COX-2 showed a tendency to increase 
in DR-fed Ercc1Δ/- (supplementary Figure 1). PDE4B mRNA was decreased in both Ercc1∆/- 
mouse groups compared with AL-fed WT mice (supplementary Figure 1). Thereupon, 
we decided to look further into protein levels of COX-1, COX-2 and PDE4B (Figure 3B). 
AL-fed Ercc1∆/- mice had significantly higher protein levels of COX-1 compared to the 
other 3 groups. DR had a significant effect on Ercc1∆/- COX-2 levels vs. AL-fed Ercc1∆/-, but 
no effect was observed in the WT groups. Sirtuins are one of the mechanisms that could 
upregulate COX-2 expression and activity;16 however we did not observe any significant 
differences in sirtuin 1 (SIRT-1) protein levels in any of the groups (Figure 3B). PDE4B was 
decreased again in Ercc1Δ/- regardless of the diet. Surprisingly, PDE4B was also decreased 
in DR-fed WT. The results indicate that both an increase of prostaglandin production 
by COX-2 in combination with a decreased metabolism by PDE4B might support the 
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emergence of prostaglandin – cAMP signaling, and improved vasodilation after DR in 
Ercc1∆/- mice.
Effects of genomic instability and DR on Ang II responses
To explore a possible role of the renin-angiotensin system we first investigated vaso-
constriction to Ang II in a subset of the diet intervention mice. Ang II responses were in 
general highly variable within each strain, and tended to be higher in AL-fed Ercc1∆/- vs. 
AL-fed WT mice (Figure 2D), although this did not reach significance over the entire CRC 
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figure 2. The effect of dietary restriction on endothelial signaling pathways and vasoconstriction respons-
es to Angiotensin II. Contribution of nitric oxide (NO) and prostaglandins to ACh-induced vasodilation of 
aortic segments from 20-wk-old AL- and DR-fed wild-type (WT) (A), and 16-wk-old AL-fed (B) and DR-fed (C) 
Ercc1∆/-mice measured in organ baths. L-NMMA (10-5 mol/L) and INDO (10-5 mol/L) resp. inhibit NO and pros-
taglandin synthesis. Responses are expressed as % relaxation of the U46619 preconstriction. (D) Vasocon-
striction to Ang II expressed as % of contraction to 100 mM KCl. Error bars: S.E.M. *P<0.05 vs. non-pretreated 
segments. &P<0.05 vs. L-NMMA-treated segments. #P<0.05, t-test on individual concentrations of Ang II of 
AL-fed Ercc1∆/-mice vs. WT littermates.
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(GLM-RM). DR-fed Ercc1∆/- animals showed a trend for a decreased response to Ang II as 
compared to AL-fed Ercc1∆/- mutants (GLM-RM, p=0.059). The results suggest a genomic 
instability-induced upregulation of the Ang II response, which is normalized by DR.
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figure 3. Expression of relevant proteins in the dietary restriction study and mRNA expression of RAS 
components and plasma renin levels in the Losartan intervention study. Relative protein expression levels 
in lung tissue of eNOS and pSer1177-eNOS/eNOS ratio (A), and of COX-1, COX-2, PDE4B and SIRT-1 (B) in 
16-wk-old Ercc1∆/- mice and 20-wk-old wild-type (WT) littermates from the diet intervention study. All pro-
tein values are corrected for β-actin and normalized to WT-AL expression levels. Relative mRNA expression 
levels of AT1a-, AT1b- and AT2-receptors in abdominal aortic tissue, of ACE in lung tissue and of renin in renal 
tissue of 12-wk-old Ercc1∆/- mice and WT littermates from the losartan treatment study (C). Plasma renin 
concentration in Ercc1∆/- mice and WT littermates from the losartan treatment study (D). Error bars: S.E.M. 
#P<0.05, one way- ANOVA; *P<0.05, Bonferroni’s post-hoc tests; †P<0.05 vs. WT, t-test.
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The losartan intervention study
In a separate cohort of Ercc1∆/- and WT mice we evaluated the effect of chronic AT1 recep-
tor blockade on blood pressure and vascular function. In agreement with our previous 
study4 blood pressure tended to be slightly higher in Ercc1∆/- mice, mainly reflected by 
systolic blood pressure ((SBP), 140.6 mmHg in Ercc1∆/-, 128.2 in WT; p-value = 0.076), and 
to a lesser extent by diastolic blood pressure (DBP), 104.2 mmHg in Ercc1∆/- mice, 97.3 
mmHg in WT; p= 0.163) (Figure 4). Chronic AT1 receptor blockade by losartan signifi-
cantly lowered SBP and DBP in both mouse strains (p< 0.01 in all cases) .
Vasomotor responses to Ang II in the losartan intervention study
In the losartan intervention cohort, Ercc1∆/- mice displayed an exaggerated response to 
Ang II as compared to WT mice (Figure 5A). Vasoconstrictions are mediated by AT1 recep-
tors and we therefore explored other indicators of increased AT1 receptor activity such 
as negative feedback on renin activity and ACE expression. Plasma renin activity was 
reduced (Figure 3D). This was not due to a change in mRNA level in the kidney (Figure 
3C). ACE mRNA in the lung was reduced (Figure 3C). Both findings are in agreement with 
increased AT1 receptor activity.
To further explore mechanisms leading to increased Ang II vasoconstrictions we 
studied vascular AT1 and AT2 receptor expression and function. We and others previously 
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figure 4. Blood pressure measurements in the losartan intervention study. (A) Systolic and (B) diastolic 
blood pressure in conscious Ercc1∆/- and wild-type (WT) mice of the losartan intervention study as measured 
by the tail cuff method. *P<0.05, t-test
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reported that AT2 receptor stimulation counteracts AT1 receptor-mediated vasoconstric-
tion17. To explore the effect of genomic instability on AT2 receptor activity, Ang II re-
sponses in Ercc1∆/- and WT animals in the presence of AT2 receptor antagonist PD123319 
were compared to those in the absence of this antagonist. PD123319 did not change the 
Ang II response in Ercc1∆/- mice, but tended (p=NS) to increase this response in WT (Fig-
ure 5A). Chronic treatment with losartan, starting from week 5 after birth until the end 
of week 12, normalized this exaggerated response in the Ercc1∆/- mice (Figure 5B), but 
had no effect on the Ang II response in WT mice (data not shown). Therefore, genomic 
instability leads to loss of counterregulation of AT1 receptor-mediated vasoconstriction 
by AT2 receptor, and not due changes in receptor expression.
To explore the possible involvement of counterregulation of Ang II-induced 
constriction by NO-cGMP signaling, which can be the result of endothelial AT2 recep-
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figure 5. Ex-vivo vascular function in Ercc1Δ/-and WT mice from the losartan intervention study. (A) Vaso-
constriction to Ang II of isolated iliac arteries in the presence and absence of PD123319. (B) Ang II responses 
in isolated iliac arteries from untreated and losartan-treated Ercc1Δ/- mice in the presence and absence of 
ODQ. (C and D) Vasodilation in isolated aortic tissue of the mice from the losartan intervention study to the 
endothelium-dependent vasodilator ACh and the endothelium-independent vasodilator, NO-donor SNP. 
All responses were measured ex vivo in small wire organ baths. Aortic tissue used to measure vasodilator 
responses was preconstricted with thromboxane analog U46619. Error bars: S.E.M. *P<0.05, GLM–RM.
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tor stimulation, Ang II responses were studied in the presence of the guanylyl cyclase 
inhibitor ODQ. This approach, rather than adding an eNOS inhibitor, was chosen be-
cause Ercc1∆/- mice show both changes in endothelial NO production as well as in cGMP 
responses of VSMC. Although the presence of ODQ tended to increase Ang II responses, 
the increase was very modest and did not reach significance in Ercc1∆/- animals (Figure 
5B), nor in WT (not shown). Apparently, the loss of NO-cGMP signaling cannot entirely 
explain the increase Ang II vasoconstrictions.
Since increased AT1 receptor signaling is believed to be involved in vascular disease 
related to endothelial dysfunction, a role that might both provoke as wells as be medi-
ated by increased blood pressure, we tested the effect of chronic losartan treatment on 
vasodilator function in Ercc1∆/- mice.
Effect of chronic losartan treatment on accelerated age-related vasodilator 
dysfunction
In the 12-wk-old Ercc1∆/- mutants vasodilator responses to ACh were significantly 
decreased as compared to WT animals (Figure 5C). The dilation response to a SNP 
concentration-response curve was also decreased in Ercc1∆/- mice (Figure 5D). Chronic 
AT1 receptor blockade with losartan in vivo did not significantly change any of the 
responses. Our findings indicate that the observed vasodilator dysfunction (persistent 
after losartan) was not blood pressure-dependent and that the detrimental effect of 
genomic instability cannot be opposed by chronic AT1 receptor blockade with Losartan.
DISCuSSION
In the present study we explored potential mechanisms that lead to DR-mediated im-
provement of vasodilator dysfunction caused by DNA damage in rapidly aging Ercc1Δ/- 
mice. These mice are known to display a stochastic increase of transcription stalling, 
indicative for increased DNA damage.2 In the liver, this could be partly reversed by DR.2 
Such measurements were not possible in aorta due to its small size, and therefore direct 
evidence for decreased DNA damage in vascular tissue cannot be provided at this stage. 
Instead we focused on the identification of the involved vasomotor signaling pathways. 
Loss of vasodilation turned out to be entirely due to loss of NO-cGMP signaling, both as 
a result of decreased endothelial NO release and decreased VSMC responsiveness to NO. 
In previous publications we already observed that the decreased NO function in Ercc1Δ/- 
mice was due to decreased eNOS expression and activation, increased PDE1 and possi-
bly also increased PDE5 activity, and for a small part due to increased ROS production.4, 5 
The present results now indicate that DR improves vascular dilation up to an age of at 
least 30 weeks. This is because DR enables aortic tissue to recruit endothelium-derived 
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vasodilatory prostaglandins, which are normally absent. In addition, the responsiveness 
of VSMC to NO is improved. A possible explanation for the emerging prostaglandin 
response is the increase in COX-2, combined with a decrease in PDE4B, which together 
should lead to improved vasodilator cAMP signaling.
We additionally explored the possible involvement of Ang II. Although defective 
DNA repair increased vasoconstrictive responses to Ang II, chronic blockade of AT1 
receptors with losartan did not rescue vasodilator responses. Also, blood pressure 
itself is not a driving mechanism in the observed vasodilator dysfunction, since blood 
pressure-lowering did not affect this dysfunction. Ang II-induced constriction most 
likely increased due to the loss of counterregulatory effects of AT2 receptors when 
Ercc1Δ/- mutants age. We found that chronic losartan treatment reversed the enhanced 
Ang II-induced vasoconstriction in Ercc1∆/- mice. This reduction could not be explained 
by physiological antagonism through effects on endothelial function, since the latter 
was unaffected by losartan. Furthermore, blood pressure lowering per se, increased 
renin release (resulting in AT1 receptor downregulation by upregulating Ang II), and the 
sustained presence of losartan (or its active metabolite) after transferring arterial tissue 
to organ baths, are also unlikely causes of this reduction, since the conditions were iden-
tical in the losartan-treated WT mice, where no reduction in Ang II response occurred. 
Thus, chronic AT1 receptor antagonism was capable of restoring the WT situation in a 
blood pressure-, circulating RAS- and endothelium-independent manner.
Preservation of endothelium-dependent responses by (lifelong) DR has been 
previously reported in aging WT rodents, involving nuclear factor erythroid-2-related 
factor-2 (Nrf2)-mediated upregulation of antioxidants.18 Vermeij et al. showed that in 
various tissues of AL-fed Ercc1∆/- mice Nrf2-related antioxidants are already increased 
as a protective mechanism (2 and unpublished observations), and that after DR, Nrf2 
is further activated.2 Previously, we showed that decreased SNP responses in Ercc1Δ/- 
involved ROS.4 In the present study SNP responses were normalized after DR (Figure 1), 
in agreement with a potential role of Nrf2. In addition to upregulation of anti-oxidant 
defenses, DR is known to increase eNOS expression and activation, the activation being 
mediated by eNOS deacetylation of the calmodulin-binding region through SIRT-1.19, 20 
These observations, made in WT rodents, are reminiscent of our result that DR increased 
baseline p-eNOS levels in WT mice. In a previous study we demonstrated that eNOS 
phosphorylation at Ser1177 was prohibited in (AL-fed) Ercc1Δ/-.4 We now show that DNA 
damage prevents the DR effect on baseline p-eNOS. Apparently, in conditions of deterio-
rated integrity, regulation of (p-)eNOS is swiftly lost. Strikingly, SIRT-1 was not increased 
by DR in Ercc1∆/- nor in WT mice. Therefore, an effect through deacetylation of eNOS by 
SIRT-1 seems unlikely. It should be noted that we performed measurements of eNOS 
in lung tissue, based on the assumption that measurements in this highly vascularized 
organ are representative for vascular tissue in general.4, 5
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In the light of failing (up-)regulation of NO signaling it is not surprising that DR in 
Ercc1Δ/- mice recruits another system to enhance endothelial function, namely vasodila-
tory prostaglandin signaling, acting through cAMP as a second messenger. To achieve 
this, COX-2 expression increased in DR-fed Ercc1∆/- mice, on top of already decreased 
PDE4B expression in those mice. It needs to be noted, however, that the changes were 
very modest. The molecular mechanism underlying the DR-induced COX2 and PDE4B 
upregulation could not be addressed in the present study. One possibility is that this 
involved a DR-induced effect on blood pressure. However, since 16 week-old AL fed 
Ercc1Δ/- (unlike the 12 week-old mice used in the losartan study) are too frail for blood 
pressure measurement, this could not be investigated. Altogether, the fate of COX 
products in the aging vasculature is certainly not uniform in diverse studies in rodents 
and humans.21 Nevertheless, our results confirm the observation that DR prevents the 
decline of plasma and renal prostacyclin levels in aging rats.22, 23 Kim et al. show rather 
diverse changes, claiming lower levels of both vasoconstrictive and vasodilatory COX 
products after DR in the aging rat aorta.24 DR was reported to increase SIRT-1, which in 
turn might increase COX-2 expression and activity.16, 20 However, our results exclude the 
possibility that this happens in Ercc1∆/-. Clearly, multiple studies indicate the participa-
tion of COX products in DR-induced changes, and future studies should now investigate 
the underlying mechanism(s).
Ang II responses increased in AL-fed Ercc1∆/- mice compared to WT, whereas plasma 
renin activity decreased. The latter result is in agreement with the observation that 
renin levels decrease with age.25, 26 Although renin levels start decreasing already when 
approaching middle age, our present findings indicate that the aging process might 
contribute to this decrease. With respect to the effect of aging on AT1 receptor-mediated 
vasoconstriction many contrasting findings have been described, depending on the 
species and the vessels that have been used.27-31 Nevertheless, our observation is in 
agreement with findings showing that in older persons blood pressure and blood flow 
responses to Ang II are elevated, especially in the presence of diabetes and/or in the 
absence of counterregulation by AT2 receptors.29, 32-34 Counterbalancing of AT1-mediated 
pathogenesis is the basis for development of AT2 receptor agonists as clinical drugs 
against cardiovascular diseases.35, 36 Conversely, increased Ang II activity via AT1 recep-
tors due to a loss of counterregulation by AT2 receptor is a mechanism observed in 
various disease models and in aging wild-type rats.35, 37 The counterbalancing effect by 
AT2 receptors is often ascribed to endothelial NO release, or might relate to a change 
in dimerization of the two Ang II receptor subtypes.38 Loss of NO signaling clearly does 
not play a role in Ercc1∆/- mutants or their WT littermates given the absence of an effect 
of ODQ, leaving receptor interaction as the alternative mechanism. The vascular dys-
function observed in the present study was clearly not related to Ang II and increased 
blood pressure. In patients, the effect of chronic AT1 receptor blockade on preservation 
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of vasodilator function is variable, having either a protective effect or not.39 It was 
assumed that this might depend on the underlying disease or the vessel type that is 
investigated. However, our study suggests that the aging process might explain such 
variation. Unfortunately, most of the human studies exploring the effect of chronic AT1 
receptor blockade focus on patients around 60 and younger, and not on the oldest old. 
However, there are clues that aging affects the effectiveness of AT1 receptor blockade. It 
has been shown that losartan becomes gradually less effective in aging rats, especially 
in the presence of hypertension and after loss of endothelium-independent NO func-
tion.40 Clinical observations show that losartan/antihypertensive treatment can lead to 
adverse cognitive effects in elderly, which is ascribed to perfusion problems.41 However, 
the same study suggests that this perfusion problem is a result of both blood pressure 
lowering and a persisting vascular dysfunction, at least in the brain. This implicates that 
vasodilator function is not improved. More dedicated studies in the oldest patients are 
necessary to resolve this paradox. There are mechanistic explanations available for this 
paradigm. In patients or in animal models of heart failure, hypertension, and/or diabetes, 
Ang II receptor blockade largely improves endothelial function due to an acute reduc-
tion of ROS formation by NADPH oxidase, increasing NO bioavailability.9 DNA damage 
largely lowers NO independently from ROS,4 and apparently this undermines the treat-
ment efficacy of AT1 receptor antagonists in our mouse model. The findings in our study 
might therefore be limited to Ercc1Δ/- mice. Although this model, like comparable DNA 
repair models, is considered as a more humanized aging model than WT mice,6 its accep-
tance as such awaits further confirmation. Ideally, tools become available to investigate 
whether the limited effectiveness of RAS treatment in humans is also due to DNA dam-
age. A multitude of DNA lesion types exist, and current tools are not sufficient to reliably 
engage such an enterprise. However, novel techniques such as single-cell RNA and DNA 
sequencing performed with nanopore sequencing techniques, as to avoid PCR-related 
aberrations, might be used to detect stochastic stalling of transcription of long RNAs 
or to count single cell DNA mutations; two surrogate markers for DNA damage. The 
cells used for this purpose have to be long-lived to detect accumulated lesions. Yet it 
should be possible to obtain them in a non-invasive manner. A potential nucleotide 
source could be circulating (adult) endothelial cells. It might be worthwhile to explore 
such possibilities: suboptimal effectiveness of and treatment response variability to RAS 
inhibition are well-known phenomena, but remain largely unexplained, and therefore 
drive studies that attempt to find prediction markers for therapy effectiveness.42, 43
Clinical perspectives
· DR is a very efficient intervention to prevent vasodilator dysfunction caused by ge-
nomic instability. In this study we set out to identify potential mechanisms that lead 
to DR-mediated improvement of vasodilator dysfunction caused by DNA damage.
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· Improvement of prostaglandin-mediated endothelium-dependent signaling and of 
VSMC responses to NO were identified as mechanisms. Vascular dysfunction induced 
by genomic instability is not reversible with chronic losartan treatment.
· Mouse models of genomic instability appear to represent the RAS blockade-resistant 
part of aging-related vascular disease, and might be tools to further explore this 
clinically relevant issue. Further study on the effect of genomic instability might offer 
a novel source of mechanistic explanations and markers with potential for clinical 
translation.
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SuPPlEMENTARy INfORMATION
Diet restriction studies 
Ercc1Δ/- mice lacking adequate ERCC1 endonuclease function due to partial removal of 
the Ercc1 gene have been described in detail elsewhere (Dollé MET, Pathobiol. Aging Age-
rel. Dis. 2011 ). Ercc1Δ/- mice and their wild type littermates (WT) were bred at the animal 
facility of the Centre for Health Protection, National Institute for Public Health and the 
Environment (RIVM), Bilthoven, The Netherlands. The diet restriction intervention has 
been described extensively in our previous publication.2 In short, the animals used in 
this study were 7-, 11-, and 16-week-old (-wk) Ercc1Δ/- mice, and 11-, 20-wk wildtype 
(WT) mice that were either exposed to AL feeding or to DR. In Ercc1Δ/- DR was started 
at 7 weeks of age, when they reach their maximum weight, with a 10% restriction, 
intensifying DR to 20% and 30% in weeks 8 and 9 respectively. Thereafter, 30% DR was 
maintained until the day of sacrifice, upon which vascular tissue was harvested for organ 
bath experiments and molecular analyses. WT animals were put on DR from the age of 
11 weeks, when they were in a comparable phase of their growth curve respective to 
Ercc1Δ/-,2 and then followed a similar procedure to Ercc1Δ/- mice. Consequently, 16-wk 
old Ercc1Δ/- mice were as long on DR as 20-wk old WT. As the DR group allowed longer 
survival of the Ercc1Δ/- mice (~25 vs. ~55 weeks, AL vs. DR, resp.),2 an additional group of 
30-wk old mice was explored to assess if any protective effect on the vasculature would 
last at least as long as the maximal life expectancy of AL-fed Ercc1Δ/-.
losartan intervention study
Male and female Ercc1Δ/- (n=28) and wild type mice (n=17) for this study were bred at 
the Erasmus MC animal facility. Changes in blood pressure and vascular function were 
visible from an age as young as 8 weeks.4 At the age of 7 weeks a non-significant trend 
towards endothelial dysfunction was already observed, which becomes significant 
between the age of 11 to 16 weeks.2,4 Blood pressure in conscious Ercc1Δ/- mice can be 
measured reliably from the age of 8 weeks at which point it is elevated. At the age of 
16 weeks and beyond the Ercc1Δ/- mice become very frail and reliable blood pressure 
measurement was not possible anymore. Ang II vasoconstrictions in iliac artery were 
measured in Ercc1Δ/- mice from the age of 12 weeks to 18 weeks and found to be higher 
than in WT (see Results section). Therefore, we anticipated that a treatment with AT1 
receptor antagonist losartan started at the age of 5 weeks, the earliest possible time 
point, and sustained until the age of 12 weeks would be an adequate approach to test 
its expected protective and blood pressure effect. From 5 weeks of age, Ercc1Δ/- and WT 
mice were divided into two groups per strain, which were either treated with losartan 
(100 mg/kg/day) in drinking water, or drinking water only. Thus, the following groups 
were created: Ercc1Δ/- losartan (n=15); Ercc1Δ/- water (n=19); WT losartan (n=7); WT water 
145
5
Dietary restriction, losartan and vasodilator function in Ercc1Δ/- mice
(n=13). The distribution of performed measurements amongst the animals within this 
study are depicted in Table 1.
Tail cuff experiments
The animals were first trained for 4 consecutive days to acclimatize to measurement 
conditions. On the subsequent 5th day representative blood pressures were measured. 
Thereafter, the animals were sacrificed and vascular tissue was taken out to measure 
vasomotor function in organ bath set-ups, and to perform molecular analyses.
Tissue harvesting and preparation
Thoracic aorta and iliac arteries were collected from mice within 5 minutes after sacrifice 
by asphyxiation, and stored overnight in cold, oxygenated (5% CO2; 95% O2) Krebs-
Henseleit buffer (in mmol/L: NaCl 118, KCl 4.7,CaCl2 2.5, MgSO4 1.2 , KH2PO4 1.2, NaHCO3 
25 and glucose 8.3 in distilled water; pH 7.4) solution. The following day, vessel segments 
were mounted in 6-mL small wire myograph organ baths (Danish Myograph Technology, 
Aarhus, Denmark) containing Krebs-Henseleit buffer at 37°C and oxygenated with 95% 
O2 and 5% CO2. The tension was normalized to 90% of the estimated diameter at which 
the effective transmural pressure is 100 mmHg. Viability of the tissue was tested through 
induction of contractions by exposure to respectively 30, 60, and 100 mmol/L KCl.
 Testing of vasodilator function
In aortic segments, after washout of KCl, a pre-constriction was elicited with 30 nmol/L 
U46619, a thromboxane A2 mimetic, resulting in 50-100% of the previously obtained 
contraction to 100 mmol/L KCl. Following pre-constriction, relaxation for the endotheli-
um-dependent vasodilator acetylcholine (ACh) were constructed by giving cumulative 
doses (10-9-10-5 mol/L), followed by exposure to the endothelium-independent vasodila-
tor sodium nitroprusside (SNP, 10-4 mol/L). To further explore the endothelium-indepen-
dent dilator we cumulatively added SNP (10-9-10-5 mol/L) in parallel rings preconstricted 
with 30 nmol/L U46619. When sufficient aortic tissue was available, the involvement 
of nitric oxide (NO) and prostaglandins in ACh responses was investigated by perform-
ing the experiments in the presence of the endothelial nitric oxide synthase inhibitor 
Table 1. Numbers of animals included in the diverse evaluations 
 Variable
WT water
total: (n=13)
Ercc1Δ/- water
(n=19)
WT losartan
(n=7)
Ercc1Δ/- losartan
(n=15)
Vasodilator function 6 10 4 8
Ang II constriction 9 13 5 12
BP 9 9 7 15
Real-time PCR 10 12 7 12
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NG-Methyl-L-Arginine acetate salt (L-NMMA, 10-5 mol/L), the cyclo-oxygenase (COX) 
inhibitor indomethacin (INDO, 10-5 mol/L) or both inhibitors. Inhibitors were added to 
the organ bath 10 minutes prior to U46619.
Quantitative real-time PCR
Total RNA was isolated with the Nucleospin RNA II kit (Machery-Nagel). RNA was reverse-
transcribed by use of Quantitect Rev. Transcription Kit (Qiagen). Four nanograms of cDNA 
was amplified by Real-time PCR on a Bio-Rad CFX96 thermocycler using iQ™ SYBR Green 
Supermix (Bio-Rad Life Sciences). β-actin was used for normalization, and comparison 
with B2M and HPRT-1 as a household gene was performed to further verify reliability. 
Since this yielded the same result, these data are not shown. Each reaction was run in 
duplicate and generation of specific PCR products was confirmed by melting-curve anal-
ysis and gel electrophoresis. Results from unreliable duplicates or melting-curves were 
discarded (values were excluded of Ct ≥ 31). Each reaction was performed in duplicate 
with SYBR Green PCR Master Mix (Applied Biosystems). The relative amount of genomic 
DNA in DNA samples was determined as follows: RQ = 2(-∆∆Ct). COX-1 and -2, adenylate 
cyclase (AC)-5 and 6, phosphodiesterase (PDE)-4B and 4D, and the prostaglandin-I2 (IP) 
receptor. Details of primers are provided in Table 2.
Western Blots
Lungs were snap frozen in liquid nitrogen and then stored at -80°C. Frozen tissues were 
homogenized in ice cold RIPA buffer (50 mmol/L HCl pH 7.4, 150 mmol/L NaCl, 1% NP-40, 
0.25% Na-deoxycholate and 1 mmol/L EDTA) containing protease and phosphatase-
Table 2. Primer sequences for SYBR green qPCR
Marker Forward primer Reverse primer
COX-1 TACTCACAGTGCGGTCCAAC GTACAGAGGGCAGAATGCGA
COX-2 GGGCCATGGAGTGGACTTAAA TCCATCCTTGAAAAGGCGCA
AC5 CCAGTGTACTGCCCAAGAACT GTAAACAGTGATTCTCCGCAGC 
AC6 CTGCGGTGAGGGAGAATCACT AGCCCTGACACGCAGTAGT
PDE4B ACTGATGCACAGCTCAAGCC CCAGCTCCTTGGCTAGATGA 
PDE4D GCAGACTTGCGAAGCGAATC CCATTGTCCACATCGAAACCAC
IP receptor ATGTACCGCCAACAGAGACG CCTCGGATCATGAGAGGCAG
AT1a receptor CCCACGTGTCCCTGTTACTAC TTTGGGGACAGTACAGGTTTC
AT1b receptor CTGTGAAATTGCGGACGTAGT AAGCCATAAAACAGAGGGTTCAG
AT2 receptor TACCCGTGACCAAGTCCTGA TACCCATCCAGGTCAGAGCA
β-Actin AGCCATGTACGTAGCCATCCA TCTCCGGAGTCCATCACAATG
ACE (lung) and renin (kidney) expression was studied using TaqMan® assays using probe sets from Ther-
moFisher Scientific with the following identities: β-Actin, Mm00607939_s1; ACE, Mm00802048_m1; renin, 
Mm02342889_g1.
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inhibitors (1mmol/L PMSF, 1 mmol/L NaVO4, 1 mmol/L NaF, 1 μg/mL aprotinin, 1 μg/
mL pepstatin and 1 μg/mL leupeptin) using a stainless-steel ultraturrax (Polytron). 
Homogenized tissues were centrifuged and protein concentration was measured in the 
supernatants using the BCA method (Thermo Scientific, USA). The samples were run on 
a criterion bis/tris gradient gels, and blotted to nitrocellulose membranes.
For eNOS, membranes were blocked with 5% milk TBS-T; for pSer1177- eNOS, COX-1, 
COX-2, PDE4B and SIRT-1 membranes were blocked with 5% BSA TBS-T. After blocking, 
membranes were incubated overnight with the primary antibodies was as follows: 
 eNOS (Santa Cruz, SC-654 1:500 in 5% milk TBS-T), pSer1177- eNOS (Santa Cruz, 
SC-21871-R 1:500 in 5% BSA TBS-T), COX-1 (Cell Signalling, #9896 1:1000 in 5% BSA TBS-
T), COX-2 (Cell Signalling, #4842 1:1000 in 5% BSA TBS-T), PDE4B (Santa Cruz, SC-25812 
1:1000 in 5% BSA TBS-T) and SIRT-1 (Abcam, ab28170 1:500 in 5% BSA TBS-T).
We used an HRP- conjugated antibody (Bio-Rad 1:2000 in 1% milk-TBS-T) to detect 
the primary antibodies. For visualization we used an enhanced chemiluminiscent sub-
strate for detection of HRP (Pierce ECL Western Blotting Substrate, Thermo Scientific). All 
protein expression levels were normalized to Actin.
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Supplementary figure 1. mRNA expression levels in lung tissue of COX-1, COX-2, AC 5, and PDE4B in 16-wk-
old Ercc1∆/- mice and 20-wk-old wild-type (WT) littermates from the diet intervention study. All mRNA val-
ues are corrected for β-actin and normalized to WT-AL expression levels. Error bars: S.E.M. #P<0.05, one 
way- ANOVA; *P<0.05, Bonferroni’s post-hoc tests.
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Blood pressure control is largely dependent on the vasodilator capacity of blood vessels, 
which for the major part requires the release of endothelium-derived relaxing factors, 
i.e., NO and endothelium-derived hyperpolarizing factor (EDHF). In conduit vessels, NO 
is most relevant, while in resistance vessels EDHF is believed to have a more prominent 
role.
NO interacts with soluble guanylyl cyclase (sGC) to convert guanosine-5’-triphos-
phate (GTP) to cGMP, which subsequently binds to protein kinase G (PKG). Two PKG 
genes (I and II) exist, and vascular smooth muscle cells express only PKGI. The PKGI gene 
expresses as 2 separate isoforms (α and β), which are splice variants of the same gene 
and differ only in sequence of their N-terminal leucine zipper (LZ) interaction domain.1 
They occur as homodimers, and their LZ domains mediate PKG binding to specific sub-
strates, via LZ–LZ co-interaction. For instance, cGMP-activated PKGIα phosphorylates 
vasodilator-stimulated phosphoprotein (VASP) (Figure). NO donors (nitrates), sGC acti-
vators/stimulators (riociguat, cinaciguat and vericiguat) and phosphodiesterase (PDE) 
1 and 5 inhibitors (which block cGMP degradation by PDE1 and PDE5, e.g., ITI-214 and 
sildenafil) target this pathway (Figure 1). Yet, their indications include angina pectoris, 
erectile dysfunction, pulmonary arterial hypertension, and neurological disorders, but 
not systemic hypertension. This might be because central blood pressure is mainly 
regulated through resistance vessels, requiring drugs to exclusively target EDHF.
EDHF-mediated relaxant pathways display great diversity, and multiple candidates 
have been proposed to act as EDHF, possibly depending on the vascular bed and species 
that are investigated. The list includes cytochrome P450 metabolites (epoxyeicosatrie-
noic acids, EETs), cyclo-oxygenase products, K+, H2O2, gap junctions and S-nitrosothiols.2 
Interestingly, H2O2 activates PKGIα in an cGMP-independent manner, by inducing the 
formation of a disulfide bond between the cysteine 42 (C42) residues of 2 adjacent 
chains in PKGIα homodimers.3 This covalent bond can be formed by virtue of the LZ 
keeping the two chains together for oxidant substances to establish the disulfide bond 
(Figure). The covalently coupled PKGIα homodimers phosphorylate large-conductance 
Ca2+-dependent K+ (BKCa) channels, thus leading to smooth muscle hyperpolarization. 
Since C42 is unique to PKGIα, it might be a promising target for the development of 
novel antihypertensive drugs predominantly acting in resistance vessels. No such drugs 
exist until now.
In this edition of Hypertension, Burgoyne et al. report their quest to identify com-
pounds capable of inducing PKGIα oxidation.4 Using an in vitro assay with recombinant 
PKGIα and dibromobimane, which fluoresces when binding to reduced PKGIα, they 
screened around 300 electrophilic small molecules. Twelve promising compounds 
emerged and were screened for bioactivity in mouse mesenteric arteries in ex-vivo 
myograph experiments. The 5 compounds that displayed the highest relaxation ef-
ficacy underwent selectivity screening in mesenteric arteries of C42S PKGIα knock-in 
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(KI) mice, i.e., arteries that cannot be activated by oxidants. This yielded one candidate 
lead compound, named G1, capable of relaxing wild-type (WT), but not KI arteries. As 
a comparator, the sGC activator cinaciguat relaxed both arteries equally well. In vivo, 
intraperitoneal bolus injection of G1 (7.4 mg/kg) in WT mice did not alter mean arterial 
pressure (MAP) due to a compensatory heart rate increase. However, in mice rendered 
hypertensive by infusion with angiotensin II, intraperitoneally administered G1 (3.7 and 
14.8 mg/kg) acutely lowered blood pressure. Also, oral intake of G1 (20 mg/kg) lowered 
MAP in angiotensin II-infused WT mice, with a swift onset of the antihypertensive effect. 
This effect appeared to wane off gradually over the 4 days that G1 was administered. G1 
was without effect in KI mice in the latter protocol (oral application), but did lower MAP 
modestly in angiotensin II-infused KI mice when administered intraperitoneally at 7.4 
mg/kg.
Although these results are exciting and might lead to the development of new anti-
hypertensive therapies, the study is still very preliminary and several concerns should be 
addressed in future investigations. First, important pharmacological questions remain 
figure 1. The vasodilator capacity of blood vessels depends on NO and endothelium-derived hyperpolariz-
ing factor(s) [EDHF(s)] released from the endothelium. NO is generated by endothelial NO synthase (eNOS) 
from L-arginine, and activates soluble guanylate cyclase to generate cGMP from GTP. Next, cGMP binds to 
protein kinase G Iα (PKGIα), capable of phosphorylating vasodilator-stimulated phosphoprotein (VASP). 
EDHFs like H2O2 induce the formation of a disulfide bond between the cysteine 42 residues of 2 adjacent 
chains in PKGIα homodimers, and this results in the opening of potassium channels, leading to hyperpo-
larization. Since cGMP is degraded by phosphodiesterases 1 and 5 (PDE1, PDE5), novel drugs are aimed at 
blocking PDE, to enhance NO-cMP signaling. In addition, sGC activators/stimulators will also upregulate 
this pathway. Finally, compounds capable of inducing PKGIα oxidation might selectively upregulate the 
EDHF pathway.
157
PKGIα Activators as Novel Antihypertensives
6
to be answered. Unlike the NO-cGMP pathway, the EDHF field is full of uncertainties, 
and given the multitude of factors involved one should perhaps rather use the term 
endothelium-derived hyperpolarization (EDH), i.e., leaving out ‘factor’. As a consequence 
of this complexity, after decades of work, no drug has emerged from this concept. Most 
studies agree on a role for endothelial small- and intermediate conductance Ca2+-
dependent K+ (SKCa, IKCa) channels in EDH.2 H2O2 is one of the many players in this field, 
and its activation of BKCa in vascular smooth muscle cells is mimicked by only a few other 
EDHFs, like the EETs.5 PKG inhibition with KT5823 blocked the ex-vivo relaxant effects 
of G1 in mesenteric arteries by ≈50%, implying that potentially half of the effect of G1 
is PKG-independent. The marginal G1-induced increase in PKGIα disulfide dimer % in 
aortic tissue (from 78 to 86%), combined with the G1-induced blood pressure-lowering 
effects in KI mice, support this view. In this regard, it is of interest to note that sGC activa-
tors might also act independent from sGC activity. For instance, during sGC inhibition 
with ODQ, the sGC activator BAY412272 still evoked vasodilation in porcine coronary 
arteries, by activating Na+-K+-ATPase.6 To what degree this involved cGMP-independent 
PKG activation or non-PKG mechanisms is unknown. Clearly, future studies should in-
vestigate what non-PKG mechanisms are activated by G1, and how sGC activators might 
exert EDH, for instance via mechanisms involving Na+-K+-ATPase activation. Since G1 
prevented VASP phosphorylation by the stable cGPM analogue 8-Br-cGMP, it is possible 
that the cGMP-activated PKGIα-VASP pathway and the oxidized PKGIα-BKCa pathway 
are mutually exclusive. If so, we need to know what exactly determines their respective 
contributions in conduit versus resistance vessels, since PKG occurs at both sites.
Second, at the organismal level, electrophilic drugs acting through formation of 
covalent binding, such as G1, could potentially be toxic, and provoke allergic or autoim-
mune responses.7, 8 This fact, together with the observation that the G1 effect disap-
pears slowly, awakens the concern that G1 and derivatives thereof should first undergo 
strict pharmacological, toxicological, and efficacy testing in chronic animal models 
before passing to patients. Despite a comprehensive discussion speculating on the 
putative non-toxicity of G1 and derivatives thereof, the authors admit that further lead 
optimization is necessary in particular to minimalize toxicity through widespread thiol 
modification: a point well-taken. The in-vivo disappearance of the effect is reminiscent 
of the tolerance phenomenon associated with nitrate use, which involves the loss of 
bioactivation of nitroglycerin. Does G1 require bioactivation, and/or does the G1 toler-
ance represent the upregulation of counterregulatory mechanisms (e.g., inactivation of 
oxidized PKGIα by thioredoxin)? 
Finally, the question arises which models are appropriate to test G1 chronically. In 
particular, when aiming at treatment of essential hypertension, G1 should be addition-
ally studied in models that do not rely on angiotensin II infusion, like the spontaneously 
hypertensive rat, and low-renin models such as the DOCA-salt rat. Here, the effects of 
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G1 on cardiac and vascular remodeling and kidney function might also be investigated, 
as PKGI activation is not limited to the vascular wall.1 In such studies, the process of 
aging could simultaneously be taken into consideration, given the age-dependency of 
hypertension, and the fact that aging is associated with an increase of PDE1 activity, 
thereby decreasing NO signaling.9, 10 Impaired NO signaling is often compensated for by 
upregulated EDHF responses, but this is not a uniform phenomenon, and thus drugs that 
improve EDHF signaling, like G1, could have great therapeutic potential even beyond 
hypertension. An obvious prerequisite is that such novel drugs are free of side-effects.
In summary, it seems that Burgoyne et al. have arrived with a fresh approach at the 
shore of the Rubicon, but are not yet ready to cross: before taking such a daring step we 
need more evidence! 
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ABSTRACT
Protein kinase G Iα mediates the vasodilatory effects induced by nitric oxide. It has been 
suggested that other endothelium-derived hyperpolarizing factors (EDHFs), such as 
H2O2, can activate protein kinase G Iα by inducing the formation of a disulfide bond 
between the cysteine 42 (C42) residues of 2 adjacent chains in PKGIα homodimers in 
a cGMP-independent manner. However, it is unknown whether all EDHFs can activate 
PKGIα.
We investigated the contribution of PKGIα to NO- and EDHF-induced vasodilation in 
porcine coronary arteries (PCAs). PCAs were mounted in organ baths, and concentration 
response curves to bradykinin, H2O2 , L-S-nitrosocysteine (L-SNC) and polychromatic 
light were constructed in the presence or absence of inhibitors of S-nitrosothiols, thiore-
doxin reductase, PKG or soluble guanylyl cyclase (sGC).
Bradykinin fully relaxed preconstricted PCAs. The sGC inhibitor ODQ prevented this 
relaxation, inducing near complete blockade when administered together with the PKG 
inhibitor KT5823. Thioredoxin reductase inhibition with auranofin potentiated bradyki-
nin ≈7-fold, both with and without ODQ, indicating that bradykinin-induced responses 
involve sGC and oxidized PKGIα. H2O2 concentration-dependently relaxed preconstricted 
vessels, and neither ODQ nor KT5823 blocked this effect. Thioredoxin reductase inhibi-
tion with 1-chloro-2,4-dinitrobenzene (DNCB) potentiated H2O2 2.2-fold. These data 
indicate that H2O2-induced relaxations involved oxidized PKGIα but not sGC. L-SNC fully 
relaxed preconstricted PCAs and this effect was only blocked by ODQ, indicating that the 
L-SNC-induced effects involve sGC, but not PKG. A 5-min light exposure relaxed PCAs by 
64 ± 3.4%. ODQ fully prevented photorelaxation while KT5823 was without effect. Both 
DNCB and auranofin tended to enhance photorelaxation. Depletion of S-nitrosothiols 
diminished photorelaxation. Yet, after such depletion, the potentiating effect of DNCB 
(but not auranofin) became significant. This indicates that photorelaxation depends 
on sGC activation by S-nitrosothiols, while only after S-nitrosothiol depletion oxidized 
PKGIα comes into play.
In conclusion, both bradykinin- and light-induced relaxation of PCAs depend, 
at least partially, on oxidized PKGIα, and this does not involve sGC. H2O2 also acts via 
oxidized PKGIα in an sGC-independent manner. Yet, S-nitrosothiol-induced relaxation is 
PKGIα-independent. Clearly, PKG activation does not contribute universally to all EDHF 
responses, and targeting PKGIα may only mimick EDHF under certain conditions.
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INTRODuCTION
Blood pressure control is largely dependent on the vasodilator capacity of blood vessels, 
involving the release of endothelium-derived relaxing factors, i.e., nitric oxide (NO) and 
endothelium-derived hyperpolarizing factor (EDHF).
NO interacts with soluble guanylyl cyclase (sGC) to convert guanosine-5’-triphos-
phate to cGMP, which subsequently binds to protein kinase G (PKG) Iα, thereby inducing 
dilation. Yet, EDHFs like H2O2 have also been suggested to activate PKGIα.1-3 This occurs in 
an cGMP-independent manner, by inducing the formation of a disulfide bond between 
the cysteine 42 (C42) residues of 2 adjacent chains in PKGIα homodimers.2 The covalently 
coupled PKGIα homodimers phosphorylate large-conductance Ca2+-dependent K+ (BKCa) 
channels, resulting in smooth muscle hyperpolarization. Oxidized PKGIα is extremely 
short-lived, as it is rapidly converted to the reduced state by thioredoxin. Thioredoxin is 
kept in the reduced state by thioredoxin reductase, and inhibitors of the latter enzyme, 
like auranofin and 1-chloro-2,4-dinitrobenzene (DNCB), will block thioredoxin activity, 
leading to an increase in the half-life of oxidized PKGIα.4
Given the great diversity of EDHF candidates,5, 6 it is questionable whether all EDHFs 
act via PKGIα. Previous studies from our laboratory in porcine coronary arteries (PCAs) 
supported a role for S-nitrosothiols as EDHF in bradykinin-induced responses.7-10 S-
nitrosothiols are also major contributors to light-induced relaxation (‘photorelaxation’) 
of PCAs.8, 9, 11 In the present study, we verified the contribution of PKGIα to NO- and 
EDHF-induced vasodilation in bradykinin- or light-exposed PCAs. For comparison, 
concentration-response curves (CRCs) to H2O2 and L-S-nitrosocysteine (L-SNC) were also 
constructed. Experiments were performed both in the absence or presence of inhibitors 
of S-nitrosothiols, thioredoxin reductase, PKG or sGC.
METhODS
Drugs
Bradykinin, 9,11-dideoxy-11α,9α-epoxy-methano-prostaglandin F2α (U46619), 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), ethacrynic acid, auranofin, DNCB, and 
KT5823 were from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Tissue Collection
PCAs were obtained from 49 slaughterhouse pigs. They were removed after the heart 
had been brought to the laboratory in cold, oxygenated Krebs bicarbonate solution of 
the following composition (mmol/l): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, 
NaHCO3 25 and glucose 8.3; pH 7.4. PCAs were stored in cold, oxygenated Krebs bicar-
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bonate solution for 12-36 hours. They were then cut into segments of approximately 4 
mm length, suspended on stainless steel hooks in 15 ml-organ baths containing Krebs 
bicarbonate solution, aerated with 95% O2 / 5% CO2, and maintained at 37°C.
Organ bath studies
Vessel segments were allowed to equilibrate for at least 30 min, and the organ bath 
fluid was refreshed every 15 min during this period. Changes in tissue contractile force 
were recorded with a Harvard isometric transducer (South Natick, MA, USA). The ves-
sel segments, stretched to a stable force of about 15 mN, were exposed to 30 mmol/l 
KCl twice. Subsequently, the tissue was exposed to 100 mmol/l KCl to determine the 
maximal contractile response to KCl. The segments were then allowed to equilibrate 
in fresh organ bath fluid for 30 min in the absence or presence of one or more of the 
following inhibitors: auranofin (3 µmol/l)4, DNCB (4 µmol/l)12, the PKG inhibitor KT5823 
(1 µmol/l)1, the sGC inhibitor ODQ (10 µmol/l), or the S-nitrosothiol-depleting agent 
ethacrynic acid (50 µmol/l)8. Vessels were then preconstricted with the thromboxane A2 
analogue U46619 (1 µmol/l) and either exposed to bradykinin, H2O2, L-SNC or light. The 
light experiments involved six 5-min exposures to light using a halogen dissection lamp 
omitting polychromatic light in a dark room. Each exposure was followed by a period in 
the dark of 10 minutes.
Data Analysis
Data are given as mean±SEM. Relaxant responses are expressed as a percentage of the 
contraction to U46619. CRCs were analyzed as described using the logistic function de-
scribed13 to obtain pEC50 (-10logEC50) values. ODQ increased basal tone by maximally 15% 
of the maximum contractile response. U46619-induced preconstrictions were corrected 
for this increase in baseline. Statistical analysis versus control was obtained by two-way 
ANOVA for light experiments, and one-way ANOVA for agonist-induced relaxations. 
P<0.05 was considered significant.
RESulTS 
Auranofin and DNCB up to a concentration of 10 µmol/l did not relax preconstricted 
vessels (n=5; data not shown). Bradykinin fully relaxed preconstricted PCAs (pEC50 7.9 ± 
0.1; n=6). ODQ (P<0.05; n=6) and KT5823 (P=NS; n=6) prevented this relaxation, induc-
ing near complete blockade when administered together (Figure 1A). DNCB non-sig-
nificantly potentiated the effect of bradykinin, both with and without ODQ (Figure 1B), 
while auranofin potentiated bradykinin ≈7-fold, both with and without ODQ (P<0.0001 
165
NO, EDHF and PKGIα
7
for both; n=6) (Figure 1C). This indicates that bradykinin-induced responses involve both 
sGC and oxidized PKGIα.
H2O2 concentration-dependently relaxed preconstricted vessels (pEC50 4.1±0.1; 
n=6), and neither ODQ (n=6) nor KT5823 (n=5) blocked this effect (Figure 2A). DNCB po-
tentiated H2O2 2.2-fold (pEC50 4.4±0.1, n=6; P<0.0001 vs. control), and a similar tendency 
was observed for auranofin (pEC50 4.3±0.1, n=6; P=NS) (Figure 2B). At concentrations 
above 0.1 mmol/l, H2O2 induced short-lasting (<60 seconds) constrictor responses (cor-
responding with <10% of the maximum contractile response to KCl) which preceded 
the relaxations (data not shown). These constrictor responses were not observed in the 
presence of DNCB (data not shown). These data indicate that H2O2-induced relaxations 
involved oxidized PKGIα but not sGC, and that enhancing these relaxations abolished 
the minor contractile responses to H2O2.
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figure 1. Bradykinin-induced relaxations of 
U46619-preconstricted porcine coronary ar-
teries in the absence (control) or presence of 
ODQ and/or KT5823, DNCB or auranofin. Data 
(mean±SEM) are expressed as a percentage of 
the contraction induced by U46619. *P<0.05, 
***P<0.0001 vs. control or ODQ alone
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L-SNC fully relaxed preconstricted PCAs (pEC50 5.0±0.1; n=5), and this effect was 
blocked by ODQ (pEC50 4.5±0.2, n=5; P<0.001) (Figure 3A), but not KT5823 (n=5), au-
ranofin (n=6), or DNCB (n=6) (Figure 3B). This indicates that the L-SNC-induced effects 
involve sGC, but not PKG.
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figure 2. H2O2-induced relaxations of U46619-preconstricted porcine coronary arteries in the absence 
(control) or presence of ODQ, KT5823, DNCB or auranofin. Data (mean±SEM) are expressed as a percentage 
of the contraction induced by U46619. ***P<0.0001 vs. control.
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figure 3. L-SNC-induced relaxations of U46619-preconstricted porcine coronary arteries in the absence 
(control) or presence of ODQ, KT5823, DNCB or auranofin. Data (mean±SEM) are expressed as a percentage 
of the contraction induced by U46619. ***P<0.0001 vs. control.
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A 5-min light exposure relaxed PCAs by 64 ± 3.4% (n= 7). Upon repetitive exposure 
to light, relaxations tended to get smaller, indicating depletion of the underlying relax-
ant factor(s) (Figure 4A). ODQ fully prevented relaxation (n= 3), while KT5823 (n=7) was 
without effect. Both DNCB (n=6) and auranofin (n=6) tended to enhance photorelax-
ation (Figure 4B and 4C). The S-nitrosothiol-depleting agent ethacrynic acid diminished 
photorelaxation (n=6; P<0.0001). Yet, after such depletion, the potentiating effect of 
DNCB (n=6) became significant (P<0.0001) while the enhancing effect of auranofin 
(n=6) remained non-significant (Figure 4B and 4C). This indicates that photorelaxation 
depends on sGC activation by S-nitrosothiols, while only after S-nitrosothiol depletion 
oxidized PKGIα comes into play.
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figure 4. Light-induced relaxations of 
U46619-preconstricted porcine coronary ar-
teries in the absence (control) or presence of 
ODQ, KT5823, DNCB, auranofin and/or ethac-
rynic acid. Data (mean±SEM) are expressed as 
a percentage of the contraction induced by 
U46619. ***P<0.0001 vs. control or ethacrynic 
acid alone.
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The present study supports the concept that oxidized PKGIα contributes to EDHF-me-
diated responses following bradykinin exposure of PCAs. The potentiating effect of the 
thioredoxin reductase inhibitor auranofin on top of sGC inhibition with ODQ illustrates 
the sGC-independency of this phenomenon. Results obtained with the thioredoxin 
reductase inhibitor DNCB did not reach significance. This may relate to the fact that 
thioredoxin reductase inhibition also prevents thioredoxin-dependent denitrosylation. 
Consequently, DNCB augments S-nitrosylation and may thus simultaneously impair 
relaxation.12 
Bradykinin-induced, EDHF-mediated relaxation of PCAs involves endothelial small- 
and intermediate conductance Ca2+-dependent K+ channels.7 Their activation, e.g., by 
S-nitrosothiols, results in K+ release and smooth muscle cell hyperpolarization.10, 14 In 
addition, S-nitrosothiols activate smooth muscle Na+-K+ ATPase in a sGC-dependent 
manner,10 and they have been reported to activate BKCa channels via S-nitrosylation of 
cysteine residues.15 Their mechanism of action involves binding to S-nitrosothiol recog-
nition sites, resulting in the S-nitrosylation of cysteine residues.15 This process occurs in 
a stereoselective manner.16-18 Since BKCa channel activation also occurs after exposure to 
covalently coupled PKGIα homodimers,1 one possibility is that S-nitrosothiols interfere 
with this phenomenon via PKGIα.
Yet, PKG inhibition was without effect towards L-SNC, and thioredoxin reductase 
inhibition tended to block L-SNC-induced relaxation (as opposed to its potentiating 
effects towards bradykinin). This suggests that oxidized PKGIα is not responsible for L-
SNC-induced relaxation. Thioredoxin reductase inhibition did potentiate H2O2, confirm-
ing that at least this EDHF acts via oxidized PKGIα in PCAs.
In agreement with the concept that S-nitrosothiol-induced relaxation does not 
involve PKGIα activation, thioredoxin reductase inhibition non-significantly potentiated 
photorelaxation. Such relaxation largely depends on S-nitrosothiols, as illustrated by the 
suppression of this effect following S-nitrosothiol depletion by ethacrynic acid. Yet, after 
depletion, the effect of thioredoxin reductase inhibition with DNCB became significant. 
This implies that photorelaxation does involves additional factor(s) that apparently 
rely on oxidized PKGIα, and that can be distinguished only when suppressing the S-
nitrosothiol component of photorelaxation. To what degree this factor is identical to the 
factor that is responsible for the EDHF response after bradykinin exposure remains to be 
determined.
Of interest, H2O2-induced relaxation, although depending on oxidized PKGIα, could 
not be blocked by the PKG inhibitor KT5823. It therefore seems that PKG activity (blocked 
by KT5823) does not necessarily have the same effect as the formation of a disulfide 
bond between the C42 residues of 2 adjacent chains in PKGIα. In our experimental setup, 
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millimolar concentrations of H2O2 induced modest, short-lasting contractions. Such con-
tractions at high (supraphysiological) H2O2 concentrations have been noted before, and 
are most likely due to superoxide and/or thromboxane A2 upregulation.19 Enhancing 
relaxation (with DCNB), most likely through physiological antagonism, abolished these 
contractile responses.
Finally, given the fact that L-SNC-induced relaxation and photorelaxation can be 
blocked by ODQ, but not KT5823, while both phenomena do involve Na+-K+ ATPase 
activation in smooth muscle cells,7, 8 our data imply that sGC links to Na+-K+ ATPase 
activation in a PKG-independent manner.
In summary, both bradykinin- and light-induced relaxation of PCAs depend, at least 
in part, on oxidized PKGIα, and this does not involve sGC. H2O2 also acts via oxidized 
PKGIα in an sGC-independent manner. Yet, S-nitrosothiol-induced relaxation is PKGIα-
independent. Clearly therefore, PKG activation does not contribute universally to all 
EDHF responses, and targeting PKGIα may only mimic EDHF under certain conditions.20 
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SuMMARy
Age remains the greatest independent risk factor for all major life-threatening disorders, 
such as cardiovascular and neurological diseases. While lifespan has increased steadily 
over the last decades, healthspan has not increased at the same pace.1 Aging used to 
be considered a non-modifiable process but in the past decade it has been shown that 
it is a complex and highly regulated biological process, and that DNA damage is a main 
causative factor.2 The evidence supporting a role for DNA damage in the age-related 
vascular dysfunction in general population and in mouse models is reviewed in Chapter 
1.
Mice with defective DNA repair are excellent exploration tools because they rapidly 
reproduce hallmarks of human aging.3 It is known that in a mouse model of genomic 
instability due to defective DNA repair (Ercc1Δ/− mice), accelerated age-related vascular 
dysfunction takes place, which is characterized by decreased NO/cGMP responsiveness 
and increased cellular senescence in the vascular smooth muscle cell (VSMC) layer.4 In 
Chapter 2 we showed that increased metabolism of cGMP by phosphodiesterases (PDE) 
was responsible for the reduced NO/cGMP signaling in VSMC of Ercc1Δ/− mice (Figure 1B), 
since PDE inhibition fully restored endothelium-independent vasodilation to the level of 
WT mice. Our data also suggest that in Ercc1Δ/− mice, the contribution of PDE1 relative to 
PDE5 is increased. Similar observations were made in human senescent VSMCs. In addi-
tion, in our candidate gene look-up using GWAS data, single nucleotide polymorphisms 
in the PDE1A gene were associated with increased diastolic blood pressure and carotid 
intima media thickness, two hallmarks of human age-related vascular dysfunction. PDE1 
has also been implicated in atherosclerosis and malignant cardiac remodeling. Hence, 
PDE1 plays a central role in age-related cardiovascular disease.
Despite previous findings and the evidence presented in Chapter 2, one important 
question that remains is whether the observed accelerated vasodilator dysfunction in 
Ercc1Δ/- mice arises from defective local vascular DNA repair or if it is a consequence of 
the systemic deterioration from which these mice suffer. To answer this, cardiovascular 
function was investigated in mouse models with defective DNA repair in either vas-
cular endothelial cells or in smooth muscle. In Chapter 3 we studied this in a mouse 
model with specific loss of Ercc1 in vascular endothelial cells (EC-KO). We found that 
local endothelial genomic instability causes macrovascular and microvascular vasodila-
tor dysfunction due to specific loss of endothelium-dependent NO signaling, i.e., not 
endothelium-dependent hyperpolarization (EDH) or prostaglandins. Endothelium-
independent vasodilation was not affected (Figure 1C). The preserved endothelial cell 
layer, as confirmed by scanning electron microscopy, normal von Willebrand factor levels 
and normal EDH excludes the loss of NO through reduced EC numbers. The reduction 
of vasodilator response was only associated with a temporary blood pressure increase. 
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figure 1. Summary of our findings on vasodilation in mouse models of vascular aging.
In normal conditions NO and EDH mediate most of the endothelium-dependent vasodilation. Contribution 
of prostaglandins varies depending on vessel type (A). In Ercc1∆/- mice NO signalling is impaired due to de-
creased eNOS expression and increased metabolism of cGMP by PDE1 and 5. Dietary restriction improves 
vasodilation in Ercc1∆/- mice by recruiting prostaglandins (B). When DNA-damage is restricted to endothe-
lial cells NO signalling is impaired while EDH is unaffected (C). When DNA damage is restricted to smooth 
muscle NO contribution to endothelium-dependent vasodilation and NO sensitivity in VSMC is decreased. 
This is compensated by EDH and prostaglandins (D).
The weight of the arrows are indicative of the contribution of that pathway. AC, adenylyl cyclase; COX, 
cyclooxigenase; EDH, endothelium-derived hyperpolarization; eNOS, endothelial NO synthase; PDE, phos-
phodiesterase; PGI2, prostaglandin I2 or prostacyclin; sGC, soluble guanylyl cyclase.
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Apart from vasodilator dysfunction, EC-KO mice showed a severely compromised 
microvascular barrier function in the kidney, potentially leading to premature death. 
Furthermore, cardiac output was affected at 5 months of age and aortic distensibility 
was reduced, suggesting increased vascular stiffness.
In Chapter 4 we studied the effects of local DNA damage in VSMC in a mouse model 
with specific deletion of the Zmpste24 gene (SMC-KO). This causes accumulation of 
prelamin A, leading to impaired recruitment of DNA damage repair proteins and check-
C
D
figure 1. (continued)
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point activation, and thus results in defective DNA damage repair, apoptosis and cell 
senescence.5-7 The findings in SMC-KO mice contrast with those in EC-KO mice. EC-KO 
mice showed a specific decrease of endothelium-dependent NO-mediated relaxation, 
whereas SMC-KO mice display a specific decrease of endothelium-independent NO-
mediated relaxation. EC-KO mice do not compensate for the loss of acetylcholine (ACh)-
induced dilation, whereas SMC-KO mice do, namely by increasing prostaglandin-induced 
dilatation and recruiting EDH (Figure 1D). Another striking finding is that EC-KO mice do 
not show increased carotid stiffness, whilst SMC-KO mice do. It may be that endothelial 
dysfunction does not lead so swiftly to increased stiffness as VSMC dysfunction. The 
observations in SMC-KO mice are in agreement with observations in Ercc1Δ/- mice, and 
suggest that DNA damage in VSMC contributes to the increase of vascular stiffness that 
is seen in aging. Thus, both DNA damage in EC and VSMC, in what seems to be a cell-
autonomous way, lead to specific changes that are relevant for aging-related vascular 
disease. This answers an important question remaining from our previous study in the 
Ercc1Δ/− mouse model, showing that NO signaling was disturbed both in EC and VSMC.
In Chapter 5 we examined whether the vasodilator dysfunction present in Ercc1Δ/- 
mice could be prevented with dietary restriction (DR) or chronic blockade of the angio-
tensin (Ang) II type 1 (AT1) receptor with losartan. DR improved vasodilation up to an 
age of 30 weeks by enabling aortic tissue to recruit endothelium-derived vasodilatory 
prostaglandins, which are normally absent (Figure 1B). A possible explanation for the 
emerging prostaglandin response is the increase in COX-2, combined with a decrease in 
PDE4B, which together should lead to improved vasodilator cAMP signaling. In addition, 
DR improved the responsiveness of VSMC to NO. Chronic losartan treatment reversed 
the enhanced Ang II-induced vasoconstriction in Ercc1∆/- mice. This reduction could not 
be explained by physiological antagonism through effects on endothelial function, since 
the endothelium-dependent vasodilation was not improved by losartan. Also, blood 
pressure itself is not a driving mechanism in the observed vasodilator dysfunction, since 
blood pressure-lowering did not affect this dysfunction.
As shown in Chapters 3, 4 and 5, in our aging mouse models the eNOS-NO-cGMP 
pathway is specifically affected, and under dietary restriction its impaired signaling is 
compensated for by prostaglandins. Disturbed eNOS-NO-cGMP signaling is observed 
not only in aging, but also in essential hypertension and hypercholesterolemia.8 Al-
though several available therapies increase eNOS-NO-cGMP signaling, none of them are 
currently indicated for the treatment of systemic hypertension. Therefore, interventions 
that improve EDH signaling could have great therapeutic relevance not only for hyper-
tension but also in other conditions associated with impaired endothelial function. In 
Chapter 6 we discuss findings from a recent study presenting proof of principle for a 
new class of antihypertensive drugs.9 Although protein kinase G Iα (PKGIα) mediates the 
vasodilatory effects induced by NO, it has been suggested that other EDH factors, such as 
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H2O2, can also activate PKGIα by inducing the formation of a disulfide bond between the 
cysteine 42 residues of 2 adjacent chains in PKGIα homodimers in a cGMP-independent 
manner.10 The candidate lead compound discovered in the discussed study targets 
EDH based on the mechanism of PKGIα activation. Because it is unknown whether all 
EDHs can activate PKGIα, in Chapter 7 we investigated the contribution of PKGIα to 
NO- and EDH-induced vasodilation in porcine coronary arteries (PCAs). Our results sug-
gest that bradykinin- and light-induced relaxation of PCAs depends, at least in part, on 
oxidized PKGIα, and this does not involve sGC. H2O2 also acts via oxidized PKGIα in a 
sGC-independent manner. Yet, S-nitrosothiol-induced relaxation is PKGIα-independent. 
Clearly therefore, PKGIα activation does not contribute universally to all EDH responses, 
and targeting PKGIα may only mimick EDH under certain conditions.
GENERAl DISCuSSION AND fuTuRE PERSPECTIVES
utility of the mouse models of vascular aging and how DNA damage leads to 
vascular aging 
The present results in cell-specific models also open novel opportunities to develop 
more accurate disease models. In general it is hard to include aging in rodent models 
because of the costs and/or an incomplete human-like aging phenotype in old wild type 
(WT) animals. The introduction of DNA repair mutants such as Ercc1Δ/- mice have led to 
opportunities to explore aging and anti-aging interventions very rapidly.3, 11 A potential 
limitation of these models for cardiovascular research is their relatively more prominent 
neurodegenerative phenotype, general frailty and small size, which will lead to prema-
ture death and restrictions to surgical interventions and organ size. Cell type-specific 
models provide a solution to a certain extent, and from the results in this thesis interest-
ing opportunities are generated. For example, atherosclerosis, another important feature 
of vascular aging, is difficult to investigate on an aged background.12, 13 Cell type-specific 
knockout models have already generated useful knowledge on the involvement of DNA 
damage response proteins in plaque progression and vulnerability.14 Our present mod-
els might help to assess if DNA damage itself is involved in plaque formation. Especially 
the role of PDE1, which is specifically increased in plaques, and the potential of PDE1 
inhibitors as a new class of medicines against aging-related cardiovascular diseases can 
be investigated properly in Ercc1-mutant mice. The role of PDE1 in SMC-KO mice still 
needs to be addressed.
Also in research regarding the effect of aging-related end-organ function our pres-
ent models offer interesting possibilities. Indeed, the models show very typical vascular 
aging features encountered in humans, thus demonstrating their potential clinical 
relevance. The strong renal phenotype of EC-KO, possibly even leading to mortality, 
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might give novel insight in the alleged role of the DNA damage response in renal func-
tion.15, 16 This topic remains virtually unexplored despite the general awareness that the 
kidney strongly suffers from the aging process.17 Regarding cardiac disease, EC-KO mice 
showed lowered cardiac output, but normal ejection fraction (EF), whereas SMC-KO 
mice showed lowered EF. Thus, the models might respectively represent the strongly 
aging-related heart failure with preserved EF vs. heart failure with reduced EF. At the 
point of changes in cardiac function we cannot exclude that these changes, especially in 
EC-KO, are benign adaptations. More long-lived models might provide answers. To this 
end, instead of Ercc1f/- or Zmpste24f/-, a milder model might be created, e.g. by making 
use of Ercc1f/Δ mice.
A central question that remains is how DNA damage leads to features of aging. An 
important consideration for solving this question was unveiled in this thesis: the effects 
of DNA damage that can also be found in aging human vasculature are generated lo-
cally within the affected vascular cells (despite the fact that the harmful agents, e.g. 
inflammatory cells producing free radicals, might be acting systemically). Why is this 
important? The answer lies in the approach that is needed to explore how the moment 
of DNA damage connects to the moment when vasomotor control derails.
Parts of the puzzle are in place: in EC eNOS expression and its ACh-induced phos-
phorylation decrease with aging. Decreased Ca2+ responsiveness in EC as a possible 
cause should be explored as a potential cause of this phenomenon. In VSMC PDE1 is 
increased, hampering cGMP signaling. The role of PDE1 and the potential of PDE1 inhibi-
tors as medicines in aging-related vascular disease can now be further elucidated. EDH 
might compensate for loss of NO signaling, and the question is then whether EDH acts 
through disulfide bridging of PKGI subunits. This is of clinical relevance now that novel 
drugs that activate this pathway are becoming available. Clearly, these drugs need to be 
tested under conditions of advanced aging.
A more appropriate approach might be to start treatment before vasomotor 
dysfunction develops. This requires a detailed insight in the chain of events that cause 
vascular aging. Here age-/time-resolved experiments might be of help. Candidate signal 
analysis as well as hypothesis-free methods are options, and the choice between these 
two is mostly a matter of personal taste of individual scientists working on this problem. 
Whatever the choice may be, it is of great importance that this thesis demonstrates that 
one has to look at vascular cell-specific changes. Hence, the use of aging WT or whole 
body DNA repair mutant mice in all likelihood will not be very efficient since it allows 
noise of unspecific signals. EC- and VSMC-specific models appear to be a much more 
effective tool. Since DNA damage effects are very local, even cell culture models might 
help. Especially 3D models have a high potential. Endothelial cells in such models bet-
ter sustain their in vivo properties.18 When using DNA repair-defective vascular cells in 
such setups, local cellular processes generated by DNA damage will not be disturbed 
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by systemic signals. Conversely, one could expose healthy young cells to serum of aged 
individuals. Thus, this approach allows a thorough dissection of the contribution of local 
DNA damage vs. external harmful signals that may act through DNA damage or not. 
Another strong advantage is that one could use human cells in this setting, allowing 
immediate translation. A limitation is the fact that only microvascular function can be 
addressed.
Angiotensin II blockade in mouse models of vascular aging
Ang II responses were not significantly affected in EC-KO or SMC-KO mice, although in 
SMC-KO mice they showed an unexpected (but non-significant) tendency to be lower. 
In contrast, when DNA repair is undermined in both cell types, such as in Ercc1Δ/- mice, 
Ang II-induced constrictions were upregulated (Chapter 5).19 Despite this paradox, 
both in Ercc1Δ/- and SMC-KO mice the opposite function of AT1 vs. Ang II type 2 (AT2) 
receptors appeared to be lost. AT2 receptors can be present both on EC and VSMC where 
they respectively fulfill a dilatory vs. an AT1 receptor-inhibiting function, which is lost 
in disease conditions.19, 20 The AT2 receptor might even invert its function to one sup-
porting constriction. How this occurs is not completely understood. Our results now 
suggest that at least DNA damage in the VSMC might prompt this change, providing a 
tool for further study, perhaps even in cell culture conditions in which DNA damage can 
be easily applied. Why this loss of AT2 receptor activity does not lead to increased Ang II 
contractile responses in the present study is not clear. The strong loss of Ca2+ responses 
in VSMC leading to very low Ang II constrictions and the still present endothelial com-
pensatory function might be responsible. If the latter is the case, only DNA damage in 
both EC and VSMC, such as occurs in Ercc1Δ/- mice, would be sufficient to increase Ang 
II-induced constriction. The Ang II responses being very low in the SMC-KO, however, call 
for reservations in the interpretation of the current results. Further exploration in mice 
lacking DNA repair in both EC and VSMC might provide a conclusive answer.
Importantly, we were able to prevent the increase of Ang II constrictions in Ercc1Δ/- 
mice by chronic treatment with AT1 receptor antagonist losartan (Chapter 5). In these 
studies, the role of AT2 receptors was unfortunately not assessed.19 AT1 receptors have 
been detected in the endothelium of some vessel types. In such vessels it is coupled to 
phospholipase C and phospholipase A signaling,21 which might result in NO and prosta-
glandin release. EC can also contain NADPH oxidase (Nox) 1 and Nox 2, which are known 
to be activated by AT1 receptors. ROS thus produced by Ang II can cause DNA damage, 
as was shown in VSMC.22, 23 Since chronic losartan treatment did not prevent endothelial 
dysfunction in aortic tissue in Ercc1∆/- mice we must conclude that in the aortic endothe-
lium Nox coupled to AT1 receptors does not appreciably contribute to DNA damage in 
vivo. Responses of VSMC to exogenously given NO, however, were improved by losartan. 
The coupling of Nox to AT1 receptors in VSMC is well known and ubiquitously present 
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throughout the vasculature.24 It would therefore be interesting to test the effect of 
chronic losartan on DNA damage and vasodilator dysfunction in SMC-KO mice. Whether 
in EC in vivo Nox coupled to Ang II simply has no role of importance or whether it is a 
matter of the explored vessel type remains the question. The first option could however 
explain why RAS blockade may not be effective in some diseases, such as HFpEF, which 
is strongly dependent on coronary artery endothelial function.25 This question could be 
addressed by submitting EC-KO mice to myocardial infarction or pressure overload and 
apply chronic losartan treatment, followed by measurement of coronary perfusion and 
coronary artery endothelial function.
Our observations suggest that effects of local DNA damage in EC and VSMC are 
likely to be cell-autonomous. Moreover, the effects display specificity towards Ang II 
since ET-1 signaling was not altered. Hence it is unlikely that DNA damage effects are 
simply due to the observed loss of medial cells or general transcriptional problems. The 
findings regarding changes in Ang II receptor signaling and resistance to losartan treat-
ment lead to potential clinical implications. Therefore, markers of DNA damage could 
help to discern the patients that will benefit from Ang II blockade. Given the variability in 
treatment response to such intervention and the relentless but until now fruitless efforts 
of scientists to find markers identifying therapy-resistant patients,26 exploration of this 
possibility is recommendable. Prelamin A levels, telomere length, genetic variations in 
DNA damage response genes and senescence markers are candidate markers for such 
studies.
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DuTCh SuMMARy
Leeftijd blijft de grootste onafhankelijke risicofactor voor alle belangrijke levensbe-
dreigende ziekten, zoals cardiovasculaire en neurologische aandoeningen. Terwijl 
de levensduur de afgelopen decennia geleidelijk is gestegen, is de gezondheid niet 
evenredig en in hetzelfde tempo meegegroeid.1 Veroudering werd altijd beschouwd als 
een onveranderbaar proces, maar de afgelopen 10 jaar is gebleken dat er een complex, 
gereguleerd biologisch proces aan ten grondslag ligt en dat DNA-schade een voorname 
drijvende kracht achter dit proces is.2 Het bewijs voor de rol van DNA-schade in leeftijds-
afhankelijke vasculaire disfunctie in de algemene populatie en in muismodellen, wordt 
besproken in hoofdstuk 1.
Muizen met een defect in hun DNA reparatie zijn een uitstekend onderzoeksmodel, 
omdat zij snel de kenmerken van menselijke veroudering vertonen.3 Het is bekend dat in 
een muismodel met genetische instabiliteit door een defect DNA-herstel (Ercc1Δ/− mui-
zen), leeftijd-gerelateerde vasculaire disfunctie versneld optreedt, hetgeen gekarakteri-
seerd wordt door een afname in de NO afgifte door het endotheel, een afname van de 
NO/cGMP respons in de laag met vasculaire gladde spiercellen (VSMC), en een toename 
van celveroudering daarin.4 In hoofdstuk 2 toonden we aan dat een verhoogd metabo-
lisme van cGMP door fosfodiesterasen (PDE) verantwoordelijk is voor de verslechterde 
NO/cGMP signalering in VSMC van Ercc1Δ/− muizen (Figuur 1B), omdat PDE-remming de 
endotheel-onafhankelijke bloedvatverwijding volledig herstelde naar hetzelfde niveau 
als bij WT muizen. Onze data suggereert ook dat in Ercc1Δ/− muizen de bijdrage van PDE1 
in verhouding tot PDE5 toegenomen is. Men ziet hetzelfde in humane verouderende 
VSMCs. In onze kandidaatgenonderzoek met gebruik van GWAS data werden boven-
dien verbanden tussen single nucleotide polymorfismen in het PDE1A-gen en een 
verhoogde diastolische bloeddruk alsmede de wanddikte van de halsslagader, twee 
kenmerken van humane leeftijd-gerelateerde vasculaire disfunctie. PDE1 wordt ook in 
verband gebracht met aderverkalking en ongunstige ventrikelremodelering. Zodoende 
speelt PDE1 een centrale rol in leeftijdgerelateerde hart- en vaatziekten.
Ondanks eerdere bevindingen en het bewijs dat in hoofdstuk 2 gepresenteerd 
wordt, blijft er één belangrijke vraag onbeantwoord: komt de versnelde disfunctie in 
de bloedvatverwijding in Ercc1Δ/- muizen voort uit defectieve lokale vasculaire DNA-
reparatie, of is het een gevolg van de systemische verslechtering waar deze muizen aan 
lijden? Om deze vraag te beantwoorden, is de cardiovasculaire functie bestudeerd in 
muismodellen met een defect in de DNA-reparatie in vasculaire endotheelcellen of in 
gladde spiercellen. In hoofdstuk 3 bestudeerden we dit in een muismodel met een 
specifieke verwijdering van Ercc1 in vasculaire endotheleelcellen (EC-KO). We vonden 
dat lokale DNA schade in het endotheel tot gevolg heeft en dat er macrovasculaire en 
microvasculaire vaatverwijdingsdisfunctie optreedt als gevolg van het specifieke gemis 
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van endotheel-afhankelijke NO signalering, dat wil zeggen, er was geen effect op en-
dotheel-afhankelijke hyperpolarisatie (EDH) of prostaglandines. Dit had geen effect op 
de endotheel-onafhankelijke vaatverwijding (Figuur 1C). De behouden endotheelcel-
laag, gecontroleerd door middel van scanning elektronenmicroscopie, bevat normale 
waarden van het transcript voor de Von Willebrand factor en normale EDH, hetgeen het 
verlies van NO door verminderde EC aantallen uitsluit. De verminderde vaatverwijdings-
respons was geassocieerd met een tijdelijke verhoging van de bloeddruk. Naast een 
slechtere vaatverwijdingsfunctie vertoonden EC-KO muizen een ernstig beschadigde 
microvasculaire barrièrefunctie in de nieren, wat mogelijk kan leiden tot een voortijdige 
dood. Bovendien was op de leeftijd van 5 maanden de pompfunctie van het hart aange-
tast en de elasticiteit van de aorta verminderd, wat duidt op een verhoogde vaatstijfheid. 
Zodoende is lokale endotheliale DNA schade voldoende om te leiden tot verschillende 
vasculaire afwijkingen die ook waarneembaar zijn bij veroudering.
In hoofdstuk 4 bestudeerden we de effecten van lokale DNA schade in VSMC in 
een muismodel met een specifieke verwijdering van het Zmpste24 gen in deze cellen 
(SMC-KO). Dit veroorzaakte een ophoping van prelamine A, wat leidde tot een verslech-
terde DNA schade reparatie, apoptose en celveroudering.5-7 De bevindingen in SMC-KO 
muizen komen niet overeen met die in EC-KO muizen. EC-KO muizen vertoonden een 
specifieke afname van endotheel-afhankelijk NO-gemedieerde relaxatie, terwijl SMC-KO 
muizen een specifieke afname van endotheel-onafhankelijk NO-gemedieerde relaxatie 
vertonen. Dit verklaart waarom in onze recente studie met het Ercc1Δ/− muismodel zowel 
de NO signalering vanuit EC als in VSMC verstoord was, en duiden op een zeer lokaal 
effect van de DNA schade. EC-KO muizen kunnen niet compenseren voor het verlies van 
acetylcholine (ACh)-geïnduceerde vaatverwijding, terwijl SMC-KO muizen dit wel doen, 
namelijk door een verhoging van prostaglandine-geïnduceerde vaatverwijding en wer-
ving van EDH (Figuur 1D). Een andere opmerkelijke bevinding is dat EC-KO muizen geen 
toegenomen stijfheid in de aorta laten zien, terwijl SMC-KO muizen die wel vertonen. 
Mogelijkerwijs leidt endotheel-disfunctie niet zo snel tot een verhoogde vaatstijfheid 
als VSMC disfunctie. De observaties in SMC-KO muizen komen overeen met observaties 
in Ercc1Δ/- muizen, en suggereren dat DNA schade in VSMC bijdraagt aan de toename 
van vaatstijfheid die gezien wordt bij veroudering. Daarom leidt DNA schade in zowel 
EC als VSMC, op een ogenschijnlijke cel-autonome wijze, tot specifieke veranderingen 
die relevant zijn voor verouderings-gerelateerde vasculaire ziekten. 
In hoofdstuk 5 hebben we gekeken of het mogelijk is om de verstoorde vaatver-
wijdingsfunctie die gezien wordt in Ercc1Δ/- muizen te voorkomen door de toepassing 
van dieetrestrictie (DR) of door permanente blokkade van de angiotensine (Ang) II type 
1 (AT1) receptor met losartan. DR verbeterde de vaatverwijding tot een leeftijd van 30 
weken door weefsel in de halsslagader in staat te stellen om vaatverwijdende pros-
taglandines uit het endotheel te werven, welke normaal afwezig zijn (Figuur 1B). Een 
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mogelijke verklaring voor de ontstane prostaglandine respons is de toename in COX-2, 
gecombineerd met een afname in PDE4B, welke samen zouden moeten leiden tot een 
verbeterde vaatverwijdende cAMP signalering. Bovendien verbeterde DR de reactie van 
VSMC op NO. Doorlopende behandeling met losartan zorgde voor het terugdraaien 
van de verhoogde Ang II-geïnduceerde bloedvatvernauwing in Ercc1∆/- muizen. Deze 
afname kon niet verklaard worden door effecten op fysiologisch antagonisme door het 
endotheel, aangezien de endotheel-afhankelijke vaatverwijding niet verbeterd werd 
door losartan. Daarnaast is de bloeddruk zelf geen aandrijfmechanisme  in de vaatver-
wijdingsdisfunctie die we zien, aangezien een verlaging van de bloeddruk geen invloed 
had op deze disfunctie.
Zoals we laten zien in hoofdstuk 3, 4 en 5, is in onze muismodellen voor veroudering 
de eNOS-NO-cGMP pathway in het bijzonder aangedaan, en bij dieetrestrictie wordt 
de verstoorde signalering gecompenseerd door prostaglandines. Verstoorde eNOS-NO-
cGMP signalering wordt niet alleen bij veroudering gezien, maar ook bij hypertensie 
zonder aanwijsbare oorzaak en hypercholesterolemie.8 Alhoewel er meerdere behan-
delingen voorhanden zijn om de eNOS-NO-cGMP signalering te verbeteren, is geen van 
deze behandelingen op dit moment  geïndiceerd voor de behandeling van systemische 
hypertensie. Om deze reden zouden interventies die de EDH signalering verbeteren 
van grote therapeutische waarde zijn, niet alleen voor de behandeling van hypertensie 
maar ook van andere ziektebeelden waarin een verslechterde endotheelfunctie een rol 
speelt. In hoofdstuk 6 bespreken we de bevindingen van een recente studie die de mo-
gelijke bruikbaarheid aantoont voor een nieuwe groep anti-hypertensieve middelen.9 
Hoewel proteïne kinase G Iα (PKGIα) de vaatverwijdende effecten veroorzaakt door NO 
doorgeeft, wordt er geopperd dat andere EDH factoren, zoals H2O2, de PKGIα kunnen 
activeren door de stimulering van de vorming van een di-sulfideverbinding tussen de 
cysteïnes op positie 42 van 2 naastgelegen ketens in PKGIα homodimeren op een cGMP-
onafhankelijke manier.10 Het mogelijke kandidaat-geneesmiddel dat in de besproken 
studie ontdekt is, grijpt aan op de EDH, uitgaande van het mechanisme van PKGIα-
activatie. Aangezien het onbekend is of alle EDHs PKGIα kunnen activeren, onderzoeken 
we  in hoofdstuk 7 de rol van PKGIa in NO- en EDH-geïnduceerde vaatverwijding in 
de coronair arterie van varkens (PCAs). Onze resultaten suggereren dat bradykinine- en 
licht-geïnduceerde relaxatie van PCAs, tenminste voor een deel, afhangt van geoxideerd 
PKGIα, en hier geen GC bij betrokken is. H2O2 stimuleert bovendien geoxideerd PKGIα 
op een sGC-onafhankelijke manier. Maar S-nitrosothiol-geïnduceerde relaxatie is PKGIα-
onafhankelijk. Daarom is het duidelijk dat PKGIα-activatie niet universeel bijdraagt aan 
alle EDH responsen, en het aangrijpen op PKGIα alleen onder bepaalde omstandighe-
den EDH zou kunnen nabootsen.
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RESuMEN EN ESPAñOl
La edad sigue siendo el mayor factor de riesgo independiente para todas las enfermeda-
des que causan más muertes en el mundo, tal como las enfermedades cardiovasculares 
y neurológicas. Aunque la esperanza de vida ha aumentado constantemente en las 
últimas décadas, la duración de los años de vida saludables no ha aumentado al mismo 
ritmo.1 El envejecimiento solía ser considerado como un proceso no modificable, pero 
en la década pasada se ha demostrado que es un proceso biológico complejo, altamen-
te regulado y que la acumulación progresiva de daño en el ADN es un factor causal 
importante.2 En el Capítulo 1 se revisó la evidencia, en población general y en modelos 
murinos, que respalda el rol del daño en el ADN en la disfunción vascular relacionada 
con la edad.
Los ratones con reparación defectuosa del ADN son excelentes herramientas de 
exploración porque reproducen rápidamente los signos distintivos del envejecimien-
to humano.3 Previamente encontramos que en un modelo murino de inestabilidad 
genómica causada por reparación defectuosa del ADN (ratones Ercc1Δ/-), se produce 
disfunción vascular relacionada con la edad de manera acelerada y ésta se caracteriza 
por disminución de la capacidad de respuesta de la vía del óxido nítrico/GMP cíclico 
(NO/cGMP) y aumento de la senescencia celular en la capa de células de músculo liso 
vascular (VSMC).4 En el Capítulo 2 se demostró que en los ratones Ercc1Δ/- el metabolismo 
aumentado de cGMP por parte de fosfodiesterasas (PDE) es responsable de la reducción 
de NO/cGMP en VSMC, ya que la inhibición de las PDEs restauró completamente la va-
sodilatación independiente del endotelio (Figura 1B). Nuestros datos también sugieren 
que en ratones Ercc1Δ/-, la contribución de PDE1 es mayor a la contribución de PDE5. En-
contramos hallazgos similares en VSMC senescentes humanas. Además, polimorfismos 
de un solo nucleótido en el gen PDE1A se asocian con el aumento de la presión arterial 
diastólica y el grosor de la íntima media carotídea, dos características de la disfunción 
vascular relacionada con la edad en humanos. Varios estudios han reportado que PDE1 
está implicada en aterosclerosis y en el remodelado cardiaco maligno. Por lo tanto, PDE1 
juega un papel central en la enfermedad cardiovascular relacionada con la edad.
A pesar de los hallazgos previos y la evidencia presentada en el capítulo 2, una 
pregunta importante que permanece es si la acelerada disfunción vasodilatadora 
observada en ratones Ercc1Δ/- es causada por la reparación defectuosa del ADN a nivel 
local en la pared vascular, o si es una consecuencia del deterioro sistémico del que 
sufren estos ratones. Para responder a esto, se investigó la función cardiovascular en 
modelos murinos con reparación defectuosa del ADN restringida a células endoteliales 
vasculares o al músculo liso. En el Capítulo 3 estudiamos ésto en un modelo murino 
con pérdida específica de la proteína reparadora de ADN Ercc1 en células endoteliales 
vasculares (ratones EC-KO). Encontramos que el daño en el ADN restringido al endotelio 
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causa disfunción vasodilatadora macro- y microvascular debido a la pérdida específica 
de la señalización de NO dependiente del endotelio; es decir, las otras vías vasodila-
tadoras derivadas del endotelio (hiperpolarización dependiente del endotelio(EDH) o 
prostaglandinas) no son afectadas. De igual manera, la vasodilatación independiente 
del endotelio no es afectada (Figura 1C). Análisis morfológicos con microscopía electró-
nica de barrido, niveles normales de factor de von Willebrand y la respuesta normal de 
la vía EDH confirman que la capa de células endoteliales está preservada; lo que excluye 
la posibilidad de que la pérdida de NO endotelial se deba a un número menor de células 
endoteliales. La reducción de la respuesta vasodilatadora sólo se asoció con un aumento 
temporal de la presión arterial. Aparte de la disfunción vasodilatadora, los ratones EC-
KO mostraron una función de barrera microvascular gravemente comprometida en el 
riñón, que podría ser la causa de muerte prematura en estos ratones. Además, el gasto 
cardíaco se vio afectado a los 5 meses de edad y la distensibilidad aórtica se redujo, lo 
que sugiere una mayor rigidez vascular en ratones EC-KO.
En el Capítulo 4 estudiamos los efectos locales del daño en el ADN en VSMC en 
un modelo murino con deleción específica del gen Zmpste24 (ratones SMC-KO). La 
deleción del gen Zmpste24 provoca la acumulación de prelamina A, lo que conduce al 
reclutamiento alterado de las proteínas que reparan el daño en el ADN y la activación 
defectuosa de los puntos de control en el ciclo de división celular, y por lo tanto, resulta 
en reparación defectuosa de los daños en el ADN, apoptosis y la senescencia celular.5-7 
Los hallazgos en ratones SMC-KO contrastan con los observados en ratones EC- KO. Los 
ratones EC-KO mostraron una disminución específica de la relajación mediada por NO 
dependiente del endotelio, mientras que los ratones SMC-KO muestran una disminución 
específica de la relajación mediada por NO independiente del endotelio. Los ratones EC-
KO no compensan la pérdida de dilatación inducida por acetilcolina (ACh), mientras que 
los ratones SMC-KO lo hacen, aumentando la dilatación inducida por prostaglandinas 
y reclutando EDH (Figura 1D). Otro hallazgo sorprendente es que los ratones EC-KO no 
muestran mayor rigidez carotídea, mientras que los ratones SMC-KO sí. Puede ser que la 
disfunción endotelial no conduzca tan rápidamente a una mayor rigidez como la disfun-
ción de la capa VSMC. Las observaciones en los ratones SMC-KO están en línea con las 
observaciones en ratones Ercc1Δ/-, y sugieren que el daño en el ADN en VSMC contribuye 
al aumento de la rigidez vascular que se observa en el envejecimiento. En conclusión, 
tanto el daño en el ADN en células endoteliales como en VSMCs, en lo que parece ser 
una manera celular autónoma, conduce a cambios específicos que son relevantes para 
las enfermedades vasculares relacionadas con el envejecimiento. Esto responde a una 
pregunta importante que quedaba de nuestro estudio anterior en el modelo de ratones 
Ercc1Δ/-, en donde encontramos que la señalización de la vía NO estaba perturbada tanto 
en células endoteliales como en VSMCs.
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En el Capítulo 5 se examinó si la disfunción vasodilatadora presente en ratones 
Ercc1Δ/- podría prevenirse con restricción dietética (DR) o bloqueo crónico (con losartán) 
del receptor tipo 1 de la angiotensina (Ang) II. La DR mejoró la vasodilatación hasta una 
edad de 30 semanas permitiendo que la aorta reclutara prostaglandinas vasodilatado-
ras derivadas del endotelio que normalmente están ausentes (Figura 1B). Una posible 
explicación de la respuesta emergente a las prostaglandinas es el aumento de la enzima 
ciclooxigenasa COX-2, combinado con una disminución de la PDE4B, que conjuntamen-
te deberían conducir a una mejora de la señalización vasodilatadora mediada por cAMP. 
Además, la DR mejoró la respuesta de VSMC a NO. El tratamiento crónico con losartán 
normalizó la vasoconstricción aumentada en respuesta a Ang II en ratones Ercc1Δ/-. Esta 
normalización no se explica por los efectos de losartán sobre la función endotelial, ya 
que la vasodilatación dependiente del endotelio no fue mejorada por este tratamiento. 
Además, la presión arterial en sí misma no es un mecanismo impulsor en la disfunción 
vasodilatadora observada, ya que en los ratones Ercc1Δ/- la normalización de la presión 
arterial no afectó a esta disfunción.
Como se muestra en los capítulos 3, 4 y 5, en nuestros modelos murinos de envejeci-
miento la vía NO/cGMP es afectada específicamente, y bajo DR esta señalización alterada 
es compensada por prostaglandinas vasodilatadoras. La señalización perturbada de la 
vía NO/cGMP se observa no sólo en el envejecimiento, sino también en hipertensión 
esencial y en hipercolesterolemia.8 Aunque varias terapias disponibles aumentan la 
respuesta de la vía NO/cGMP, ninguna de ellas está actualmente indicada para el tra-
tamiento de la hipertensión sistémica. Por lo tanto, las intervenciones que mejoren la 
señalización de otras vías vasodilatadoras derivadas del endotelio, tal como la vía EDH, 
podrían tener una gran relevancia terapéutica no sólo en hipertensión, sino también 
en otras condiciones asociadas con alteración de la función endotelial. En el Capítulo 6 
se discuten los hallazgos de un estudio reciente que presenta una prueba de concepto 
para una nueva clase de fármacos antihipertensivos.9 Aunque la proteína quinasa G Iα 
(PKGIα) media los efectos vasodilatadores inducidos por el NO, se ha reportado que otros 
factores EDH, como el peróxido de hidrogeno (H2O2), también pueden activar PKGIα al 
inducir la formación de un enlace disulfuro entre los residuos de cisteína 42 de dos cade-
nas adyacentes en homodímeros de PKGIα, de una manera independiente de cGMP.10 El 
compuesto candidato descubierto en el estudio discutido, se basa en ese mecanismo de 
activación de PKGIα. Debido a que se desconoce si todos los EDH pueden activar PKGIα, 
en el Capítulo 7 se investigó la contribución de PKGIα a la vasodilatación inducida por 
NO y EDH en las arterias coronarias porcinas (PCA). Nuestros resultados sugieren que la 
relajación de las PCAs inducida por bradicinina y por luz halógena depende, al menos 
en parte, de PKGIα oxidada, y dicha señalización no implica la guanililciclasa soluble. 
H2O2 también actúa vía PKGIα oxidada de una manera independiente de guanililciclasa 
soluble. Sin embargo, la relajación inducida por S-nitrosotioles es independiente de 
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PKGIα. Es claro, por lo tanto, que la activación de PKGIα no contribuye universalmente a 
todas las respuestas de EDH y la activación de PKGIα sólo puede imitar dicha EDH bajo 
ciertas condiciones.
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